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ABSTRACT

Bercich, Rebecca A. Ph.D., Purdue University, May 2016. Improving the Mechanistic
Study of Neuromuscular Diseases through the Development of a Fully Wireless and
Implantable Recording Device. Major Professor: Pedro Irazoqui.

Neuromuscular diseases manifest by a handful of known phenotypes affecting
the peripheral nerves, skeletal muscle fibers, and neuromuscular junction. Common
signs of these diseases include demyelination, myasthenia, atrophy, and aberrant
muscle activity—all of which may be tracked over time using one or more
electrophysiological markers. Mice, which are the predominant mammalian model for
most human diseases, have been used to study congenital neuromuscular diseases for
decades. However, our understanding of the mechanisms underlying these pathologies
is still incomplete. This is in part due to the lack of instrumentation available to easily
collect longitudinal, in vivo electrophysiological activity from mice. There remains a need
for a fully wireless, batteryless, and implantable recording system that can be adapted
for a variety of electrophysiological measurements and also enable long-term,
continuous data collection in very small animals.
To meet this need a miniature, chronically implantable device has been
developed that is capable of wirelessly coupling energy from electromagnetic fields
while implanted within a body. This device can both record and trigger bioelectric
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events and may be chronically implanted in rodents as small as mice. This grants
investigators the ability to continuously observe electrophysiological changes
corresponding to disease progression in a single, freely behaving, untethered animal.
The fully wireless closed-loop system is an adaptable solution for a range of long-term
mechanistic and diagnostic studies in rodent disease models. Its high level of
functionality, adjustable parameters, accessible building blocks, reprogrammable
firmware, and modular electrode interface offer flexibility that is distinctive among fully
implantable recording or stimulating devices.
The key significance of this work is that it has generated novel instrumentation in
the form of a fully implantable bioelectric recording device having a much higher level of
functionality than any other fully wireless system available for mouse work. This has
incidentally led to contributions in the areas of wireless power transfer and neural
interfaces for upper-limb prosthesis control. Herein the solution space for wireless
power transfer is examined including a close inspection of far-field power transfer to
implanted bioelectric sensors. Methods of design and characterization for the iterative
development of the device are detailed. Furthermore, its performance and utility in
remote bioelectric sensing applications is demonstrated with humans, rats, healthy mice,
and mouse models for degenerative neuromuscular and motoneuron diseases.
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CHAPTER 1.

1.1

INTRODUCTION

Neuromuscular Diseases

Inherited pathologies of the muscles, peripheral nerves, or neuromuscular
junctions fall under the broad classification of neuromuscular diseases. Some prominent
examples include inherited peripheral neuropathies (IPNs), muscular dystrophies,
myasthenic syndromes, and myasthenia gravis. It is estimated that one in 3,500 people
worldwide suffers from one of these diseases [1]. In some cases the disease symptoms
are barely noticeable and patients live normal, unimpaired lives [2]. For others, though,
these diseases lead to muscle weakness and atrophy; numbness or pain in extremities,
scoliosis, wheelchair reliance, and cardiovascular or pulmonary complications [3-5]. The
ability to improve the compromised quality of life for these individuals hinges on a
thorough understanding of neuromuscular disease mechanisms, from which effective
therapies can be developed.
IPNs represent a large subset of neuromuscular diseases which will be used
throughout this work as an illustrative example, allowing for more specific discussions
on the study of disease pathologies and mechanisms. IPNs can lead to premature
muscle weakness, dysfunction, and atrophy. They are distinguished from other
neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) or myopathies
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like muscular dystrophy (MD) by the fact that their primary pathophysiology occurs in
the peripheral axons rather than the motor neuron cell body, neuromuscular junction,
or within the muscle fibers themselves. Changes in muscle behavior, strength, and mass
in patients afflicted with an IPN are attributed to the impairment of efferent nerves.
However, hereditary neuropathies can also affect afferent and autonomic nerves,
causing sensory deficits [6] or impairment of the sympathetic and parasympathetic
nervous systems [5].
IPNs affect millions of people worldwide with symptoms often manifesting early
in life—typically adolescence or early adulthood [7]. This can lead to functional deficits,
diminished quality of life, and decreased mobility in patients with severe afflictions of
the disease [8]. The most common IPN is demyelinating Charcot-Marie-Tooth (CMT)
Type 1 disease [9]. CMT is referred to as a Mendelian disease, meaning it is linked to
(and defined by) the mutation of a single gene [10, 11]. CMT types are broadly classified
by their primary pathophysiological phenotype: either demyelinating (CMT1 and its
subclass, CMT4), axonal (CMT2), or both (DI-CMT and CMTX) [5].
Age of onset and symptom severity vary greatly among patients diagnosed with
CMT, even within a particular classification [12]. This is likely due, in part, to
environmental factors that either exacerbate or moderate the effects of the main gene
mutation. Another possible explanation is the influence of modifier genes on the
presentation of main gene mutation phenotypes. Previous work examining a variety of
degenerative disease such as retinal dystrophy [13], Parkinson’s disease [14], and CMT
[15, 16] have suggest that epistatic states can occur in which the phenotypic
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presentation of a particular gene mutation depends on the expression of genes from
modifier loci occurring within the genetic background. In this way the effects of multiple
mutations can synergize to alter disease presentation and progression. This can, in turn,
blur the boundaries between disease subclasses and make precise diagnoses difficult
[12].
One of the ways in which our understanding of these often complex disease
mechanisms can be improved is by creating more advanced tools that allow new or
higher quality data to be collected from animal disease models. Sections 1.1.1 and 1.1.2
identify a range of metrics used to characterize neuromuscular disease mechanisms and
the experimental protocols used to collect those metrics. These protocols are most
often carried out in mice, which serve as the premier mammalian model for most
inherited human diseases. In vivo electrophysiology is often utilized for direct
observation and quantification of disease markers over time. Section 1.2 offers an
overview of established methods for long-term electrophysiology in mice. This overview
exposes a gap in available instrumentation for untethered, freely behaving mice. Finally,
the common need for improved bioelectric sensors in both the study of animal
neuromuscular disease models and human clinical applications is addressed in Section
1.3.

1.1.1 Metrics of Neuromuscular Disease Progression
Many difference methods and metrics are used to characterize neuromuscular
diseases. In addition to genetic strategies such as DNA sequencing, there are
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histopathological and electrophysiological means of discerning disease origins and
progression. Amongst these are nerve biopsies, imaging techniques such as magnetic
resonance neurography, nerve conduction velocity (NCV), electromyography (EMG), and
nerve action potentials (NAPs) [17, 18]. In some instances spontaneous, aberrant
activity may also be measured. For example, uncontrolled fasciculation and fibrillations
are well-documented in human patients having ALS [19, 20] and MD.
Some metrics such as NCV and compound motor action potential (CMAP) are
triggered by applied stimuli. While useful, stimulus evoked potentials only reveal a
subset of the functional characteristics of the peripheral nervous system. In some
situations, particularly those involving the analysis of disease states, it may be necessary
to also observe voluntary evoked potentials in the nerves or muscles.
Animal models—particularly transgenic and knockout mice—play a crucial role in
understanding the genetic and molecular factors that contribute to neuromuscular
diseases like IPNs [21, 22]. Information can be extracted from these animal models and
used to improve understanding disease mechanism, evaluate new therapies, and
improve the quality of genetic counseling. This work will focus on the
electrophysiological metrics that can be measured in mouse disease models over time
to create signatures for disease progression. What follows is a discussion of the different
experimental methods that may be used to record bioelectric data from the affected
targets of neuromuscular disease, particularly the peripheral nerves and muscles.
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1.1.2 Experimental Design
The first decision that must be made in a long-term electrophysiological
examination of a disease model is which signal or metric is going to be obtained This will
depend on the study hypothesis and what is already known about the model’s
phenotypes. Once the experimental objective is set, it must be decided whether the
data are to be collected from ex vivo preparations or in vivo. The study of the
neuromuscular system and its associated disorders requires functional readouts of
muscle and nerve function that can be—and often are—obtained in reduced
preparations at fixed time points. Such preparations limit mechanistic interpretations
and in vivo relevance as well as the ability to track disease progression.
If in vivo data collection is part of the experimental protocol, then the benefits of
using a single animal over time should be weighed against the use of acute animal
cohorts at fixed time points. The benefits of using a single animal over time include
expending fewer animals, enabling higher temporal resolution in measured parameters,
and allowing data to be normalized internally to each animal for ease of comparison.
The relative benefit of using animal cohorts is that it avoids repeated surgical
procedures in the same animal and ensuing post-operative care. It is possible for
longitudinal single animal studies to enjoy the same benefits as acute animal group
studies by using tethered or wireless headstages, which only require a single surgical
procedure. These solutions are examined in more detail within the discussion on
instrumentation for chronic electrophysiology in Section 1.2.
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Finally, the decision should be made whether or not the target signal can and
should be measured under anesthesia. Stimulus evoked behaviors will likely be easier to
measure if the animal is subdued. However, voluntary evoked and spontaneous
aberrant bioelectric activities are suppressed under anesthesia, and will need to be
recorded from awake and freely behaving animals.

1.2

Instrumentation for Longitudinal Electrophysiology in Mice

Voluntary evoked nerve and muscle activity carry important information about
neuromuscular disease mechanisms. The various instrumentation options for collecting
these bioelectric signals in mice over time are covered in this section. The use of
tethered apparatuses for longitudinal stimulation and recording of neuromuscular
activity in mice is observed only a handful of times within the literature [23, 24].
Tethered setups involve the connection of an animal subject to a data processor
through a cable that connects to a headstage, which is typically fixed on top of the
animal’s head or on the back of the neck. This practice is far more prevalent in
experiments that use larger rodent models such as rats: an observation that points to
the technical difficulty of installing and anchoring bulky hardware in animals as small as
mice. Tethered systems do offer some advantages such as large bandwidth and DC
power supplies. However, they can be impractical for collecting longitudinal
neuromuscular information. Headstage unseating and lead wire breakage are common
culprits in premature termination of animal experiments. Moreover, the physical
connection between the animal and the bench top instrumentation impose limitations
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on the animal’s testing environment. For example, a tethered animal cannot be placed
in water or made to move in and around obstacles. In fact, most tethering apparatuses
offer very little leeway and confine the animal to a small testing space. This raises
additional concerns about the potential for behavioral constructs resulting from the
unnatural influence confining and burdening the animal.
Wireless headstages serve as an alternative to tethered headstages, but tend to
be bulky and cumbersome. This can cause them be dislodged or damaged during
behavioral tests or normal animal activity. Moreover, wireless headstages are typically
intended and configured for neural recording in the cortex. In order to measure signals
from the peripheral nerves and muscles, these devices would have to be fitted with
longer leads that can be routed to remote targets.
Table 1.1 compiles the performance specifications for a series of fully wireless and
commercially available devices that may be used for chronic biopotential measurements
in mice. Four crucial observations should be made about the information in Table 1.1.
First, there is no fully wireless recording device which enables both biopotential
acquisition and stimulation, which would be an incredibly powerful tool for closed-loop
control of bioelectric systems. Some fully wireless standalone stimulators have been
developed for mice [25-27], but they do not have biopotential recording capabilities.
Second, none of these sensors gives the user the ability to adapt the functional protocol
for different experimental needs, making them one-size-fits-all solutions. Third, the
bandwidths and associated sampling rates of these fully wireless systems are, in almost
all cases, too low for a majority of useful nerve and muscle measurements, which can
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have frequency content up to a few kHz. Lastly, almost all of these systems rely on
batteries and therefore have finite lifespans (typically one to two months). It should be
noted that the recording device from Triangle BioSystems, which does offer a large
enough bandwidth for EMG and NAP is a battery powered headstage with a battery
lifespan of up to 4.2 hours [28].

Table 1.1 Summary of available fully wireless bioelectric sensors for mice. Devices that
are not wirelessly powered utilize a battery power supply.
Wireless
Power
(Yes/No)

Integrated
Stimulator
(Yes/No)

Adapt.
1
Program
(Yes/No)

Device
Volume
3
(cm )

Min.
Animal
Mass (g)

Number of
Biopotential
Channels

Channel
Bandwidth
(Hz)

HD-X11
(Data Sciences
International [29])

No

No

No

1.4

19

1

0.1-200

F20-EET
(Data Sciences
International [29])

No

No

No

1.9

20

2

1-50

EPOCH-MSE-SYS
(BIOPAC Systems, Inc.
[30])

No

No

No

0.76

10

2

0.1-100

MT10B
(Millar [31])

Yes

No

No

1.4

22

1

2-440

No

No

No

4.54

--

5

0.8-7,000

Product

2

W-Series
(Triangle BioSystems
International [28])
1

Adaptable programming refers to the ability to change the sensor’s functional protocol
in firmware.
2
This product is a battery powered headstage and is not fully implantable.

1.2.1 Battery Powered Implants
Battery powered devices have the advantage of storing energy chemically, which
reduces energy waste and makes it more efficient than any other wireless powering
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solution [32]. An onboard battery is an appealing powering solution for fully wireless
recording device. The best evidence for this might be the ubiquitous use of batteries in
commercial hardware as shown in Table 1.1. Batteries are highly portable and
proximate energy reservoirs that evade the losses from free space energy dissipation
and tissue attenuation, which are significant concerns in wireless power coupling [3335]. However, the energy storage capacity of a battery is directly related to battery
volume, which has implications for the implant size. The most significant disadvantage
of single-charge (primary) batteries is the repeated, invasive surgery required to replace
them. It is worth noting that in some cases a hybrid system consisting of a rechargeable
(secondary) battery or capacitor in combination with remote powering for cyclical
charging and discharging can be an effective powering strategy [36, 37]. However,
continuous data collection at high sampling rates precludes the use of any battery
power source for long-term, fully implantable solutions.

1.2.2 Potential for Energy Harvesting Implants
Energy harvesting or scavenging is a broad term for the collection, storage, and
use of energy (thermal, mechanical, metabolic, photonic, etc.) from a system’s
environment [32]. Energy harvesting might be used to collect trace amounts of energy
from proximate sources, convert it to electrical energy, then use that energy to power
an integrated circuit (IC) that can measure or modulate some biological activity. Since
the sources of energy come from the environment it may be thought of as “free” energy
and, if sufficient levels of energy can be collected, might negate the need for a battery
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or tethered connection to a power source. However, many harvesting strategies either
exhibit low conversion efficiencies or face significant practical limitations that limit their
usefulness in active implantable devices. The efficiency of a mechanical piezoelectric
system, which depends on its material and resonance of the mechanical stimulation, is
in one case reported to be 0.46%. When one considers that the existing energy in this
source is already extremely low, it seems this strategy may only be sufficient for
extremely low power systems. The lack of solar energy available within the body
prevents the use of more efficient photovoltaic cells and inadequate temperature
gradients make effective thermal energy conversion within the body difficult [38].

1.2.3 Wireless Power Transfer Strategies for Implants
Wireless power transfer (WPT) is a method of converting incident
electromagnetic fields generated in the radio frequency (RF) band into an electrical
current [39]. This current can then be used to power an IC that can perform the desired
tasks of recording, filtering, transmitting, and stimulating biological signals. This idea of
remote powering is an extremely powerful one for implantable systems as it offers a
continuous supply of energy constrained only by the efficiency of the wireless link and
the limits for exposure of tissue to RF electromagnetic fields—a concern which will be
explored thoroughly in Section 2.2.
Remote powering has been employed in a variety of implantable device
applications because it circumvents many of the previously discussed detriments of
battery powered implants or tethered apparatuses for chronic collection of bioelectric
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information. Different WPT strategies can be categorized by the type of link between
the source of the electromagnetic field and the receiving structure. These links may be
inductive, radiative, or a combination of inductive and radiative. Inductive links couple
energy in the near-field region whereas radiative links collect energy from the far-field
region of an electromagnetic field source. The transition from near-field to far-field is
gradual, but a typical heuristic used to define the upper bound of the near-field is
⁄ where D is the largest dimension of the radiating body and λ is the wavelength of
the RF source [40].
Near field (inductive) coupling is the most prevalent form of WPT used for
implantable devices. This is, in part, a result of over a century of work devoted to
characterizing and optimizing the behavior of inductive links [41]. Inductive energy
coupling is the same phenomenon used in a transformer; a current applied to a primary
conductive coil generates a magnetic field which induces current in a separate
(secondary) conductive coil. Crucially, the amount of energy transferred in this
arrangement is strongly affected by the alignment, proximity, and matching of both coils’
physical properties [39, 42]. This knowledge dates back to the work of Nikola Tesla, who
revealed the significance of coil turning and resonance to energy coupling efficiency,
which he used to wirelessly illuminate vacuum tubes [43]. The other reason that
inductive power coupling is frequently used for WPT to implants is the fact that
biological tissue has an extremely low magnetic susceptibility, making it is essentially
invisible to magnetic fields [39, 44].
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One of the early successes for inductive power coupling in active biomedical
implants was its use to charge a cardiac pacemaker battery in 1960 [45]. Today, this
form of WPT is used for a variety of biomedical applications such as cochlear implants
[46, 47], blood pressure monitors [37], electrocardiogram (EKG) sensors [48], EEG
electrodes [49], and human EMG acquisition [50]. The broad application of near-field
inductive power coupling for biomedical and other commercial applications stems from
many years of experimentation with different parameters (coil diameter, number of
turns per coil, coil alignment, operating frequency, etc.) to improve PTE [51-53]. It is well
known that the PTE of an inductive link is strongly affected by the mutual inductance of
the primary and secondary coils. This mutual inductance is derived from the physical
properties and spatial relationship of the primary and secondary coils and can decrease
rapidly as a result of increased separation or angular misalignment of the two coils
relative to one another [34, 39, 42, 54]. A study conducted by William Heetderks in 1988
evaluated five inductive coil arrangements for powering relatively small implants within
various parts of the body. The results of this study indicate that there are inherent
inefficiencies in inductive systems when there is a large discrepancy between powering
and receiving coil size [51], which would invariably be the case for a miniature system
suitable for implantation within a mouse.
The relationship between PTE and coil size in inductive links is one that is
disadvantageous to WPT in very small animals. Solenoid coils are bulky and, with an
increasing number of turns, comes additional mass and volume--both of which are at a
premium. The use of pancake coils is one strategy that exists to sidestep this problem.
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Printed spiral coils are one implementation of the pancake coil and are fabricated by
printing the desired coil shape with a conductive material on an insulating substrate.
This may be done using a strategy like photolithography or milling from a copper-clad
sheet. Uei-Ming and Ghovanloo demonstrated a PTE between pancake coils as high as
86% at a separation distance of 1 cm in free space [54]. These sorts of flat coils have the
potential to be integrated with clothing on account of their thin profiles and flexibility
when fabricated on very thin substrates. This could be useful for powering implantable
systems for collecting neural information for directing a prosthesis or monitoring
physiological parameters [55]. Sections 3.3.3 and 4.2.2 detail the fabrication of printed
spiral coils designed specifically for implantation in small animal monitoring. When
paired with a purely inductive power coupling scheme, however, these pancake coils
present the same limitation as solenoid coils. That is, mutual inductance (and thereby,
PTE) can vary drastically—and unpredictably in the case of a freely behaving animal—as
a result of even minor misalignments and separations of more than a few centimeters
between the primary and secondary coils [34, 53]. For these reasons a purely inductive
WPT link is deemed unsuitable for an implantable system in freely behaving animals.
Far-field RF powering distinguishes itself from near-field RF powering in that it
extracts energy from the radiating region of an electromagnetic field rather than the
nearby inductive region. Traditional applications of far-field wireless links include radar,
wireless communication, and radio frequency identification (RFID) tags [41].The
transmission and collection of far-field power transfer took off in the 1960s when it was
first demonstrated that radiative fields could be focused in space rather than spreading
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isotropically. This vastly improved the transmission efficiency of far-field links, making it
a more attractive solution for those interested in coupling energy from radiating fields
[56, 57].
The improvements in far-field efficiency that came with the development of
waveguide transmission were accompanied by improvements to RF rectifiers, which can
be used to generate stable DC currents from oscillating electromagnetic fields. This
progress was aided greatly by advances in semiconductor diodes [58]. There have since
been a number of efforts in the way of increasing RF rectifier efficiency [59, 60]. Soon
after the development of the RF rectifier came the conception of the rectenna: a
rectifier circuit plus a receiving antenna in one portable assembly. One of the first
applications of the rectenna was a remotely powered helicopter, which was an effort
headed by William Brown in the 1960s. Brown pointed out that the changing orientation
of the target device (in this case a helicopter) necessitated a powering strategy with
some immunity to the constantly shifting physical arrangement of the receiver relative
to the source [61]. This idea carries over into the field of chronically implanted sensors
as there is, likewise, a good deal of inherent unpredictability in defining the spatial
relationship between the device within the animal and the external powering unit.
One prevalent and related use for far-field powering and telemetry is RFID tags.
The rapid growth of the technology came as a result of miniaturization and expanded
capabilities of complementary metal-oxide semiconductor (CMOS) technology. RFID
tags are used for applications such as highway tolling and merchandise tracking.
Occasionally these devices perform the desired tasks using only incident RF energy as a
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power source. Each tag has an integrated transponder or IC that allows it to emit either
a fixed identification or recorded signal of interest when interrogated [60, 62].
The ubiquitous nature of far-field links in today’s world and the robustness of
these links to changes in receive antenna orientation might lead one to expect that farfield power transfer for implantable sensors is common practice. However, application
of far-field WPT in implantable devices is limited. This might be partially attributed to
the added complexity of antenna design when its functional properties can be altered
by the properties of proximate dielectric mediums such as biological tissue [63, 64]. The
more likely impediment, though, is the fact that operating frequency and signal
attenuation of radiative electromagnetic fields in lossy dielectric mediums such as
biological tissue are positively correlated [33, 35]. Additionally, smaller antennas (which
are needed for very small implants) resonate at higher frequencies. The resonant
frequency of the receiving antenna has a bearing on the antenna gain, so energy loss
occurs when the incident electromagnetic field frequency does not match the resonant
frequency of the antenna. Thus, it is prudent to assign antenna dimensions based on the
intended operating frequency. There is the additional point that far-field RF links have
traditionally operated at higher frequencies to take advantage of increased bandwidth
and reduced interference with other wireless transmissions [65]. Combining this
information results in the following crucial point: the interplay between antenna size,
electromagnetic field (operating) frequency, and energy attenuation in tissue must be
well understood in order to create an effective WPT link and may render far-field WPT
unsuitable for some applications.
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This might serve to illustrate why far-field WPT has been largely dismissed as a
viable solution for continuous power transfer to microelectronics implanted in a body.
Some exceptions include the work of Le et al [59] and Radiom et al.[66]. Their results
suggest that perhaps in the right environment, with a carefully configured
electromagnetic field source, and an implantable device with appropriately low power
consumption, far-field power coupling may be sufficient for continuous device operation
within a freely behaving animal. Chapter 2 explores the feasibility of a far-field RF power
coupling strategy for this application. It also contains a detailed analysis of the complete
power link budget for a far-field RF link, a summary of findings from a model using finite
element method (FEM) analysis, and a discussion of the broader implications of those
findings for the utility of far-field WPT for implantable sensors.
The final wireless powering strategy that will be considered here is magnetic
resonance coupling (MRC), which uses series resonators to optimally impedance match
both the primary and secondary coils. This is a way of tuning the system and thereby
increasing the quality factor, Q, for a particular set of non-optimal conditions for
inductive links (poor angular alignment, large coil-to-coil separation, etc.). The quality
factor is a numerical representation of the strength of coil coupling which depends on
the previously discussed mutual inductance, operating frequency, and series resistance
of the coils [67]. In this way MRC has the potential to greatly exceed the PTE observed in
inductive links under conditions in which the primary and secondary coils are poorly
coupled [68, 69]. Since this was the key impediment to using purely inductive power
coupling to run devices implanted in freely behaving animals, MRC presents an exciting
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alternative that ultimately proves to be the most efficacious wireless powering solution
for this application.
The development of an implantable, single-channel recording device that is
compatible with MRC power transfer between two poorly coupled inductive coils is the
subject of Chapter 3. Recently, the same theory governing MRC between two
conductive coils was used to create a resonant cavity structure which offers the largest
available WPT environment for freely behaving animals [70, 71]. The subject of Chapter
4 is the design and implementation of a multifunctional device capable of functioning
while implanted in freely behaving animals housed within the resonant cavity.

1.3

Wirelessly Powered Sensors for Upper-Limb Prosthesis Control

In addition to the multitude of potential animal research applications, fully
wireless bioelectric sensors also have utility in the human clinical sphere. An exciting
frontier in rehabilitation of upper-limb amputees is how myoelectric control systems can
be made to work synergistically with chronic intramuscular electromyography (imEMG)
to improve the performance of sophisticated electric-powered prostheses [50, 72].
For many upper-limb amputees the devastation of limb loss is often coupled with
disappointment in the performance of commercially available prostheses. When a
replacement limb falls short of a patient’s expectations—that is, the control is
unintuitive, the response to a mental command is excessively delayed, or the prosthetic
itself is heavy and uncomfortable—the frustration can lead the patient to abandon the
prosthesis entirely [73, 74]. The human arm has 28 degrees of freedom [75]; it is a highly
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dexterous and complex system, which makes it difficult to replicate and command.
There is a need to address these frustrations, which are so common amongst upper-limb
amputees. There is an especially critical need for improved neural interfaces for
transhumeral, shoulder disarticulation, and bilaterial amputees. These individuals have
lost significant ability, may be highly dependent on others, and present unique
challenges to prosthetic design and control.
It comes as a surprise to some that the main adversity to meeting the
expectations of upper-limb amputees is not a lack of sufficiently advanced prostheses.
In fact, a robotic (powered) upper-limb prosthesis capable of over twenty degrees of
freedom has been developed [76]. Additionally, there is a well-developed solution space
for prosthesis control algorithms that work with various neural interfaces [77-83].
However, the use of sophisticated prostheses and control algorithms are both limited by
the lack of sufficient motor control information. In both cases there is a need for a
greater number of independent channels of neural information in order to decipher and
manage the dynamics of so many degrees of freedom simultaneously [73, 84].
Most upper-limb amputees who are fit with an electric-powered prosthesis use
surface electromyography (sEMG) to control their artificial limb [85]. The selection of
recording locations on the residual limb depends on the level of amputation (transradial,
transhumeral, shoulder disarticulation, etc.), whether or not the patient is willing to
undergo additional surgery such as targeted muscle reinnervation (TMR) [84], and
whether conventional amplitude-based [77] or pattern recognition control methods [84,
86] are used.
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Regardless of electrode location, sEMG is often limited in its use by signal crosstalk as well as variability in electrode impedance and position from sweating, shifting of
the socket, and donning/doffing of the prosthetic; all of which can necessitate
recalibration of the system [78] or reduce the functional performance of the control
system [72, 80]. While more invasive, imEMG offers significant advantages when it
comes to signal reliability and specificity, which could enable the use of more advanced
and efficacious control algorithms not just in the controlled environments of labs and
clinics, but in-home as patients take on diverse daily tasks.
The last five years have seen some advances in chronic, wirelessly powered
intramuscular recording systems for upper-limb amputees [87-89], including the first
human trials [50]. However, due to the purely inductive method of power coupling
employed by these systems, the efficacy of their WPT links can vary drastically as a
result of minor misalignments or separations of the primary and secondary coils [53,
90].These systems of are useful in applications where all target muscles are relatively
close together and/or positioning of the on-board coil(s) are fixed relative (and in close
proximity) to the external coil. Their use may be limited in other configurations where
the external coil is prone to shifting or when an external coil cannot be wrapped around
all target muscles. A compelling example of this might be an array of devices embedded
in muscles within the chest and shoulder of an amputee following TMR surgery, which
has been established as a pragmatic method for enhancing the performance of
myoelectric prosthesis control, particularly in proximal upper-limb amputees [84, 91].
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The surgical procedure for TMR in upper-limb amputees was pioneered by Dr.
Todd A. Kuiken and Dr. Greg Dumanian. The surgery itself involves rerouting various
branches of the residual brachial plexus nerve bundle to denervated muscles in the
shoulder or chest of an amputee. Over the course of three to six months these muscles
become reinnervated by the nerves that used to be responsible for directing
movements in the hand and arm. So these reinnervated muscles will contract in unique
ways in response to motor commands intended for the missing limb. The ultimate
advantage of this procedure is that is provides easier access to electrical activity that can
be correlated with the intent of the patient, enabling intuitive control mechanisms in
which the patient does not have to re-train their motor cortex. All of the learning is
done by a processor equipped with a control algorithm.
TMR surgery takes advantage of a process called hyper-reinnervation, which
refers to the regrowth of axons when a nerve containing a greater number of fibers is
affixed to a smaller, previously incised nerve containing fewer fibers. The smaller nerve
is distal to the larger nerve and usually innervates either a single muscle or a small group
of muscles. Hyper-reinnervation increases the odds that a fiber in the smaller nerve will
form a connection with a fiber in the larger nerve and eventually lead to muscular
reinnervation [92]. The process of muscular reinnervation takes place as a result of
axonal regrowth guided by residual Schwann cells from old nerve sheaths. This process
reestablishes the link from the brain’s motor cortex to a muscle’s neuromuscular
junctions so that muscle contracts are once again evoked as a result of motor
commands [93]. There are a number of interesting phenomena that occur as a result of
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hyper-reinnervation, some of which have proven to be highly advantageous to the
rehabilitation of transhumeral and shoulder disarticulation amputees [94, 95].
Hyper-reinnervated muscle exhibits some unique characteristics compared to selfreinnervated muscle (resulting from re-appending the two ends of the same nerve
following an incision) or native muscle. First, hyper-reinnervated muscle recovers more
mass and strength due to the increased probability of any give muscle fiber being
reinnervated and the increased chance for polyneuronally innervated fibers. The most
important artifact of hyper-reinnervation, though, is the spatial segmentation of motor
units. Hyper-reinnervated muscles tend to have smaller motor units that cluster
together instead of being distributed homogenously among other motor units, which is
the case in native muscle [92, 96]. This behavior would improve signal selectivity of an
implanted bioelectric sensor by granting the ability to place that sensor within clustered
muscle fibers belonging to the same motor unit. Since a single motor unit encodes
information about a very specific motor command, this would address the previously
declared need for a greater number of independent channels of neural information in
order to realize the full potential of sophisticated robotic prostheses and control
algorithms.
Furthermore, muscle has been demonstrated to be a viable environment for
chronic implants. Long-term acceptance of an implanted device by proximate muscle
can be expected provided the implant packaging is biocompatible and hermetically
sealed [97]. Following implantation the encapsulation and anchoring of implants has
been observed, which may initially change the amplitude and spectrum of the recorded
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potentials. However, the tissue environment surrounding the implant will eventually
stabilize, leading to output signals which have consistent qualities over time [98, 99].
In summary, the TMR procedure offers a number of advantages that could work
synergistically with fully wireless and implantable imEMG sensors to greatly improve
upper-limb prosthesis control for upper-limb amputees [79, 100]. However, due to the
abnormal arrangement of motor units at reinnervated muscle sites [101], a viable
companion system for chronic imEMG acquisition would need to be able to
accommodate variable and scattered device positions. Even upper-limb amputees using
EMG from native muscle to control their prosthesis would benefit from a more versatile
wireless powering strategy that can accommodate imperfect or non-stationary
alignment inherent in real-world use. The desired level of flexibility in orienting remote
sensors to an electromagnetic field source for this application presents a similar
challenge to the one faced in freely behaving animal monitoring. In short, they both
require a flexible, robust WPT strategy and an implantable recording device that is
compatible with that WPT strategy, so it is possible that both instrumentation needs
might be addressed at the same time. Chapter 3 includes a demonstration and
discussion of how the wireless recording devices developed in this work might
contribute to the clinical field of upper-limb prosthesis control.

1.4

Conclusion

The ongoing study of neuromuscular disease pathogenesis could be aided by tools
which enable long-term electrophysiology in mice under conditions that do not involve
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tethering or anesthesia. There is no fully wireless system either on the market or within
the literature that can both record from and stimulate excitable tissues in awake, freely
behaving mice. Existing wireless systems for biopotential acquisition are limited by at
least one of the following points: finite lifespan from battery power supply, low quality
of data resulting from low (200 Hz or less) bandwidth, limited information output from
by a single recording channel, and unsuitability for implantation owing to large
dimensions.
This leads to the principle objective of this work, which is to create novel
instrumentation that will augment the study of neuromuscular disease mechanisms by
significantly improving the ability track relevant electrophysiological metrics in a single
mouse over time. A fully wireless and implantable device with the ability to both
measure and evoke bioelectric activity would, in many ways, represent a significant
improvement over current devices intended for electrophysiology in untethered, freely
behaving mice (see Table 1.1). This implant would also be uniquely advantageous for
studying certain other diseases. For example, cortical activity in rodent epilepsy models
could be measured continuously to predict and then possibly curtail spontaneous
seizure events through stimulation. The breadth of potential uses for an implantable
closed-loop device are exciting but outside the scope of this work. However, hereditary
motoneuron diseases like ALS manifest through phenotypes which are often similar to
those observed in neuromuscular diseases and will be considered herein.
The challenge of making an active, fully implantable sensor that is suitable for longterm implementation in very small animals requires careful consideration and balancing
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of key system characteristics such size, performance, adaptability, reusability, and
biocompatibility. This engineering design problem tenders the following criteria for
success: 1) the device must be small enough to be fully implanted in a mouse; 2) the
device must have sufficient functionality to be useful for a variety of electrophysiological
experiments; 3) once implanted, the device must be able to function longitudinally in
the living environment; 4) the device as well as its paired environment for WPTmust
enable the continuous, long-term collection of bioelectric activity from freely behaving
mice.
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CHAPTER 2.

FEASABILITY OF FAR-FIELD WIRELESS POWER TRANSFER FOR
IMPLANTABLE ELECTRONICS

2.1

Introduction

The material presented in this Chapter incorporates content from the journal
article “Far Field RF Powering of Implantable Devices: Safety Considerations” by R.
Bercich, D. Duffy, and P.P. Irazoqui, which is published in IEEE Transactions on
Biomedical Engineering [35]. © 2013 IEEE.
Wireless energy coupling offers clear advantages over wired, battery powered,
and energy scavenging strategies for chronically implanted sensors and stimulators (see
Sections 1.2 and 1.3 for discussion on these strategies). Wireless powering negates the
need for recurrent surgeries to replace batteries and sidesteps the issues with lead
wires that risk infection by breaching the skin barrier and are prone to break or dislodge
as a result of fatigue and micromotion.
It is useful here to reexamine the criteria for success for this work, which are
summarized in Section 1.4. Briefly, a miniature, multifunctional device that supports
continuous WPT while enabling long-term data acquisition is needed for chronic animal
and clinical applications. It is important to note early on in the design process that these
objectives are interdependent and oftentimes destructive to one another. For example,
it may be desirable to implement sixteen channels of recording so that large quantities
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of neural information may be collected. However, this would add complexity to the
device’s functional protocol, increase power consumption, and likely add volume to the
implant. This could result in a finished product that is too large to be implanted or one
which requires more power than can be reliably and continuously coupled from the
source.
Much of the work that goes into developing WPT solutions seeks to improve some
form of power transfer efficiency (PTE). In the case of WPT to an implanted device, PTE
is defined as the percentage of energy from a source that is received by the target
device and may be expended for some useful purpose such as lighting an LED for
optogenetics [102, 103] or driving an IC that samples and transmits bioelectric data. It is
crucial that the range of a wireless link’s PTE is well characterized when devising a
strategy for WPT to a device having an unpredictable location and orientation—as
would be the case within a freely behaving animal. This is important because the
minimum PTE must be sufficient to meet the power requirements of the device and the
maximum (peak) PTE must not be so large that damage might be done to the circuit
components, which have voltage and power dissipation limits. The limitations of a
purely inductive WPT strategy have been detailed in Section 1.3.2.
Far-field RF powering is an attractive solution to the challenge of coupling energy
to non-stationary remote devices because its PTE is less dependent on proximity of the
electromagnetic field source and the receiving device than that of near-field RF
powering. This is due to the fact that the energy density in the radiative field decreases
inversely with the square of the distance(proportional to 1/r2) as compared to the
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inductive field in which energy density decreases with 1/r3 where r is the distance
between the field source and the receiver in free space [104, 105]. However, far-field
powering in the application of implantable devices introduces the obstacle of power
density attenuation as the electromagnetic waves pass through tissue and tissue
boundaries. Absorption and reflection of radiated energy in addition to the free space
path loss all diminish the power return at the receiving antenna and decrease the PTE of
the WPT link.
The obvious solution to high energy losses from energy spreading and attenuation
in tissue might be to increase the power output at the source. However, there are
exposure limits set by the Federal Communications Commission (FCC) that restrict how
much power may be incident on the surface or absorbed in a given volume of tissue
[106] as excitation from oscillating electromagnetic fields can have adverse effects on
tissue by way of both thermal and non-thermal mechanisms [107-110]. Thus, a careful
consideration of the safety thresholds is necessary and will set the constraints for an
analysis of the power link budget. Understanding the receive power capabilities of a farfield WPT link will be assistive in determining the value of this solution compared to
other wireless powering strategies.
The viability of safely coupling energy from the far-field of a radiating body to
power an implantable recording device is explored in Sections 2.2 through 2.4. It will
also be important to demonstrate that local temperature spikes resulting from thermal
discharge of the implanted microelectronics will not cause damage to proximate
biological cells and tissues. It is important that the temperature of the tissue
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surrounding the device does not increase by more than a few degrees as various studies
have shown that temperature increases greater than 2 °C can have adverse effects on
living cells [111-114]. An experiment that tests the thermal safety of active implantable
is the focus of Section 2.5.

2.2

Safety Constraints for Far-Field RF Power Transfer

The first point that should be noted in building a power transfer link in tissue is
that the PTE will be affected significantly by the chosen operating frequency, f. This is
because the efficiency of the receiving structure—an antenna in this case—is strongly
impacted by the wavelength, λ, of the incident electromagnetic field which is related to
f by the relationship f = c/λ where c is the speed of light. In order to maximize the
efficiency of energy transfer, the receiving antenna should be tuned by precise selection
of its dimensions for the chosen operating frequency. For example, dipole antennas are
often used as receivers of far-field RF waves and will resonate with the oscillating field
when their length is λ/2 or λ/4. Resonant conditions are desirable as they minimize
losses and improve overall PTE, however the antenna length needed to achieve
resonance is inversely proportional to the operating frequency. Resultantly, there is a
lower limit for the RF field frequency when working with very small receiving devices
(such as those that are suitable for implantation in mice) where the antenna length may
be limited to a few centimeters. For this reason the proceeding far-field WPT analysis
will examine the effects of f in the range of hundreds of MHz to GHz.
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The extent of RF energy absorption in tissue will also be affected by f since the
dielectric properties of tissues are frequency dependent [115]. Furthermore, it is known
that RF attenuation is positively correlated with f [116]. This would encourage a lower
operating frequency, which stands in opposition to the incentive to use higher
frequencies for the sake of smaller receiving antennas. As a result f must be chosen such
that antenna losses are balanced with losses from tissue attenuation. In practice, it is
best to use an operating frequency which lies within an industrial, scientific, and medical
(ISM) radio band since these are approved and reserved for purposes such as
implantable devices. For this reason, the following ISM band frequencies will be
considered in this analysis: 915 MHz, 2.4 GHz, and 5.8 GHz.
The first safety consideration for the use of a radiating source is the time averaged
surface exposure of tissue. The standards for maximum permissible exposure (MPE) are
outlined in Table 1 of Section 1.131 in Title 47 of the Code of Federal Regulations, which
outlines permissible use of telecommunication systems. The FCC standard for
uncontrolled exposure to an intentional radiator depends on the operating frequency.
The MPE limit for exposure to an electromagnetic field is given as an average over 30
minutes and is 2 W/m2 in the range of 30—300 MHz; f/1.5e8 W/m2 in the range of
300—1,500 MHz, where f is the operating frequency in Hz; and 10 W/m2 in the range of
1,500—100,000 MHz. This translates into an average MPE limit of 6.1 W/m2 at 915 MHz
and 10 W/m2 at 2.4 GHz and 5.8 GHz [106]. These particular limits will be used in the
subsequent theoretical and numerical link budget analyses as their corresponding ISM
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frequencies (915 MHz, 2.4 GHz, and 5.8 GHz) are considered suitable for the scale of the
receive antenna needed for this work.
The second safety standard established by the FCC for an antenna operating at RF
frequencies is a set of restrictions for power absorption in tissue. This includes a wholebody average specific absorption rate (SAR) limit, which is 0.8 W/kg, as well as a peak
spatial SAR limit evaluated over any 1 g cube of tissue, which is 1.6 W/kg [106]. The
surface exposure and the SAR experienced by any nearby human or animal tissue must
remain below these established safety limits while power transfer is taking place to an
implanted device.
The efficiency of energy transfer between an electromagnetic field source in free
space and a receive device embedded in tissue will depend on many factors. These
include characteristics of the source such as output power, efficiency (which takes into
account dielectric and parasitic losses), directivity, and operating frequency. It will also
depend on free space dispersion, tissue attenuation, and reflections at boundaries
between materials with different dielectric properties such as air, skin, adipose, muscle,
bone, etc. After all of these losses have been accounted for there will be some power
flux density incident on the receiving antenna which can be converted into usable
energy. The conversion between this power flux density at the surface of the device and
the power budget available to run the device’s embedded microelectronics will depend
on the directivity and efficiency of the receiving antenna as well as the efficiency of the
rectification circuit used to convert the incoming AC current to a stable DC supply
voltage. This evaluation of power transfer which accounts for all potential losses in a
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wireless link is referred to as a link budget analysis. What follows is the complete link
budget analysis for far-field RF power transfer between an external radiating source and
a device implanted in mammalian tissue.
The amount of energy that exists at some distance from an electromagnetic field
is often given per unit area in the form of power flux density. In free space the power
flux density at some distance, x, from the radiating source can be found using the
following relationship [40]:

( )

(2.1)

where EIRP is the equivalent isotropically radiated power from the antenna (equal to
the product of antenna input power, Pt; antenna gain, Gt; and the efficiency of the
antenna’s matching network, emn). By setting S(x) equal to the MPE limit (for example,
10 W/m2 at a frequency of 2.4 GHz), a relationship emerges between antenna-tissue
separation and the transmitting antenna characteristics that must be satisfied in order
to guarantee safe exposure levels:

√

(2.2)
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For example, if the radiating antenna is isotropic (gain of 0 dB in all directions), has a
matching network efficiency of 100%, and is given an average input power of 1 W (30
dBm), then the minimum separation distance between that antenna and any part of the
body must be 8.92 cm. This is one constraint to consider when constructing a model for
the WPT link and in practice if this wireless powering strategy is used.
The second safety constraint established by the FCC pertains to energy absorbed
in a volume of tissue. Assuming a one-dimensional power flux though a volume of tissue
having a cubic form factor, the peak spatial SAR can be expressed as:

(

)

(2.3)

where S0 is the power flux density transverse to one face of the cube, Sa is the power
flux density transverse to the opposite face of the cube, and a is the side length of the
cube. Using the average density of human tissue, ρ = 1.04 g/cm3 [115], the side length, a,
corresponding to a tissue mass of 1 g is calculated to be 9.87 mm. It is also known that
the power flux density will decreases exponentially over the distance, a, in accordance
with the following relationship:

(2.4)
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(2.5)

√

where f is the powering frequency, μ0 is the permeability of free space (1.257e-6 N/A2),
and σ is the conductivity of the tissue at a given frequency. The term λd refers to the skin
depth—the depth at which the amplitude of the electromagnetic field is reduced by a
factor of e-1 [116]. So if the powering frequency is set to 2.4 GHz (at which point the
conductivity of human tissue is 1.81 S/m [115]), the skin depth will be 7.64 mm.
Substituting (2.4) into (2.3) yields an expression for the power absorbed by a cube of
tissue depending on the power flux density at the surface of the cube:

(

)

(2.6)

Rearranging (2.6) gives an equation for the absolute maximum power flux
density that may occur in tissue:

(2.7)
(

)

Using the known values of a and λd while substituting the peak spatial SAR limit (1.6
W/kg) for Pabs in (2.7) yields an absolute power flux density limit of 17.76 W/m2. This
results in the following guidelines for RF field exposure at 2.4 GHz: the average power
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flux density averaged over 30 minutes cannot exceed 10 W/m2 because of the MPE limit
and the average flux density cannot for any length of time exceed 17.76 W/m2 because
of the local SAR limits. Equation (2.6) may be used to estimate the peak local SAR under
the condition that the MPE limit has been reached by substituting 10 W/m2 for S0. This
yields a peak local SAR of 0.90 W/kg. This number will serve as a point of comparison
and validation for the FEM analysis described in Section 2.4.
The antenna-tissue separation needed to meet peak local SAR limits can be
found using the peak power flux density and the relationship in (2.1). Given the same
powering conditions as the previous example (isotropic antenna with 100% efficiency
and 30 dBm input power), the calculated minimum separation is 6.69 cm. This is less
than the antenna-body separation required to meet the MPE limits (8.92 cm), so it can
be said that these powering conditions are within the safe limitations for RF
electromagnetic field exposure so long as the antenna-body separation is >8.92 cm. This
series of calculations can be performed on any set of powering conditions in order to
establish the minimum antenna-body separation and corresponding maximum input
power that will satisfy the FCC safety guidelines. For example, imagine that the desired
antenna-body separation for a particular application is 1 cm. The average input power
to an isotropic antenna would need to be reduced from 30 dBm to 11 dBm in order to
satisfy the MPE limit and the free-space loss would, likewise, decrease by 19 dB. In the
case of an isotropic source antenna this might be a good power saving strategy since the
power flux density incident on the tissue surface remains at MPE limit yet the power
input to the source has been reduced by a factor of almost 80. However, when an
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antenna with directive gain is used, moving that antenna closer to the body may
significantly restrict the space in which a device can receive adequate power. This would
not be an optimal scenario in the case of a freely behaving animal which may be placed
in a variety of environments for data collection. It would be necessary that the entire
volume of the selected testing environment be within an area of the radiating
electromagnetic field where the power flux density is larger enough to sustain the
implant’s power budget. For this reason the radiation pattern, antenna-tissue
separation, input power, and exposure limits must all be taken in to consideration when
designing a practical far-field RF powering system for implantable devices.

2.3

Power Link Budget for Far-Field RF Energy Coupling

The power link budget is a calculation of the amount of power received from a
wireless link once all losses and inefficiencies have been accounted for. The powering
conditions calculated in Section 2.2 are used here to approximate the link budget for a
far-field RF WPT link to a receive device embedded in tissue. This will be used to draw
conclusions about the receivable power limits and, as a result, the feasibility of far-field
power transfer for this particular application.
The theoretical power link budget analysis begins with the assumption that all
power incident on the tissue surface is absorbed. In this way a boundary condition for
the power flux density may be imposed at the tissue surface and will be set to the MPE
limit, which is a function of the electromagnetic field frequency. Equation (2.4) may then
be used—with the MPE boundary condition substituted for S0—to calculate the average
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power flux density at the depth of the implant, Sd. The amount of useable power
received by the device after voltage rectification, Pr, will depend on the incident power
flux density, Sd, as well as the efficiency of the rectification circuit, erec; the efficiency of
the matching network, emn; the receiving antenna power gain, Gr; and the field
wavelength, λ, according to the following relationship [40]:

(2.8)

The power gain of the receive antenna (Gr) is the product of the antenna’s
directivity (measured in dBi) and efficiency. Equation (2.8) illustrates how the level of
power received by an implanted device can be influenced by the RF-to-DC conversion
circuit efficiency as well as the gain of the receive antenna. It is worth noting that the
efficiency of an RF-to-DC conversion circuit tends to increase as the amplitude of the
input RF power increases. This behavior has been observed in previously developed
rectenna assemblies designed to operate at 2.45 GHz, which have conversion
efficiencies that range from 48% at -5 dBm [117] to 15.7% at -20 dBm [118]. Receive
antenna gain can also vary significantly with the antenna’s size, geometry, and
construction [117]. The size constraints imposed by small implantable devices –
specifically those appropriate for implantation in mice—make efficient antenna design
difficult. This is especially true at lower operating frequencies where longer wavelengths
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necessitate larger antenna dimensions in order to achieve resonance and higher power
gain.
In one example constructed by Chow et al. [119], a quarter wavelength antenna
is designed for implantation in the anterior chamber of the eye in order to measure
intraocular pressure. The operating frequency in this example is 2.4 GHz, which means
the implanted antenna is approximately 3.1 cm in length. The simulated gain of this
antenna, which is looped into a semicircle, is -6 dBi. This antenna is intended for
implantation in the eye of a rabbit or human and is too large for very small animal
studies. A receive antenna that is suitably small for implantation in mice or for devices
arrayed in a muscle for clinical applications such as prosthetic control would have to be
much smaller than this and would likely fall into the range of what is described as
electrically small antennas. An electrically small antenna is one in which the largest
dimension (such as the length of a monopole antenna or the diameter of a loop antenna)
is less than λ/10. This leads to a crucial point, which is that any antenna small enough to
suit the application of chronic data acquisition in mice will likely be an electrically small
antenna. This might be avoided by increasing the operating frequency to tens or
hundreds of GHz (the wavelength being only 3 mm at 100 GHz). However, it is expected
that power loss from tissue attenuation will be even more dramatic at these higher
frequencies and will negate the benefits of using a half wavelength or quarter
wavelength antenna.
The narrowing of the antenna solution space to electrically small antennas is a
practical and realistic constraint. It also allows for a more concrete discussion of

38
expected antenna gain and matching network efficiency, which will be assistive in
developing a realistic power link budget analysis and drawing conclusions about the
suitability of this WPT strategy. The critical inefficiency of using an electrically small
antenna is not the gain of the antenna itself. In fact, a standard half-wave dipole has a
known gain of 2.15 dBi while a short dipole with a length of λ/10 can have a gain of 1.77
dBi [120]. This gain assumes that the input impedance is well matched to the RF source
impedance (typically 50 Ω). However, implementing this matching network in
electrically small antennas comes at a price. What makes the electrically small antenna
less efficient in practice is the high reactance component of its input impedance, which
necessitates large-value reactive components (inductors and capacitors) in the matching
network. These components—especially inductors—are accompanied by significant
resistive losses, which can drastically decrease the efficiency of the matching network
(emn) [120, 121]. An approximation of power loss through a matching network for
electrically small antennas which accounts for practical and finite quality factors of
inductors is derived in [120] with a result of around -20 dB. This number will serve as a
sufficient approximation for emn in the link budget analysis.
It is possible that the overall PTE through an electrically small antenna might be
improved by designing it to have a higher directivity, which is a measure of the power
density in the direction of strongest radiation. However this reduces the antenna’s
effective area by focusing the emitted energy into a smaller range of space. Recall from
Section 1.3.2 that the dependence on precise source and receiver alignment is one of
the key issues with inductive power coupling, making it an impractical solution for
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power transfer to freely behaving animals. For the same reason it is not desirable to give
the receiving antenna high directivity because changes in the animal’s posture and
facing would dramatically change the PTE and lead to frequent shutdown of the
implanted device. For the purposes of the link budget analysis, it is assumed that the
receive antenna is isotropic; that is its gain is uniform and 0 dB in all directions. It should
be noted that an isotropic antenna is a hypothetical antenna. It is modeled as a point
source for electromagnetic waves and has no physical equivalent [116]. However, it can
be used in this link budget analysis for a best case scenario calculation since a receive
antenna with no directionality would be optimal for this application.
The assumption that the receive antenna gain is equal to 0 dB and has a
matching network loss of 20dB may be combined with (2.4) and (2.8) to calculate a
realistic approximation of the power link budget for a device embedded in tissue. The
result will depend on the type of tissue and depth at which the receive antenna is
implanted. It is expected that the implant will be placed subcutaneously in rodents as
their skin is loose, which can provide plenty of space that is also far from the vital organs.
Even mice weighing 15 g can accommodate a device as long as 12 mm when placed
subcutaneously [122]. For clinical applications it is possible that the device may be
placed either subcutaneously or intramuscularly. For comparison a subcutaneous
implantation is assumed, so the thickness of human versus rodent skin must be
considered. The average skin thickness for humans is 2.58 ± 0.07 mm whereas the
average thickness of rat skin (hairless) is 0.86 ± 0.06 mm and the average thickness of
mouse skin (hairless) is 0.41 ± 0.02 mm [123]. The conductance of skin, which is needed
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to calculate the skin depth used in (2.4), is acquired from [115]. In the absence of data
for rodent skin conductance, the measured human skin conductance as a function of
frequency is used for all calculations. The resulting power link budget for a device with a
rectifier efficiency of 20%, 40%, and 60% is given in Figure 2.1.

Figure 2.1 Calculated maximum power coupled through far-field RF link to a device
implanted subcutaneously as a function of the electromagnetic field source frequency.
Power budget given for human skin (thickness = 2.58 mm), rat skin (thickness = 0.86
mm), and mouse skin (thickness = 0.41 mm) at rectifier efficiencies of 20% (green), 40%
(blue), and 60% (orange). The frequency dependent maximum permissible exposure
(MPE) limit is imposed on the skin surface boundary. Receive antenna is treated as an
electrically small isotropic antenna with a matching network loss of 20 dB.

Recall that the boundary condition used for this theoretical link budget analysis is
the MPE limit at each operating frequency. This limit is calculated as an average over 30
minutes, which means that the RF field exposure may exceed this limit for short periods
of time. That isn’t to say that the power flux density at the surface of the skin can be
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increased unboundedly with shorter and shorter periods of exposure. There is still an
absolute maximum power flux density limit as a result of the SAR safety threshold given
by (2.7). Figure 2.2 shows the absolute maximum power flux density limit for skin
resulting from the SAR safety threshold as a function of field frequency.

Figure 2.2 Absolute maximum power flux density that may be present in mammalian
skin tissue based on peak spatial SAR constraint for energy absorption from
electromagnetic fields. Tissue mass is assumed to be 1.04 g/cm3 and the dielectric
properties of the absorbing medium are based on data from human skin tissue.

Figure 2.1 illustrates the severe power losses that may be sustained in the far-field
link budget at higher and higher frequencies. Regardless of the species, receive power
drops to below 0.25 mW at a frequency of 1 GHz through skin. The power budget is
further reduced in all cases to below 0.1 mW at 2.4 GHz and below 0.01 mW at 5.8 GHz.
At the 915 MHz ISM band, the wavelength is still long enough (32.8 cm) that only an
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electrically small antenna would be feasible in an implant suitable for mice. It is worth
nothing that as the frequency continues to increase, resonant antenna design becomes
more realistic and matching network losses might decrease. However, the exponential
decrease in RF field power through tissue with the increasing frequency means that
even a quarter-wavelength antenna at 5.8 GHz (which would have a length of
approximately 13 mm) with no matching network losses would only yield a power
budget of up to 1 mW. This estimate is calculated under the condition of subcutaneous
implantation in a mouse and assumes a rectifier efficiency of 60%.
At this point it is reasonable to take the theoretically derived power link budget
and compare it to the power demands of existing wireless biomedical sensors. Table 2.1
offers a list of active devices that have been created for the purpose of wireless
biopotential acquisition. These devices are designed for a variety of purposes and each
has been developed under a unique set of constraints, which can make fair comparisons
difficult. However, there are some fundamental building blocks of a bioelectric sensor,
including an amplifier stage for signal conditioning, analog to digital converter (ADC),
microprocessor or other digital logic circuit to mediate device tasks, and a transmitter
for data telemetry.
The type of bioelectric signal targeted by each system is listed along with the
number of channels and sampling rate per channel that each solution offers. Total
sampling rate (the product of the number of channels and the sampling rate per channel)
is included since higher data rates increase the power consumption of RF transmitters,
which typically draw more current than any other functional block of active wireless
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sensors. The list shown in Table 2.1 is not exhaustive, but it does give a sense for the
range of power requirements needed to run electronics that can perform the essential
tasks of conditioning, sampling, and transmitting bioelectric data.

Table 2.1 Comparison of power consumption for active biomedical sensors configured
for wireless data telemetry. Number of channels and sampling rate per channel are
reported as these strongly affect the power consumption.
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Sampling Rate
Per Channel
(kHz)
30

Total Power
Consumption
(mW)
8.8*

Neural (general)

1

0.625

30

Harrison et al. [125]

EEG

1**

15

13.5

Szuts et al. [126]

EEG

64

20

645

Fan et al. [127]

EEG

16

30

27.8

Zhang et al. [128]

EEG

1†

0.1

>77.2

Chang et al.[129]

ECoG

16

12.5

27.6

Charvet et al. [130]

ECoG

32

1

100

Parramon et al. [131]

EMG

2

14.6

22.5

Prabhav et al. [132]

EMG

1

1

33

Russell et al. [133]

EKG

1

2

16

Hsieh et al. [134]

Bioelectric (general)

7

0.22††

12

Target Signal

Number of
Channels

Chow et al. [65]

Neural (general)

Chestek et al. [124]

Publication

*This system is solely a transmitter for biomedical sensors and does not include the additional power
consumption contribution of signal amplifiers or ADC
**Can select from one of an array of 100 electrodes
† This device also includes three stimulating channels. Reported power consumption reflects transceiver
and microcontroller contributions only.
††Average sampling rate per channel is given, however each channel’s sampling rate is configured for a
different signal.

An evaluation of the range of reported power requirements for existing wireless
bioelectric sensors shown in Table 2.1 suggests that these would not be compatible with
a far-field WPT link. The theoretical link budget analysis summarized in Figure 2.1
indicates that the only way to couple adequate levels of power (at least 8 mW) would be
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reducing the frequency to below 100 MHz. It seems possible based on the positive
correlation between power consumption and number of recording channels that a
system having only one recording channel would have a lower power consumption and
might be amenable to WPT in the frequency range shown in Figure 2.1. However, the
theoretical link budget is calculated under the assumption that the receive antenna is
electrically small with a characteristic length of λ/10. Even at 434 MHz—the lowest ISM
band considered—a λ/10 characteristic length equates to 7 cm. Considering that the
body length (from nose to base of tail) of a normal, healthy mouse is 7.5—10 cm [135],
this would still be too large for implantation.
This analysis covers far-field power transfer to subcutaneous implants in rodents
and humans. One can imagine that the low PTEs observed under these conditions will
only get worse with deeper implantations, such as those envisioned for the clinical
application for upper-limb amputees discussed in Section 1.3. In order to quantify the
expected far-field RF power transfer through multiple tissue layers, a more complex
model will need to be constructed. The evaluation of energy absorption and reflection
between disparate tissues can rapidly become a computationally intensive endeavor, so
a numerical solver is employed in proceeding section in order to model and simulate the
electromagnetic fields in a more complex model—a human chest wall. The numerical
results will also serve to validate the prior theoretical approximation and allow for a
decision to be made as to whether or not far-field RF power transfer is a feasible WPT
strategy for either of the desired applications of this work.
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2.4

FEM Analysis of RF Electromagnetic Fields in Biological Tissue

The link budget analysis performed in Section 2.3 is a good theoretical
approximation but is limited in its application by some of the assumptions imposed. For
instances of subcutaneous power transfer where the tissue boundary may be
approximated by a single homogenous medium, the theoretical link budget is sufficient.
However, the human clinical application of this wireless recording device, which is
discussed in Section 1.3, is more complex owing to the variable depth of implantation
and multiple tissue mediums through which the electromagnetic energy will pass. As a
result the analysis of the WPT link for this application requires a more sophisticated
model that accounts for the disparate dielectric properties of different types of tissues
as well as the energy reflections which take place at the boundaries between the
different tissues. A 3-dimensional tissue model for the human chest and an
electromagnetic field source are simulated in this section using finite element method
(FEM) software. The simulation is performed in ANSYS High Frequency Structure
Simulator (HFSS®) 13.0 and will serve to corroborate the conclusions from the
theoretical analysis and illustrate the power dispersion in a more complex tissue model.
A field frequency of 2.4 GHz is used to illustrate one construction of the model and
iteration of the simulation. The simulation environment is set up using a half-wave (6.25
cm for an operating frequency of 2.4 GHz), center-fed dipole antenna placed parallel to
the z-axis and a three-layered body model. The three layers of the model are skin,
adipose, and muscle; each is assigned a thickness and dielectric properties based on
known characteristics of tissue in the human chest wall [115, 136, 137]. The tissue
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model is placed one wavelength along the y-axis from the center of the antenna so that
the model resided in the far-field region of the electromagnetic field. A cross-sectional
view of the model in the simulation environment is shown in Figure 2.3.
.The first simulation performed serves to check that the model has been set up
correctly. In Section 2.3 the minimum antenna-tissue separation for an EIRP of 1 W
(resulting from an input power of 1 W to an isotropic antenna with a matching network
efficiency of 100%) is calculated using (2.2) to be 8.92 cm. Since the antenna-tissue
separation in the 2.4 GHz field simulation is 12.5 cm, it is expected that the power flux
density in the tissue model will fall below the MPE limit. In order to check that this is
true, the 1 W EIRP powering condition will be replicated in the simulation environment
and the resulting peak power flux density at the surface of the tissue model will be
measured and compared to the MPE limit.
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Figure 2.3 Simulation environment for a three-layer tissue model of the human chest in
the far-field of a radiating antenna. Tissue model cross section is shown here from the
perspective of the positive x-axis. Dipole-tissue separation is one wavelength, λ (12.5 cm
at 2.4GHz). Skin layer thickness is 0.2 cm, adipose layer thickness is 0.84 cm, and muscle
layer thickness is 2.16 cm. © 2013 IEEE.

The antenna depicted in Figure 2.3 radiates uniformly in the xy-plane in free space.
However, its radiation pattern changes when objects are introduced into its
electromagnetic field. In order to ensure a 1 W EIRP in the direction of the tissue (along
the y-axis), the radiation pattern of the antenna must be known. This is measured in
HFSS® and is shown in Figure 2.4. The tissue model is constructed such that its length in
the z- and x-directions are both twice the antenna-tissue separation. This places the
tissue model between -45° and 45° on the antenna’s radiation plot. The peak gain in the
direction of the tissue is -2.3029 dB and lies at ϕ = 90° and θ = 90° (in the direction of
the y-axis). Continuing with the assumption that the matching network efficiency for the
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radiating antenna is 100%, the power input to the antenna can be set to 1.7 W to
compensate for its less-than-unity gain, which leads to a peak EIRP of 1 W.

Figure 2.4 Radiation pattern of a half-wave dipole in the HFSS® simulation environment
with a 3-layer tissue model at 2.4 GHz when (a) φ = 90° and θ is swept from 0° to 180°
and (b) θ = 90° and φ is swept from 0° to 180°. Due to its dimensions and separation
from the antenna, the tissue lies within the region defined by 45° ≤ φ ≤ 135° and 45° ≤ θ
≤ 135°. The local maximum gain within this angular region is -2.3029 dB. © 2013 IEEE.
Oftentimes the resonance of an antenna will shift when objects are introduced to
or moved within its electromagnetic field. For this reason the S11 reflection coefficient
of the dipole antenna was measured in HFSS®, yielding a bandwidth of 2.06—2.48 GHz.
This means the dipole antenna is still an effective radiator for a 2.4 GHz RF source in the
simulation environment even with the effects of the tissue model in the
electromagnetic field.
The distribution of the power flux density incident on the tissue can be imaged by
plotting the real part of the Poynting vector at the air-tissue boundary plane. It is
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expected that the peak incident power flux density will be less than the FCC limit (10
W/m2). The actual simulated maximum is 8.11 W/m2, which is (as expected) within the
safe operating space for RF exposure. One of the benefits of using a high frequency field
simulator is that is can easily and accurately model the reflection of energy at a
boundary between two materials having unique dielectric properties. The power flux
density at the air-tissue boundary in the skin (after reflection on the skin surface) is
shown in Figure 2.5. The maximum power flux density that passes through the skin is
6.56 W/m2.

Figure 2.5 Poynting vector field (directional power flux density) in tissue at the air-tissue
boundary with 1 W EIRP output from a half-wave dipole radiating at a frequency of 2.4
GHz. The maximum power flux density is 6.56 W/m2, which occurs at the surface of the
skin on the y-axis. This is expected since the maximum EIRP condition is imposed along
the y-axis. © 2013 IEEE.
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Further validation of the virtual model may be done by examining the maximum
power absorbed by 1 g of tissue and demonstrating that the SAR limits are not exceeded.
This would corroborate the safe power guidelines established by the theoretical analysis.
The maximum SAR evaluated over 1 g of tissue is evaluated using the HFSS® field
calculator. This is done by first identifying the magnitude and coordinates of the peak
local SAR. Unsurprising, this maximum is found to occur at the origin of the axes on the
surface of the skin where the directional gain of the antenna is largest. The following
equation is used to calculate the total energy absorbed by a 1 g cube of tissue per FCC
specifications:

(2.9)

where Pin is the total power entering a 1 g cube of tissue having mass, m, and Pout is the
total powering leaving the same cube. The net power through a single face of the cube,
Pnet, can be found by taking the dot product of the Poynting vector, S, and the unit
vector normal to the face and integrating over the area of the cube face, F:

∬(

̂)

(2.10)
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A 1 g cube of tissue with a side length of a is defined in the simulation
environment using six square plane. Each face of the cube is assigned a number as
follows: face 1 (F1) lies on the xz-plane and transects the y-axis at the origin, face 2 (F2)
transects the x-axis at x = a/2, face 3 (F3) transects the y-axis at y = a, face 4 (F4)
transects the x-axis at x = a/2, face 5 (F5) transects the z-axis at z = a/2, and face 6 (F6)
transects the z-axis at z = -a/2. The total power absorbed by the tissue in this cube, Ptot,
would then equate to the following:

(2.11)

The field calculator in HFSS® can be used to calculate each of the net power flux terms in
(2.11). The total amount of power absorbed by this cube can then be determined by
substituting the numerator of (2.9) with the sum of the net power flux terms, Ptot. This is
evaluated in the simulation environment with a field frequency of 2.4 GHz, resulting in a
peak absorbed power of 0.36 W/kg in 1 g of tissue. This is much less than the peak
spatial SAR limit (1.6 W/kg over 1g of tissue), which further supports the compatibility of
the tissue behavior in the simulated environment with expected theoretical results.
However, the power flux density in skin at the air-tissue boundary necessary to reach
the FCC’s peak spatial SAR limit in the simulated tissue model calculated is 29.14 W/m2,
which is greater than the 17.76 W/m2 predicted by the theoretical analysis. This
discrepancy between the analytic and numerical peak local SAR calculations can be
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attributed to the observance of the reflection phenomenon as well as the different
tissue dielectric properties in the HFSS® environment.
A comparison can now be made between the power attenuation within the
chest wall at different electromagnetic field frequencies using the validated tissue
model in HFSS®. The model is adapted for operation at 915 MHz and, subsequently, 5.8
GHz. The powering conditions for the simulation at each frequency are made uniform by
equating the power flux density at the surface of the skin to the time-averaged MPE
safety limit at each operating frequency. The simulated power flux density incident on
the implanted device at various implant depths are shown in Table 2.2. Also contained
in Table 2.2 are estimates of the receiving device’s power budget for each implant depth
and field frequency. These estimates are calculated using (2.9) under the assumption
that the receive antenna radiates isotropically and has a matching network loss of 20 dB.
The results are given for three RF-to-DC conversion circuit (rectifier) efficiencies so that
the likely power budgets for different scenarios can be easily compared.
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Table 2.2 Power flux density and estimated implant power budget at four implant
depths within an HFSS® model of a human chest at three ISM bands: 915MHz, 2.4GHz,
and 5.8GHz. In all cases the time-averaged MPE safety limit is imposed on the surface of
the skin to create conditions for maximum allowable power transfer. Usable power is
estimated under the assumptions that there are no losses from the receive antenna
(gain of 0 dB) and matching network loss is -20 dB. © 2013 IEEE.

Powering
Frequency

915 MHz

2.4 GHz

5.8 GHz

Implant Location

Average
Power Flux
Density at
Implant
(W/m2)

Average Usable Power (μW)
Given erec =

Between skin and adipose

4.93

20%
84.4

40%
169

60%
253

Between adipose and muscle

4.64

79.4

159

238

1 cm into muscle

2.37

40.6

81.2

123

2 cm into muscle

1.21

20.7

41.4

62.1

Between skin and adipose

4.38

10.9

21.8

32.7

Between adipose and muscle

3.16

7.86

15.7

23.6

1 cm into muscle

1.57

3.90

7.80

11.70

2 cm into muscle

0.561

1.40

2.80

4.20

Between skin and adipose

4.88

2.08

4.16

6.24

Between adipose and muscle

2.20

0.936

1.872

2.81

1 cm into muscle

0.129

0.0549

0.110

0.165

2 cm into muscle

0.0150

6.38e-3

1.28e-2

1.91e-2

The trend in power loss observed in Table 2.2 is closely correlated with the
results of the theoretical analysis in Section 2.3. The relatively low quantities of power
that may be expected from a far-field WPT link compared to the range of power
requirements for wireless bioelectric sensors reported in Table 2.1 suggest that sourcing
power solely from radiative electromagnetic fields would be insufficient to continuously
operate an active implantable sensor. It is possible that a sensor having a lower average
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power consumption than those given in Table 2.1 could be powered using a far-field RF
WPT link. This might be achieved by implementing power cycling of the entire device or
just the transmitter, which typically consumes the most power. For example, a single
channel recording device with a desired sampling rate of 5 kHz could be turned on once
every 200 μs to sample and transmit the desired signal and then turned off for the rest
of the time. During the off-phase, energy could be accumulated and stored in a
capacitor for use during the next on-phase. If the sampling and transmission of each
data point could be achieved in less than 2μs, then the duty cycle of the on-phase could
be reduced to 1%--conceivably reducing the average power consumption of the device
by a factor of 100. Even more strategic solutions might be implemented such as utilizing
a low power mode to sample and store multiple data points in a buffer and then
transmitting them all at the same time. This would reduce the frequency of transmitter
startup and shutdown, which comes with some power consumption overhead. The
ability to utilize far-field WPT for a wireless implantable sensor would, resultantly, be
contingent upon the design of a system that can implement sufficiently small duty cycles
to reduce average power consumption into the range shown in Table 2.2

2.5

Thermal Safety of Active Implantable Systems

Active implantable devices dissipate heat into surrounding tissue. Sustained
temperature increases can permanently damage or otherwise affect tissue proximate to
the device. The relationship between temperature, time-at-temperature, and extent of
cell death/tissue damage is complex and will depend on the type of biological matter

55
surrounding the heat source [138, 139]. The intended location for implantation of the
wirelessly powered recording device is either subcutaneous or intramuscular, so safe
thresholds for thermal exposure of skin, muscle, and adipose are considered here.
Empirical data for these thresholds exist but are difficult to generalize. However, the
following heuristics might be used: tissue temperature should not exceed 43 °C for
greater than 10 min. and a tissue temperature of less than 39 °C is considered safe for
any length of time [140].
Evaluation of local temperature spikes due to heat diffusion from an active
implantable device is performed by dispersing various quantities of energy in 16.4 mm 3
samples of bovine muscle. This is achieved by supplying a range of voltages across a 1
kΩ resistor. Given Ohm’s Law and power dissipation through a resistive load being the
product of current and differential voltage, the voltage drop across a resistance, R,
necessary to consume a known power level, P, can be equated to √

. For example, a

desired power dissipation of 10 mW is achieved by applying 3.16 V across the 1 kΩ
resistor. The resistor is sealed within a medical epoxy package having dimensions of
11.85 mm x 5.50 mm x 3.95 mm. These dimensions were selected such that they would
resemble the form factors of previously developed implantable myoelectric sensors [141,
142], which have been implanted into muscles at depths up to 1 cm. All muscle samples
are maintained at body temperature (37 °C) throughout the experiment using an
incubator. The device is continuously powered for approximately 15 min. until the
temperature adjacent to the device reaches a steady state. This experiment is repeated
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three times (n = 3) at four different power levels: 10, 20, 30, and 40 mW. Tissue
temperature adjacent to the device within the muscle is recorded in each trial using a
thermocouple paired with LabVIEW for data acquisition. The increase in local tissue
temperature due device heating can be seen in Figure 2.6.
This experiment is intended to estimate the temperature change in tissue
proximate to a device which is drawing current and expelling heat, but a moment should
be taken to acknowledge the limitations of in vitro thermal measurements. Bioheat
transfer is a complex phenomenon—the complete characterization of which includes
irregular boundary conditions, varying thermal characteristics of tissues (density,
specific heat, thermal conductivity, etc.), and complex geometries of the environment.
Additional mechanisms that play a role in thermal regulation include blood perfusion
and metabolic heat production: neither of which is present during in vitro analysis [143].
However, the local temperature measurements in bovine muscle samples give a first
order approximation of temperature changes that may be expected as a result of
thermal diffusion. The results of this experiment indicate that it would take a power
consumption of 40 mW in order to elevate the local temperature in muscle by more
than 1 °C. Since 40 mW far exceeds the amount of power than can be safely coupled
through a far-field wireless link—regardless of the depth of implantation—these results
suggest that unsafe temperature elevation in tissues from thermal diffusion would not
be the primary safety concern in devices that employ far-field RF power transfer.
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Figure 2.6 Temperature increase in bovine muscle measured immediately adjacent to a
device consuming between 10 and 40 mW of power. Three samples (n = 3) are tested at
each power amplitude. Local temperature changes are measured with respect to a
normal body temperature baseline (37 °C) using a thermocouple. © 2013 IEEE.

2.6

Conclusion

The relative potential for health and safety hazards suggested by the results of the
RF exposure and thermal diffusion analyses suggest that the effects of RF exposure —
both thermal and non-thermal—is a greater concern than local temperature elevation
from the thermal discharge of microelectronics. Prior to drawing any conclusion about
the feasibility of far-field RF power transfer for implanted bioelectric sensors, it is crucial
to note that the theoretical and numerical analyses contained in this chapter are all
based on the presumption that MPE limits have been reached. This is a way of
examining the best case scenario for the WPT link. In reality, a freely behaving animal
will rarely be in the optimal location where MPE limits are reached, which only further
diminishes the prospects of far-field RF power transfer for long-term monitoring of
bioelectric activity in small animals.
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However, as noted in Section 2.4, a significant reduction in the duty cycle of a
sensor’s on-phase could reduce the average power consumption to the point that the
power link budget afforded by far-field RF power transfer might be sufficient—even
when MPE limits are not reached. This solution would necessitate the design of a
microelectronic system that achieves sufficiently low on-phase duty cycles of the
transmitter while incorporating an effective power storage strategy. Without significant
examination of the limitations of CMOS design, it is not certain that a system meeting
these requirements is achievable. For this reason, alternative WPT strategies are sought
for continuous power transfer to devices implanted in freely behaving animals.
It is also evident that far-field RF power transfer is not a feasible WPT strategy for
the clinical application of this work. While it is certainly possible that MPE limits could
be consistently applied in the controlled environment of an upper-limb prosthesis, the
extremely low power budgets that can be expected—even under the condition that
MPE limits are reached—for devices embedded 1 cm and 2 cm into muscle are orders of
magnitude less than the power requirements of existing myoelectric sensors. This leads
to the conclusion that an alternative WPT strategy is also needed for the purpose of
delivering power to devices embedded deep in the muscles of amputees.
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CHAPTER 3.

THE MYONODE: AN IMPLANTABLE SINGLE-CHANNEL RECORDING DEVICE

3.1

Introduction

The material presented in this Chapter incorporates content from the journal
article “Enhancing the Versatility of Wireless Biopotential Acquisition for Myoelectric
Prosthetic Control” by R. A. Bercich, Z. Wang, H. Mei, L. H. Smith, K. L. Seburn, L. J.
Hargrove, and P.P. Irazoqui, which has been accepted for publication in the Journal of
Neural Engineering pending revisions. All procedures involving live animals are reviewed
and approved by the Purdue Animal Care and Use Committee. Mice are obtained from
The Jackson Laboratory (Bar Harbor, ME). All experiments involving human subjects are
approved by the Northwestern University Institutional Review Board.
The practical limitations of near-field inductive coupling outlined in Section 1.3.2
and the extremely low far-field power link budget derived in Chapter 2 seem to suggest
that neither inductive nor radiative power coupling is sufficient for continuous WPT to
devices implanted in freely behaving animals. However, recent advancements in the
area of MRC [144, 145] have led to improved PTEs in inductive links that are poorly
coupled (e.g. disparate in size, misaligned, or far from one another). This methodology
utilizes bandpass filter theory to implement optimal impedance matching conditions,
resulting in precisely tuned inductive systems in which the maximum attainable PTE is
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realized. This has been previously suggested as a viable option for power transfer in
long-term animal monitoring with both stationary [146, 147] and non-stationary [148]
external coils
Implementation of the MRC methodology by Henry Mei, a graduate research
assistant in the Center for Implantable Devices at Purdue University, led to the
demonstrated ability of an MRC link to sufficiently couple tens of mW of power to a coil
having a diameter of 1.2 cm using an external coil with a diameter of 13 cm outputting 1
W of power. This corresponds to a PTE in the range of 1-5% rather than < 0.1%, which
may be expected from far-field WPT per the link budget analysis performed in Section
2.3. The implication here is that MRC can enable levels of power transfer between two
coils—having greatly disparate diameters—that would be sufficient to run many of the
wireless bioelectric sensors described in the literature (see Table 2.1). The sufficient PTE
of this particular pairing of coils (13 cm external coil and 1.2 cm receive coil) is
demonstrated in free space with coil-to-coil distances up to 5 cm. Concerns about
power attenuation in tissue are abated by the fact that MRC achieves energy transfer
through magnetic fields, the power flux densities of which are largely unaffected by
biological tissue.
The primary motivation for this work is to develop novel instrumentation for the
study of neuromuscular disease mechanisms in freely behaving mice. Being only 13 cm
in diameter and 5 cm in vertical range, the WPT environment made possible through the
application of MRC methodology is not very large. However, it is sufficient for a mouse
to ambulate normally and is compatible with a receive antenna that is appropriately
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small for subcutaneous implantation in mice (1.2 cm), both of which enable a first pass
at a fully wireless bioelectric sensor. The secondary motivation is to improve neural
interfaces between muscle and upper-limb amputees. Since both of these aims entail
some evaluation of muscle activity, the first microelectronics system is designed
specifically for EMG acquisition and is given a simplified task set: to record and transmit
one channel of data. This single-channel recording system specifically for fully wireless
EMG acquisition is referred to as the Myonode
Two implementation of the Myonode are presented here: one using CMOS
technology and the other using only commercial off-the-shelf circuits on a custom
printed circuit board (PCB). The construction, bench top analysis, and applied in vivo
performance of both designs are summarized in this chapter.

3.2

ASIC Implementation of the Myonode

The first implementation of the Myonode uses CMOS technology to create an
application-specific integrated circuit (ASIC). This method affords the most flexibility and
customizability since the designer may judiciously strip away unnecessary sources of
current consumption to create a system that meets only the necessary functional
requirements. Reduction of average power consumption (a direct corollary of current
consumption) serves as one of the primary objectives for this ASIC as this lessens the
burden on the WPT link, improving its robustness once the device implanted in an
animal.
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The necessary functional blocks for the Myonode’s ASIC include an amplifier, ADC,
RF transmitter, voltage regulators, and digital logic. Figure 3.1 shows a block diagram of
the ASIC within the conceptual design of the full EMG recording device. The design and
simulated performance of the EMG amplifier is described in Section 3.2.1. The
remaining functional blocks of the ASIC are designed by other students from the Center
for Implantable Devices at Purdue University. Specifically, the ADC and clock are
designed by Hansraj Bhamra; the transmitter is designed by Oren Gall; the voltage
regulators are designed by Ashir Shah; and the digital logic is designed by Jithin Joseph.
CMOS design is done on the X-FAB 180 nm process using Cadence software. Bench top
performance of the full system ASIC is summarized in Section 3.2.2. An analysis of
prospects for the ASIC-based Myonode in the context of project needs is the subject of
Section 3.2.3.
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Figure 3.1 Conceptual block diagram of the full Myonode system including the EMG
sensor and transmitter ASIC designed in CMOS (blue), power supply (green), and
expected input signal (red).
3.2.1 EMG Amplifier Design in CMOS
The amplifier block of the EMG sensor ASIC is designed to be fully differential so
that common mode noise sources are effectively rejected from the measured signal.
Power line noise, for example, is a frequent artifact observed in bioelectric signals, so
differential recording is common practice for both sEMG and imEMG [96, 149]. A folded
cascode operational transconductance amplifier (OTA) topology [150] is selected owing
to its relatively low power consumption and pervasive use in CMOS neural amplifiers
within the literature [151-154]. The system is constructed such that it can run off of one
supply voltage (1.8 V). In an effort to keep the first design simple and avoid integration
of voltage inverters, the entire circuit operates in single supply mode, which sets the
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ADC input voltage range between 0 and 1.8 V. This means that the ADC cannot read a
negative voltage. Since differential EMG will exhibit both positive and negative
amplitudes, both inputs need to be level-shifted to the mid-range voltage of the ADC
(900 mV). This is implemented using common mode feedback within the differential
amplifier circuit.
The peak-to-peak amplitude of measured EMG is very much dependent on the
size of the muscle, strength of contraction, and electrode configuration. While it is true
that a larger inter-electrode space will lead to a higher measured amplitude, signal
attenuation through tissue will increasingly affect signal amplitude as separation
between the source and the electrodes increases [155]. When measuring EMG on the
surface of the skin, it is easy to implement larger inter-electrode spacing, but this will
impact signal specificity, amplitude, and frequency content. For this reason it is
important to consider the signal source and characteristics of the desired signal when
selecting an electrode, placing electrodes, and configuring the gain response of the
amplifier.
The maximum amplitude that may be expected from sEMG recorded with gel or
metal dome electrodes is in the range of a few millivolts. Stimulus-evoked potentials,
however, can reach tens of millivolts in peak-to-peak amplitude [149]. The Myonode is
intended to collect both voluntary evoked potentials and stimulus-evoked potentials, so
a low gain of 50 (34 dB) is the target for the bandpass region. It would be best under
circumstances such as these—when different signals having amplitudes that differ by at
least an order of magnitude—to implement adjustable gain. This feature is not included
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in the ASIC in an attempt to keep the operating protocol simple on the first run. The
intention being that, all other elements working properly, this ability may be integrated
on subsequent systems. The resistive and capacitive elements which influence the gain
of the amplifier also impact the bandpass cutoffs of the frequency response. A
simulated gain of 34.7 dB, which is sufficiently close to the 34 dB specification, is
achieved as a result of balancing desired gain and filtering specifications.
The majority of power in sEMG signals is contained in the frequency band from
10 to 500 Hz [149]. The high-pass cutoff used for sEMG ranges from 3 to 20 Hz as it’s
been suggested that some useful information can be obtained about motor unit firing
patterns at frequencies as low as 3 Hz [156]. A low-pass cutoff of 500 Hz is commonly
used for sEMG signals. However, biological tissue behaves like a low-pass filter [157159], so the bandwidth of sEMG is lower in the frequency domain than EMG recorded
from a group of fibers within a muscle or immediately adjacent to a single muscle fiber.
For this reason the low-pass cutoff for imEMG is typically higher than that of sEMG:
between 1 and 10 kHz [149]. Since the Myonode is intended for collection of both sEMG
and imEMG, a bandpass region of 3 Hz to 1 kHz is the design specification.
A two-pole low-pass filter is implemented in the CMOS amplifier through
feedback on the differential amplifier (first stage) and by passive low-pass filters in the
second stage. Figure 3.2 shows a schematic of the full amplifier circuit with stages
delineated. In contrast to ideal operational amplifiers, which have a theoretical output
impedance of 0 Ω, folded cascode OTAs have a large output impedance. As a result, the
feedback resistors (R1 and R2 in Figure 3.2) need to be very large (> 10 GΩ) in order to
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achieve the desired low-pass cutoff. Given process variation in fabrication and the
relationship between resistor length and value, it is impractical and unwise to use very
large resistors or create large resistances by placing many smaller resistors in series.
Some circuit designers have used transistors biased in the sub-threshold region to
create large pseudoresistances [160, 161]. However, this requires additional biasing
circuitry so, instead, a MOS-bipolar device described in [125] is implemented here to
create a large pseudoresistance in place of R1 and R2 (see Figure 3.2).

Figure 3.2 Circuit schematic of fully differential amplifier implemented on X-FAB 180 nm
CMOS process. First stage is designed using a folded cascade operational
transconductance amplifier (OTA) topology. Amplifier is AC coupled using front-end
capacitors. Two-pole low-pass filter is implemented through feedback in the first stage
and passive filtering in the second stage.

The second stage is buffered on both sides to isolate the passive filter and
prevent shifting of the pole frequency due to influences of the first stage or loading
from the ADC. The combined result of these filters is a simulated low-pass cutoff of 1.03
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kHz, which is sufficiently close to the 1 kHz specification. The amplifier is AC coupled
with capacitors C1 and C2 in order to prevent DC offsets or very low frequency signals—
such as motion artifact—from reaching the amplifier inputs, which might cause
saturation and railing at the outputs.

3.2.2 Full System ASIC Evaluation
The full system’s functional protocol is clocked at 250kHz and has a data rate of
50 kbps. The ADC sampling rate is fixed at 5 kHz, which is selected based on the Nyquist
frequency of the intended signal to avoid aliasing. The RF transmitter uses an on-off
shift keying (OOK) protocol with a 4-bit start code and a 4-bit stop code to communicate
each digitized 10-bit sample of EMG data. Figure 3.3(a) illustrates the full system ASIC
layout in Cadence with the amplifier block highlighted in yellow. The final fabricated
chip along with its physical dimensions is shown in Figure 3.3(b). Table 3.1 outlines the
key performance specifications of the full system alongside the measured results for the
same parameters from a sample system.
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Figure 3.3 Full system ASIC designed in 180 nm CMOS process for single-channel EMG
recording and telemetry with the amplifier circuit highlighted in yellow. (a) ASIC layout
in Cadence software and (b) image of the fabricated full system chip with a measured
footprint of 0.55 mm x 1.25 mm.
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Table 3.1 Summary of simulated and measured parameters of the single-channel EMG
recording and telemetry ASIC.
Parameter

Simulated

Measured

Units

Peak gain

34.7

36.2

dB

High-pass cutoff

2.32

32

Hz

Low-pass cutoff

1.03

1.45

kHz

ADC resolution

10

10

bits

Max. input amplitude

33

28

mVpp

Sampling rate

5

5

kHz

Supply voltage

1.8

1.8

V

Power consumption

0.67

1

mW

Transmitter Frequency

2.4

2.46

GHz

The measured results shown in Table 3.1, which represent the performance of a
sample Myonode ASIC indicate that this chip is able to perform the assigned task set of
amplifying, filtering, sampling, and transmitting EMG. It may be noted that some
parameters such as filter cutoff frequency have drifted—possibly as a result of process
variation. Two clear advantages of this ASIC should be highlighted: first, the low power
consumption relative to other bioelectric sensors (see table 2.1) and, second, the small
footprint, which is amenable to subcutaneous implantation in very small animals.
This ASIC is used for in vivo EMG acquisition in an anesthetized mouse in parallel
with a commercial preamplifier so that the measured signal of both instruments may be
compared. The experimental procedure begins with blunt dissection to the sciatic nerve
of a mouse. A two-contact platinum iridium cuff electrode is placed around the sciatic
nerve and two needle electrodes are inserted into the biceps femoris muscle on the
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ipsilateral side such that the inter-electrode spacing is 5 mm. Then a stimulus current is
applied to the sciatic nerve through the cuff electrode and the evoked CMAP is recorded
from the muscle. The stimulus current amplitude is gradually increased—recruiting
more axons and their innervated muscle fibers—until the amplitude of the CMAP
response stops increasing. This yields a maximum CMAP which is congruous with
published results [23]. The same maximum CMAP recorded from both a commercial
preamplifier (P511, GRASS Technologies) and the Myonode ASIC are pictured in Figure
3.4.

Figure 3.4 Compound motor action potential (CMAP) recorded acutely in a wild-type
mouse using needle electrodes with an inter-electrode spacing of 5 mm. The same
CMAP is recorded from the biceps femoris muscle of a mouse using the Myoode ASIC
(blue) and a neural preamplifier (P511, GRASS Technologies) with the gain adjusted to
35 dB (red).
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During this experiment the Myonode ASIC is powered using a DC voltage supply.
The closely matched waveforms measured by the Myonode ASIC and a standard bench
top apparatus shown in Figure 3.4 are a promising outcome for the ASIC-based system.
This might encourage the next logical step to be taken: integrate the Myonode ASIC with
a rectifier and coils designed for MRC power transfer so that the system may be
wirelessly powered. However, there are significant functional and practical impediments
to using this ASIC in chronic animal studies or for clinical neural interfaces for upperlimb amputees. An evaluation of these obstacles as well as possible solutions is
conferred in Section 3.2.3.

3.2.3 Limitations of ASIC-Based System
One of the most critical limitations of the ASIC-based Myonode is the extremely
low yield of working ASICs (less than 5%) from the fabricated wafer. This is a significant
practical concern given the time needed to test each system, which is done using a
probe station owing to the very small size of the input and output pads. Additionally, the
ASIC must be adjoined to a rectifier and some implement for wireless power coupling
before the system can operate in a WPT environment. This has the advantage of
modularity but increases complexity in an already delicate and miniature build process.
Neither of these obstacles is necessarily a showstopper. However, the ultimate
limitation is that the ASIC is one-trick pony without any flexibility in operation or
performance. This makes the effort and expense of putting together even a small
quantity of devices that could be implanted in animals fall out of balance with the utility
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of the end-product. Specifically, the gain, bandwidth, sampling rate, and telemetry cycle
of the ASIC—all of which are fixed—mean that a different system would need to be
designed for each signal of interest.
Alternatively, it is possible that some flexibility might be built into the ASIC
through features like programmable gain, tunable filters, and flash memory for
reprograming the device’s functional protocol. These are highly advanced elements,
though; which means they require large amounts of time and expertise to implement.
Not to mention the three- to four-month lead-times associated with fabrication of
CMOS ICs. But perhaps the most compelling reason to avoid building such a complex
system in CMOS is the fact that much of the effort is put into building circuit elements
that may be thought of as “overhead”—that is, a replication of circuits that already exist
and are available off-the-shelf. These commercial ICs are designed by experts for a
variety of general and niche applications Moreover, the natural progression towards
miniaturization in electronic technology means that most ICs come in very small form
factors. Using only commercial ICs would allow a system to be built up from relatively
small—in both function and size—components while leveraging the availability of
sophisticated and reliable circuits. This has the added benefit of being replicable by
other investigators interested in building and using the tool rather than negotiating the
use of a proprietary circuit, which is better for the purposes of knowledge sharing in the
scientific community.
This is not to say that a final, polished design wouldn’t be best implemented in
CMOS. However, given the developmental state of the project and the fact that the
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engineering design process is iterative in nature, it is wisest to work with modular and
easily integrated parts for quick prototyping and testing. For this reason device design in
CMOS is deferred and the remainder of this work is focused on the development of
miniature microelectronics systems for fully wireless bioelectric data acquisition that is
built using only commercially available, off-the-shelf components.

3.3

Custom PCB Implementation of the Myonode

The second implementation of the Myonode uses only commercially available ICs
and passive components assembled on a custom designed PCB. This leverages the
cutting edge in state of the art electronics while simultaneously increasing the reliability
of the end device. This system offers a comprehensive and non-proprietary solution to
many of the logistical challenges associated with device development as well as
recording biopotentials chronically in both humans and small animals.
All microelectronic elements are available off-the-shelf and include an established
ARM Cortex-M0 processor. This sidesteps many of the practical impediments of working
with ASIC-based systems by simplifying replication of the system and facilitating rapid
changes to its functional protocol afforded by reprogrammable firmware. In fact, one of
the most exciting prospects of this technology is the ease by which more advanced
processing tasks could be outsourced to the onboard microcontroller. For example,
some processing tasks for advanced pattern recognition prosthetic control algorithms
[86] might be incorporated in firmware so that directives rather than raw data are
telemetered to the prosthetic limb. By integrating some level of processing or decision-
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making prior to data transmission, a prosthetic control algorithm’s performance might
be augmented, accelerated, or in other ways enhanced. Flexible data processing and
consolidation implemented in rewritable firmware may also prove to be a means of
reducing total device power consumption by reducing the amount of data that is
transmitted (and thereby reduce the RF transmitter’s “on” time).
The circuit design, integration, prototype build process, packaging, and bench
top evaluation of the custom PCB-based Myonode are covered in this section.
Throughout the design phase, particular attention is given to the size constraints that
come with working in mice. The maximum physical dimensions and permissible weight
of the implant become even more restrictive when one considers that mouse models for
neuromuscular diseases tend to be smaller than their wild-type counterparts owing to
dysfunctional development or atrophy of skeletal muscle [162, 163]. Conceding that the
device must be suitable for implantation both healthy and disease model mice results in
a single-channel bioelectric sensor with a significantly smaller volume and mass than
any comparable commercially available system.
The task set for the custom PCB-based Myonode is the same as the task set for
the ASIC-based Myonode: continuous acquisition and telemetry of EMG. Key duties
performed by the microelectronics integrated on the custom PCB include filtering,
sampling, digitizing, and transmitting recorded data in real-time. The analog front-end
(AFE) circuit for amplifying and filtering EMG prior to digitization is described in Section
3.3.1. The circuit structure for wireless power rectification and management is
described in Section 3.3.2. The integration of the AFE, power management circuitry, the
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MCU that orchestrates the functional protocol of the device, and the MCU’s required
peripherals is the subject of Section 3.3.3. Layout of the custom PCB and build
procedure for the Myonode is also covered in Section 3.3.3. The bench top performance
of the PCB-based Myonode is presented in Section 3.3.4.

3.3.1 AFE Design Using Commercial ICs
The AFE of the custom PCB-based Myonode is a differential recording channel
comprised of a low-gain instrumentation amplifier (Texas Instruments, INA333) followed
by a second gain stage that incorporates an active low-pass filter (see Figure 3.5 for a
circuit schematic of the full AFE). The INA333 is selected for its high common-mode
rejection ratio (CMRR) (100 dB), high input impedance (100GΩ), low power
consumption (50μA), and appropriately small footprint (3 mm x 3 mm) [164]. One
significant advantage to building the system from off-the-shelf components is the ability
to adjust gain and bandpass filter cutoff frequencies as needed. Typically a majority of
the gain is allocated to the second stage so that any DC offsets and low frequency
signals from motion artifact or rectification of high-frequency noise is removed prior to
significant amplification as these may otherwise cause the signal to rail.
Gain on the first stage is typically 10 (20 dB)—the minimum necessary to achieve
the peak CMRR from the INA333. This gain is set using a single resistor as directed in
[164]. The second stage gain is usually 30 (29.5 dB) for sEMG, resulting in a total AFE
gain of 300 (49.5 dB). Second stage gain is usually 100 (40 dB) for imEMG, resulting in a
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total AFE gain of 1,000 (60 dB). Second stage bandpass gain may be calculated using the
known gain equation for an inverting operational amplifier:

(3.1)

Prior to the instrumentation amplifier, the signal passes through a first-order,
low-pass filter. Both inputs are DC biased to a mid-supply common mode voltage
(designated CM in Figure 3.5) using pull-up resistors (R1 and R2 in Figure 3.5), which is
necessary when using the INA333 in single-supply mode. Following passage through a
buffer, this mid-supply voltage (designated REF in Figure 3.5) also provides a reference
voltage to which the INA333 level-shifts its output. This same buffered voltage reference
is supplied to the non-inverting input of the second stage op amp to maintain the midsupply offset at the output of the AFE, which goes directly to the ADC. This DC offset is
necessary since the SoC operates in single supply mode and its ADC can only read
positive voltages. The buffer in Figure 3.5 prevents high frequency noise that may shunt
to the common-mode supply voltage (CM in Figure 3.5) from coupling into the second
stage of the amplifier and injecting noise into the downstream signal path.

77

Figure 3.5 Analog front-end (AFE) of the custom PCB-based Myonode. The AFE consists
of a low-gain first stage instrumentation amplifier and a higher gain second stage
inverting amplifier. A mid-supply reference voltage is generated by a low drop-out (LDO)
regulator and buffered to create a low impedance source. A low-pass filter prior to the
instrumentation amplifier serves to remove high frequency noise from induced by the
incident electromagnetic field necessary for wireless power coupling. A high-pass filter
between the first and second stages AC couples the signal and an active low pass filter in
the second stage allows for selection of the low-pass cutoff frequency.

The front end low-pass filter serves to shield alternating currents induced by the
incident electromagnetic fields (which have frequencies in the single to tens of MHz)
from the instrumentation amplifier inputs where they can be rectified into large
amplitude, lower frequency noise that lies within the signal bandwidth. The bandwidth
of the entire AFE may be estimated using established RC filter equations as follows:
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(3.2)

(3.3)

where fhp is the high-pass cutoff frequency and flp is the low-pass cutoff
frequency.
More precise estimations of the AFE frequency response and small signal
transient response are done using Simulation Program with Integrated Circuit Emphasis
(SPICE)-based software. TINA-TI, a circuit simulator developed by Texas Instruments, is
used here to take advantage of its library of component macros, which includes the
INA33. Figure 3.6 shows the Bode magnitude and phase responses of the AFE
configured for measurement of imEMG in a mouse. Figure 3.7 shows the simulated
small signal response to a 100 Hz, 1 mVpp for the same AFE configuration. The TINA-TI
circuit simulation is also used to select the appropriate passive component values to
attain desired AFE gain and bandwidth for other applications such as sEMG for
prosthetic control.
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.
Figure 3.6 Bode gain and phase responses of the Myonode analog front-end (AFE)
simulated in TINA-TI. AFE is configured for with a bandpass gain of 60 dB and a
bandwidth of 10—1,000 Hz.

Figure 3.7 Small signal transient response of Myonode analog front-end (AFE) to a 1
mVpp sinusoidal input waveform at 100 Hz, where the phase delay is exactly 180°.
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3.3.2 Power Management Circuitry
Conversion of applied magnetic fields into a usable voltage supply is achieved by
the rectifier and power management circuit shown in Figure 3.8. Alternating currents
induced in receiving coil are capacitive filtered through an impedance matching network
(K-inverter) before being rectified to a DC voltage. The rectifier topology used in this
device is a single stage bridge rectifier. A storage capacitor on the output of the rectifier
serves to buffer the supply voltage during short bursts of elevated current consumption,
such as those that occur when the transmitter is turned on to send data. The rectified
voltage is regulated to 1.8 V by a low-dropout (LDO) linear voltage regulator. This
regulated voltage supply is used to power all active circuit components. Subsequently,
this voltage is down-regulated to 0.9 V to provide a stable common-mode reference
voltage to the AFE (see Figure 3.5). Stabilizing capacitors are used at the outputs of both
regulated voltages and decoupling capacitors are placed proximate to IC power supply
pins to reduce the effects of electromagnetic interference (EMI).

81

Figure 3.8 Power rectification and management circuitry on the custom PCB-based
Myonode. Incoming alternating currents are capacitive filtered in the k-inverter (C1 and
C2) and rectified to a DC voltage in a single stage bridge rectifier. A stabilizing capacitor
(C5) serves to buffer the supply voltage from spikes in current consumption and is
placed in parallel with a 5.6 V Zener diode, which protects the regulator from rectified
voltages above its maximum input voltage.

All power necessary to run the Myonode’s microelectronics is wirelessly coupled
to the system using the MRC strategy implemented by Henry Mei. This design method
enables the realization of maximum attainable PTE. This method works by implementing
analytically derived optimal impedance matching conditions suggested by the bandpass
filter model of inductive links. This allows the WPT link to be precisely tuned for optimal
PTE to single or multiple receive devices [165, 166].
The WPT link is designed for operation at 13.56 MHz. This is selected by a
combination of factors including desired dimensions of the testing environment (which
influences the geometry of the external coil) as well as considerations for the
designated ISM radio bands. The source for the electromagnetic field is supplied by an
RF signal generator (Agilent, N5182A) and amplified by a class E amplifier (Mini-Circuits,
ZHL-1-2W-S+). In the course of all bench top and animal work the power level emitted
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by the external coil is kept below maximum output power requirements as designated
by the FCC regulations for intentional radiators [106].

3.3.3 Full System Integration and PCB Design
Device logic is mediated by a central MCU. The MCU employed in this device is a
32-bit ARM® Cortex™ M0 within a low-power system-on-chip (SoC) package (Nordic
Semiconductors, nRF51822). This SoC has a built-in 8/9/10-bit ADC which receives data
in the range of 0-1.8V from the AFE. It also has an embedded 2.4GHz transceiver which
outputs modulated data packets through a balun and finally to a ceramic 2.4GHz chip
antenna (Johanson Technologies, 2450AT07A0100). System logic and operations are
clocked at 16 MHz by means of an off-chip crystal oscillator. Figure 3.9 shows a
schematic of the microcontroller and its peripherals.
The Myonode is enabled with wireless data telemetry through an embedded
transceiver on the low power SoC. The sampling rate of the system is typically set to 5
kHz, which requires the MCU to wake up from sleep mode every 200 μs, record a data
point, then go back to sleep. Utilizing sleep mode is one of multiple strategies employed
to reduce total power consumption. In addition to running all active components on the
lowest possible voltage supply (1.8 V), the device is able to save power by putting
samples into packets for transmission rather than sending each sample independently.
This minimizes overhead power consumption from transmitter startup and reduces the
total amount of time in which the transmitter is active; a state in which it draws a
current of approximately 14 mA. However, as the packet size increases, the probability

83
of data corruption during wireless transmission becomes higher. To balance between
efficiency and data integrity, a payload length of 32 bytes is chose. Once 31 bytes of
data is collected, the microcontroller triggers the transmit task and the transmitter uses
direct memory access to retrieve the 31 samples stored in memory and puts them in the
payload. Each packet of data consists of a 5-bit preamble and 5 bytes of address
information followed by the payload (1-byte packet ID + 31 bytes of data) and, finally, a
2-byte cyclic redundancy check. The firmware for the Myonode is written in C
programming language by Grant Wang, a member in the Center for Implantable Devices
at Purdue University.
The device communicates with a base station using the telemetry protocol
developed by Nordic Semiconductor. The base station’s functional tasks are regulated
by the same Nordic Semiconductor SoC as the Myonode. It receives data packets
through the integrated receiver which has a sensitivity of -85 dBm for a 0.1% bit error
rate (BER) at 2 Mbps. The data is sent via a serial-peripheral interface (SPI) to a
computer where is can be plotted in real-time and saved. In the case where multiple
devices are operating in an array, the base station can receive data from up to eight
channels simultaneously by the sharing the SPI bus. Additionally, each device is assigned
a unique 2 MHz-wide channel within the 2.4 GHz ISM band to avoid interference and
synchronization issues. In all cases the wireless signal is modulated using Gaussian
frequency shift keying (GFSK).
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Figure 3.9 Circuit schematic of the system-on-chip (SoC) and its essential peripheral
components for timing and data transmission, which are used in the custom PCB-based
Myonode. The nRF51822 SoC has an integrated analog-to-digital converter (ADC), 2.4
GHz transceiver, and 32-bit ARM® Cortex™ M0.

The AFE, power rectification and management circuitry, MCU, and necessary
MCU peripherals are integrated on a custom 4-layer PCB fabricated by Sierra Circuits.
Efforts to miniaturize the finished device implored that the following custom PCB
specifications be used: 0.004” minimum trace width/spacing, 0.006” minimum via
diameter, 0.03” finished board thickness and one blind via set on an FR-4 dielectric
substrate. A low temperature solder paste (Chip Quik, SMDLTFP) is used to assemble
microelectronic components on the board. Following assembly the firmware is
programmed into the MCU’s flash memory through a peripheral 10-pin M50 vertical
male header that is not part of the final device. This header is detached and the extra
board material is removed to minimize the size of the finished device, which has
dimensions of 5mm x 8 mm x 2.7 mm.

85
The recording electrode pair is connected to the microelectronics through two
0.3 mm vias and set with a two-part silver conductive epoxy (8331S-15G, MG Chemicals).
Devices built for chronic implantation use 304 series stainless steel wire (0.051 mm
diameter) insulated with nylon to connect the board to two gold pad electrodes
deposited on a parylene substrate similar to a patch or epimysial electrode. The
geometry of the electrode pads used for the in vivo experiments is square with a side
length of 0.5 mm and an inter-electrode spacing (center to center) of 3 mm.
The receiving coil for chronic implantation in mice is assembled using 22 AWG
magnet wire (Belden, 8051) and is formed by making three turns around a rod with a
diameter of 12 mm. The coil is connected to the PCB by soldering to pads connected to
the inputs of the K-inverter. The receiving coil adjoined to the PCB can be seen in Figure.
3.10. The final step in assembly is the process of sealing the device, which is done using
parylene C deposition. Parylene C is a conformal dielectric with demonstrated biological
inertness [167]. It is vapor deposited onto the device to a thickness of 20 μm prior to
implantation.
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Figure 3.10 Myonode device constructed from commercial microelectronics integrated
on a custom PCB which measure 5 mm x 8 mm x 2.7 mm once assembled. The PCB is
affixed to a rigid receive coil having a diameter of 1.2 cm and a thickness of 3 mm, which
is tuned for MRC power transfer with an external transmitting coil having a diameter of
13 cm.

Alternatively, coils printed on a thin, flexible substrate are designed to reduce
the effective footprint of the receive coil and better sustain dynamic loading and flexural
stress, which are expected in both applications of the Myonode. These coils are 15 mm x
15 mm and are printed on a polyimide substrate fabricated by FlexPCB (see Figure 3.11).
They have a total thickness of 0.13 mm and a minimum bend radius of 0.91 mm, which
allows them to conform to the shape of a body. This may improve biocompatibility for
subcutaneous implantations in mice and simplify integration with fabric body liners for
the purposes of sEMG control of upper-limb prostheses.
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Figure 3.11 (a) Rendering of receive coil fabricated on a flexible polyimide substrate with
2 oz. copper deposition and insulating polyimide coverlay. Coil footprint is 15 mm x 15
mm and has a finished thickness of 0.13 mm. (b) Picture of the fabricated flexible coil.

3.3.4 Bench Top Performance of the Myonode PCB
The assembled Myonode PCB is put through a series of engineering confidence
tests prior to being used for bioelectric data acquisition. These include a fidelity check, a
wireless powering check, and a soak test. The data fidelity check is performed by
applying a sinusoidal waveform across the differential inputs and comparing the known
input waveform to the reconstructed signal following digitization, transmission, and
reconstruction. An example of this is given in Figure 3.12 for a device configured to
collect sEMG. The wireless powering check entails placing the finished device in the WPT
environment and observing successful device power up and data transmission. The soak
test is carried out through submersion of the packaged device in 0.9% phosphate buffer
solution (PBS) for 24 hours followed by a second wireless powering check.
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Figure 3.12 Data fidelity test for a device configured for sEMG collection. Analog frontend (AFE) gain is set to 300 (49.5 dB)

The frequency response of the AFE circuit is measured using a dynamic signal
analyzer (Agilent, 35670A) and is shown in Figure 3.13. The measured result is a close
match with the Bode plot generated by the TINA-TI circuit simulation given in Figure 3.6.
The input-referred noise of the system is quantified by measuring the power spectral
density (PSD) at the AFE output when the differential inputs are shorted together and
subsequently factoring out the gain response. Integrating the measured PSD, which is
shown in Figure 3.14, over the recording channel bandwidth yields the peak-to-peak
input-referred voltage noise, which is 2.3 Vpp.
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Figure 3.13 Measured frequency response of the custom PCB-based Myonode analog
front-end (AFE) configured for intramuscular EMG (imEMG) recording. Bandpass gain is
60 dB, high-pass -3 dB cutoff is 10 Hz, and -3dB cutoff is 1 kHz.
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Figure 3.14 Measured input-referred noise power spectral density (PSD) of the analog
front-end (AFE) on the custom PCB-based Myonode. Integration of the PSD over the
bandwidth results in a total input-referred noise of 2.3 μVpp.
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The common-mode gain of the recording channel is measured on the dynamic
signal analyzer by shorting the differential inputs together and applying a sinusoidal
input waveform with an amplitude of 700 mVpp while sweeping the frequency across
the bandwidth. The input waveform amplitude is selected so that it is large enough to
be detected at the highest common-mode attenuation without railing the AFE at the
frequency of lowest common-mode attenuation. Using both the differential and
common-mode gain measurements allows the CMRR of the AFE to be calculated:

( )

(

( )
)
( )

(3.1)

where Ad(f) is the frequency dependent differential voltage gain and Acm(f) is the
frequency dependent common-mode voltage gain. Figure 3.15 plots the calculated
CMRR from 1 Hz to 5 kHz and reveals that the CMRR is greater than 80 dB from 1 to 100
Hz. This is important because the largest expected common-mode noise source is power
lines, which create electromagnetic fields oscillating at 60 Hz. It is of interest to note
that the reported CMRR of the INA333 instrumentation amplifier is >100 dB . The reason
for this discrepancy is the addition of passive elements (resistors and capacitors) prior to
the instrumentation amplifier input (see Figure 3.5). These circuit elements are
necessary for single supply function within the WPT environment, but cause CMRR
depletion due to mismatch in their values (surface mount chip components of this size
tend to have tolerances between 1 and 5%). While on the low end, a CMRR of 80 dB
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meets the minimum recommended specification for EMG [168].Table 3.2 serves to
consolidate this and other performance specifications for the custom PCB-based
Myonode.
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Figure 3.15 Measured common-mode rejection ratio (CMRR) of the analog front-end
(AFE) on the custom PCB-based Myonode. Input waveform was common to both AFE
inputs and was 700 mVpp in amplitude.
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Table 3.2 Summary of custom PCB-based functional parameters. Minimum and
maximum values given for adjustable parameters and reflect ranges used in this work.
Typical values represent default settings or measured characteristics.
Parameter

Conditions

Min

Typ.

Max

Unit

Bandpass gain

40

60

66

dB

High-Pass filter cutoff

0.1

10

--

Hz

Low-Pass filter cutoff

--

1

5

kHz

ADC digital resolution

8

8

10

bits

ADC analog resolution

--

4.7

0.6

µV

f = 10Hz to 1kHz

--

2.3

--

µVpp

f = DC to 60Hz

--

>80

--

dB

Sampling rate

--

5

20

kHz

Transmission (data packet send) rate

--

161

--

Hz

-20

4

4

dBm

Transmission center frequency

--

2.4

--

GHz

Transmission channel bandwidth

--

2

--

MHz

Input-referred voltage noise
Common-mode rejection ratio

Transmitter output power

Average current consumption

Sampling Rate = 5kS/s

--

1.6

--

mA

Average power consumption

Sampling Rate = 5kS/s

--

2.9

--

mW

3.4

In Vivo EMG Acquisition in Mice

The in vivo validation of the Myonode involves implantation of the device in both
wild-type and disease model mice. The purpose of these experiments is threefold: first,
to confirm that the packaging strategy is viable for device implantation; second, to
determine whether or not the device is suitably small for subcutaneous placement in
mice; and third, to observe the fidelity of power transfer within the WPT environment.
An explanation of the surgical methods and experimental procedures used to
successfully measure voluntary and spontaneously evoked EMG in both wild-type mice
and a familial MD disease model are contained in this section.
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3.4.1 Experimental Design and Methods
The first in vivo test for the fully wireless Myonode is to measure a known
stimulus-evoked response with animal under anesthesia. This serves as a final check to
be sure that the electrode design and configurable circuit parameters have been chosen
and implemented correctly. The device’s recording electrodes are placed on the surface
of the lateralis gastrocnemius (LG) muscle and 100 μs-long stimuli are applied to the
sciatic nerve using a bench top stimulator. Stimulus frequency is kept low (0.5 Hz) to
avoid time-dependent changes in the measured response as a result of nerve
desensitization or muscle fatigue, and the evoked responses are recorded at a sampling
rate of 5 kHz. The stimulus current amplitude is gradually increased until an evoked
response is observed. Figure 3.16 illustrates a series of five stimulus-evoked CMAPs
measured by the Myonode in response to a stimulus pulse with a current amplitude of
72μA (charge of 7.2 nC per cycle).

Figure 3.16 Five superimposed compound muscle action potentials (CMAPs) measured
from the lateral gastrocnemius (LG) muscle by the fully wireless Myonode in response to
100μs, 72μA stimulation applied to the ipsilateral sciatic nerve.
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Following demonstration that the device—as well as its supporting hardware
and software—can collect and reconfigure a CMAP response, the device is implanted in
a mouse to record chronic, voluntary evoked EMG. The surgical procedure includes a 1
cm incision transverse to the animal’s midline while in the prone position. Blunt
dissection technique is used in the midsection of the back to create a pocket for the
device to be inserted subcutaneously. The electrode pads are placed on and sutured to
the surface of the biceps femoris. Electrode sutures are placed at the junction between
the electrode leads and pads and the device is secured to the fascia by two suture loops
around the receive coil. The biceps femoris muscle is the selected target for the first
implantation since it is close to the animal’s midsection, where the bulky device will fit
under the loose skin without inhibiting motion of the limbs. This allows the surgeon to
avoid making a larger single incision or second incision in order to reach a target that is
more remote relative to the device. Following recovery the animal is placed inside the
WPT environment for data collection.
The WPT testing environment constructed for untethered mouse work consists
of a two-turn transmitting coil made from 10 AWG copper wire made to fit around the
base of a tub with a 13 cm diameter as shown in Figure 3.17. The dimensions of this
environment are selected such that there would be sufficient coupling between the
transmitting and receiving coil at any point within the enclosed space and sufficient
room for the mouse to comfortably move. Both of these aims are achieved within while
maintaining an output (transmitting) power below 1 W using the testing environment
shown in Figure 3.17.
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Figure 3.17 Experimental setup for chronic implantation of custom PCB-based Myonode
in freely behaving, untethered mice. The wireless power transfer (WPT) environment
consists of a power transmitting coil encircling a tub with a 13 cm diameter (green). The
RF signal is sourced from a waveform generator (blue) and amplified through a class E
amplifier (orange). Data is telemetered from the implanted Myonode to a base station
(yellow), which relays the data to a software interface (red) through a USB interface.

3.4.2 Collection of Voluntary Evoked EMG in Wild-Type Mice
All wild-type mice are from the C57BL6/J (Black 6) strain. The in vivo EMG
collected from a freely behaving wild-type mouse is shown in Figure 3.18 along with
baseline data collected while the mouse is under anesthesia. These data are recorded
from epimysial (pad) electrodes on the biceps femoris. The data collected on day 1 show
the characteristic, periodic interference patterns as the mouse moves around the WPT
environment. This is an exciting outcome as it demonstrates that the device and
integrated WPT strategy can enable collected of voluntary evoked EMG from an
untethered, freely behaving animal. However, after three days post-implantation, the
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EMG signal is visibly deteriorated and eventually lost within the noise floor. It is
suspected and subsequently confirmed that this is due to a mechanical failure of the
electrode leads, which caused one of the differential inputs to float.
The wild-type mouse experiment is terminated at day 16 so the device can be
explanted and inspected. Importantly, though, the device continued to work in the WPT
testing environment, suggesting that the surgical and packaging strategies will support
long-term viability.
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Figure 3.18 EMG recorded from biceps femoris muscle of a mouse over the course of 16
days. Baseline data is collected from anesthetized animal immediately following device
implantation. Signal deterioration over time is due to a mechanical failure at the
junction between the electrode pad and lead. Device operation and telemetry is
successful for 16 days at which point the experiment is ended so that the device may be
explanted and examined. All data has been digitally bandpass filtered (5Hz-1kHz
passband) and notch filtered at 160Hz and all 160Hz harmonics to remove periodic noise
associated with data transmission.

3.4.3 Collection of Aberrant Muscle Activity in Neuromuscular Disease Model
A Myonode device is implanted in a mouse model for familial MD to collect
disease-related aberrant muscle activity. The surgical procedures and device placement
are identical to those used for chronic implantation in wild-type mice. In this case the
device is implanted in a mouse that has a mutation of the nmf417 allele in the LAMA2
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gene (strain C57BL/6J-Lama2dy7J/J). Mutations of the LAMA2 gene cause congenital MD
type 1A in humans [169]. This model is characterized by hypomyelination, muscular
degeneration, and eventual loss of hind limb function. As peripheral nerves and muscle
become affected, large, transient muscle fasciculation can be seen. This overt
phenotype is the reason that this particular disease model is selected for early
applications of the Myonode. EMG associated with these fasciculation can be recorded
from the mouse during stationary periods in which spontaneous contractions of the
hind limb are observed.
Figure 3.19 illustrates aberrant muscle fasciculation collected from a familial MD
model mouse using the fully wireless Myonode in the WPT testing environment. This
electrophysiological phenotype is recorded during a stationary period (no ambulation)
which spontaneous contractions of the hind limb are observed. This is one example of a
disease signature that can be tracked with relative ease using a fully wireless and
implantable biosensor. This signature can be used to better understand disease
progression or evaluate novel therapies without the potential confounds introduced by
a tethered apparatus or battery replacement in a battery-powered system.
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Figure 3.19 Aberrant muscle fasciculation measured from the biceps femoris muscle of a
mouse model for familial muscular dystrophy (MD). The animal is stationary during the
recording period during which time spontaneous contractions of the hind limb are
observed.

3.5

Human EMG Measurement for Prosthetic Arm Control

In this section the custom PCB-based Myonode is used to collect human imEMG
and sEMG, which is subsequently integrated with established myoelectric control
schemes to direct both virtual and electric-powered upper-limb prostheses. One of the
goals for the wireless, single-channel Myonode is to embed multiple devices in an array
within muscles to create reliable neural interfaces for upper-limb prosthesis control. The
current shape and size of the device does not permit intramuscular implantation, so
further refinement of the device and an institutional review board (IRB) approval is
needed before this can happen. In the interim, however, two of the most critical
capabilities of the device may be tested: first, its ability to measure the desired signal
and, second, its ability function when placed in an array with other devices.
Human-subject imEMG is collected to demonstrate that the device can retrieve
useable EMG from a differential electrode pair embedded in muscle. Human-subject
sEMG is used to test an array of eight devices functioning simultaneously. In both cases
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the usability of the measured EMG is demonstrated by interfacing it with established
myoelectric prosthetic control systems.

3.5.1 Collection of imEMG from an Able-Bodied Human Subject
An imEMG signal from the extensor carpi radialis longus (ECRL) muscle in an
able-bodied human subject is collected with the fully wireless device and used to control
a powered prosthetic arm in development at the Rehabilitation Institute of Chicago
[170]. The imEMG is collected using bipolar fine wire EMG electrodes (Natus Medical,
Inc.) that are connected to the Myonode through an interposer board. Fine wires are
introduced into the ECRL muscle using a hypodermic needle. The insertion location is
guided by reference texts [171] and confirmed with corresponding test contractions.
The EMG is sampled at 5 kHz. The mean absolute value (MAV) of the EMG signal is
calculated from a 250 ms sliding window with a 50 ms frame increment. The MAV is
used as the input to a three-state configuration of single-site myoelectric control [77].
The magnitude of the MAV signal is mapped to one of three possible states in
this myoelectric control system: no motion, hand close, or hand open. The mappings is
determined by two thresholds on the MAC signal, which delineated three ranges
corresponding to the three states. The no motion state resulted from MAV activity less
than the lower threshold; the hand close state resulted from MAV activity between the
two thresholds, and the hand open state resulted from MAV activity greater than the
higher threshold. Threshold values are set empirically by the experimenters—similar to
clinical methods—such that the user could repeatedly differentiate between all three
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states without fatigue. When in either of the two active states, the prosthesis is moved
at a constant velocity.
Figure 3.20 depicts imEMG collected by the Myonode from the ECRL muscle of
an able-bodied patient. While configuring the three motion classes of the myoelectric
control system, the patient is directed to produce three isolated contractions at a selfselected “high-intensity” followed by two isolated self-selected “low-intensity”
contractions, which can be seen distinctly in Figure 3.20. These data are streamed in
real-time and used to differentiate between three states of a single degree of freedom,
resulting in real-time myoelectric control of a prosthetic hand. Figure 3.21 portrays the
setup for this experiment.

Figure 3.20 Intramuscular EMG (imEMG) collected by a fully wireless Myonode from the
extensor carpi radialis longus (ECRL) muscle of an able-bodied human subject (gain = 54
dB). Subject is directed in this instance to produce three self-selected “high-intensity”
contractions followed by two self-selected “low-intensity” contractions.
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Figure 3.21 Experimental setup to collect imEMG from extensor carpi radialis longus
(ECRL) muscle to direct hand open and hand close in both a virtual and robotic
prosthetic arm. Fine wire needle electrodes are fed through an interposer board to
connect to the Myonode device on the bench top.

3.5.2 Myonode Cuff Array for Multi-Channel sEMG Recording
In addition to wirelessly powering a single device, the MRC optimization
methodology can be expanded to incorporate multiple receivers by strategically
controlling the power distribution [172]. Power coupling to eight devices is achieved by
application of an anti-Helmholtz transmitting coil designed by Henry Mei. This coil is
intended to be worn around the forearm as shown in Figure 3.22(a) in a manner similar
to current inductive power links for transradial amputees [50]. The transmitting coil is
made using 8 AWG copper wire and consists of two coils strategically wound in opposite
directions then connected in parallel from the feed point indicated in Figure 3.22(b) to
achieve an anti-Helmholtz magnetic field distribution. This field distribution is
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characterized by magnetic fields which point outward and perpendicular to the surface
of the forearm as shown in Figure 3.22(c). This allows for adequate and equivalent
coupling between the transmitting and receiving resonators sufficient to power eight
devices positioned circumferentially around the forearm.

Figure 3.22 Simulation of the transmitting anti-Helmholtz coil for power transfer to an
array of Myonode’s placed circumferentially around the forearm. (a) Intended
placement of the transmitting coil around a human body model in HFSS®. (b)
Transmitting coil dimensions when viewed from the side and top. (c) Illustration of the
magnetic (H) field vectors characteristic of the anti-Helmholtz construction.
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The flexible receive coils described in Section 3.3.3 are used here as they will
conform the surface the forearm and put less stress on the junction with the PCB. The
intended arrangement of eight printed spiral coils within the anti-Helmholtz coil is
depicted in Figure 3.23. Figure 3.24(a) shows the assembled fabric forearm cuff with
eight Myonode devices connected to dry metal dome electrodes (Motion Control, Inc.)
embedded in the fabric cuff. This arrangement allows for eight channels of differential
sEMG to be measured around the circumference of the forearm. Minimal adaptations
were required of the Myonode PCB in order to make it compatible with the forearm cuff.
A stainless steel extension spring is connected to the each differential input via on the
PCB by way of a copper post potted in the via at one end and inserted into the extension
spring at the other end. The copper post is soldered at both junctions for stability and
electrical continuity. Metal snap connectors are soldered to the free ends of the
extension springs so that they could be easily connect and disconnected from the dry
metal dome electrodes. Figure 3.24(b) shows one of these modified Bionodes adapted
for integration with the fabric cuff.
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Figure 3.23 Transmitting anti-Helmholtz coil modeled in HFSS® with eight flexible
receive coils positioned equidistant from one another around the inside coil the
transmitting and spaced equidistant from one another on the surface of the forearm
(purple).

Figure 3.24 Adaptation of the Myonode for integration of multiple devices on an
adjustable forearm cuff for multi-channel surface EMG (sEMG) recording. (a) Fabric
forearm cuff with eight pairs of embedded dry metal dome electrodes. Electrodes
interface with the differential recording inputs of the Myonode through metal snaps. (b)
Single Myonode adapted for the forearm cuff. Metal snaps are soldered to an extension
spring which is connected to the Myonode through copper post potted in a via. The rigid
receive coil is replaced by a flexible coil that will conform to the curve of the forearm.
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During testing the fabric cuff is secured snugly around the proximal third of the
subject’s forearm—near the center of the brachioradialis muscle. An elastic bandage is
wrapped around the cuff and forearm to protect the microelectronics. The antiHelmholtz coil is then slipped over the top of the cuff and the elastic bandage. A
pattern recognition system is used to correlate the streaming sEMG data from the array
of devices to the intended motion of the user. In order to train the system, the user
provides four repetitions of training contractions, which are comprised of 3-second
contractions for each of the following seven motion classes: no motion, pronation,
supination, wrist flexion, wrist extension, hand open, and hand close. A set of time
domain features—the Hudgins set—is used, which includes MAV waveform length,
number of slope sign changes, and zero crossing rate [173]. Additionally sixth order
autoregressive features are calculated for each channel from 250 ms sliding windows
with a 50 ms frame increment. Finally, a linear discriminant analysis (LDA) classifier is
trained using features extracted from the training contractions. The user is then able to
use the classifier to direct three degrees of freedom in a virtual prosthetic arm. During
real-time control the LDA classifier successfully predicted which motion class the user
wished to generate from newly produced sEMG features and the corresponding velocity
output to the virtual arm is made proportional to the mean sEMG amplitudes produced
and normalized by motion class [174].
This experiment demonstrates that eight Myonode devices can be wirelessly
powered simultaneously using an anti-Helmholtz transmitting coil with a power output
of less than 1 W. The usability of the retrieved data is exemplified through successful
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categorization of seven different motion classes using established myoelectric
prosthetic control algorithms. Figure 3.25 shows an image of the experimental setup for
multi-channel sEMG acquisition and control of a virtual arm.

Figure 3.25 Experimental setup for multi-channel sEMG collection from an able-bodied
subject. Data are collected from eight Myonode devices integrated on a fabric forearm
cuff and powered through a wireless power transfer (WPT) link utilizing magnetic
resonance coupling (MRC). Data are classified in real-time using a pattern recognition
control system which is subsequently used to direct three degrees of freedom in a
virtual arm.

This experiment offers the following key result: that multiple Myonode devices
can be successfully powered in an eight-channel array while retrieving usable EMG. The
eventual goal of this project is to collect motor control information from within the
muscle, which will require further reduction in the dimensions and an alternative
packaging strategy. It is worth noting that the Myonode in its current form may offer
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some benefit to sEMG-modulated prostheses that are presently issued to patients.
Specifically, multiple Myonode devices might be embedded in prosthetic sockets or
elastomeric liners in order to wirelessly collect sEMG. This might simplify the patientprosthesis interface by removing all rigid electrical connections between the prosthesis
and the electrodes. The Myonode would serve as a wireless preamplifier connected
directly to the electrodes and close to the signal source and it would telemeter the
sEMG data to the processor rather than sending it through a rigid adapter. This would
lessen restrictions on how the prosthesis is designed and mounted. Moreover, it would
eliminate the chance of an electrical failure or interruption due mechanical stresses and
failures. Lastly, it would significantly streamline the use of elastomeric liners, which can
improve suspension of the prosthesis and the electrode-skin contact [175].
The potential uses for the Myonode in prosthetic control are not limited to upperlimb amputees. Lower-limb amputees are an important patient population to consider
as they significantly outnumber upper-limb amputees [174] and EMG collection has
been shown to improve control of powered prosthetic legs [176, 177]. Lower-limb
amputees could benefit from chronic, wireless imEMG recording for many of the same
reasons as upper-limb amputees (higher signal selectivity, signal permanence, etc.), but
also because sEMG recorded in lower-limb prosthetic sockets contain substantial
motion artifact caused by heel-strike [178]. This issue could be negated by permanent
recording channels implanted in the residual muscle.
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3.6

Conclusion

The Myonode represents the first pass at a fully wireless and implantable
bioelectric sensor for freely behaving mice. One implementation of the Myonode
attempts to build the functional circuit blocks in CMOS in hopes of benefiting from the
smaller size and power consumption that come with ASIC-based systems. This resulted
in a circuit that is capable of recording and transmitting bioelectric data on a power
budget of 1 mW, but suffered from an overwhelmingly low production yield, difficulties
interfacing with the ASIC chip, and functional rigidity. A second, more successful,
implementation of the Myonode is designed and built using commercial off-the-shelf ICs
and passive components integrated on a custom-designed PCB. This results in a finished
device which is larger and demands more power than the ASIC. However, the additional
size and power draw are counterbalanced by significant benefits such as configurability,
customizable firmware, quick prototyping, and—most importantly—use of cutting edge
microelectronics. This takes advantage of the state of the art in circuit design as well as
quality control procedures already in place for commercial ICs, assuring greater
reliability of the end-product.
The Myonode is designed specifically for EMG collection and is used to observe
voluntary evoked muscle activity from a wild-type mouse and spontaneous aberrant
muscle activity in a mouse model for familial MD. These are exciting outcomes as they
demonstrate that the device is capable of collecting useful metrics for tracking
neuromuscular diseases over time (see Section 1.1.1). It also affirms the viability of MRC
power transfer to receiving devices implanted in freely behaving animals. Additionally, a
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known and repeatable CMAP waveform is measured to validate the in vivo data
digitized and transmitted by the Myonode. This stimulus evoked response is collected
mid-surgery while the animal is under anesthesia. However, CMAP responses are
needed to normalize voluntary muscle activity in each animal over time in a longitudinal
study. The amplitude of the CMAP response itself can also be an indicator for muscle
atrophy [23]. A single channel of EMG is sufficient for a proof of principle, but a more
advanced instrument is needed to accurately interpret changes in muscle behavior over
time. For this reason the fully implantable device will need an integrated stimulator to
evoke the CMAP and be tuned appropriately to measure the CMAP.
Chronic electrophysiology in freely behaving animals faces many of the same
obstacles as chronic electrophysiology in humans for prosthetic control. For this reason
the work that went into developing an implantable system for mouse work also offered
an opportunity to contribute to amputee rehabilitation. The human clinical work
reported in this chapter includes three important results: 1) The Myonode is able to
record usable imEMG, making it functionally suitable for intramuscular electrodes; 2)
multiple Myonodes can be simultaneously powered to generate eight usable channels
of sEMG; and 3) the Myonode in its current form could improve the interface between
current socket liners and prosthetic sockets by using it as a permanently integrated
preamplifier. The immediate utility of the Myonode for elastomeric liners as well as the
Myonode’s compatibility with a more flexible and efficient WPT strategy (MRC)
represent advancements in neural interfaces for prosthetic control.
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The next phase of this work will expand the capabilities of the Myonode and
tackle its critical limitations. These limitations include single-tasking, weak mechanical
properties of the electrode interface, and the small WPT testing environment. These
fixes and new features result in a more sophisticated and versatile device termed the
Bionode—the development and application of which is the subject of Chapter 4.
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CHAPTER 4.

THE BIONODE: A FULLY IMPLANTABLE RECORDING AND STIMULATING
DEVICE FOR LONG-TERM SMALL ANIMAL MONITORING

4.1

Introduction

The material presented in this Chapter incorporates content from the journal
article “Bionode for Fully Wireless Recording and Stimulating of Bioelectric Events in
Rodents within a Large Volume Cavity Resonator” by R. A. Bercich*, S. T. Lee*, D. J.
Pederson, Z. Wang, M. A. Arafat, H. Mei, C. Quinkert, G. Albors, J. P. Somann, J. G. R.
Jefferys, and P.P. Irazoqui, which has been submitted for publication to IEEE Transaction
on Biomedical Engineering. This chapter also incorporates content from the journal
article “Cavity Resonator Wireless Power Transfer System for Freely Moving Animal
Experiments” by H. Mei, K. A. Thackston, R. A. Bercich, G. R. Jefferys, and P. P. Irazoqui,
which has been submitted for publication to IEEE Transactions on Biomedical
Engineering. All procedures involving live animals are reviewed and approved by the
Purdue Animal Care and Use Committee.
The development and application of the Myonode device—a fully wireless and
implantable single-channel bioelectric sensor—is detailed in Chapter 3. This chapter is
dedicated to the development and application of the Bionode, which evolved from the
Myonode. Functionally and practically the Bionode greatly improves upon the Myonode,
but there are five key advancements that make the Bionode amenable to a wide range
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of electrophysiological studies and truly state-of-the-art for fully wireless animal
monitoring. First, it has an integrated biphasic, current-controlled stimulator for precise
evocation of biopotentials. Second, it offers two independently configurable recording
channels. Third, the electrode interfaces are fully redesigned for reusability as well as
improved mechanical and electrical stability. Fourth, it is enabled with bidirectional
telemetry for open communication between the implanted device and an external base
station, which allows for immediate changes to functional protocol and stimulus
directives. Lastly, the Bionode is compatible with a large, resonant cavity WPT
environment which affords more space and flexibility for freely behaving animal
experiments. These advancements along with some minor improvements to the system
are described in Sections 4.2 through 4.4.
The Bionode device described in this chapter reflects the end result of three
design iterations. The first iteration used single supply mode on all microelectronics and
a high side stimulator (meaning that both output electrodes are driven to high voltages
that are disparate in amplitude by the product of current and electrode impedance
during stimulation). The second iteration addressed stimulus artifacts that occur on
startup due to improper default switch configurations within the stimulator circuit as
well as high amplitude, transient current spikes that would occur at the onset of each
stimulus pulse as a result of switching noise. The third iteration moves segments of the
AFE and stimulator into dual supply mode and implements a low side stimulator to
address current shunting to the AFE inputs, which causes sustained saturation of the
recording channels during stimulation.
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Recent progress in cavity resonator-based WPT system lead by Henry Mei has
produced large volume animal testing environment that itself serve as a magnetic field
source and container The cavity resonator is designed to maximize PTE through optimal
impedance matching in a manner similar to the MRC power transfer method employed
for the Myonode [70, 71]. The electrical and physical characteristics of the cavity dictate
its resonant frequency and thereby the operation frequency of the WPT link. The
resonant cavity used in this work is 60 cm x 60 cm x 30 cm and is made out of sheet
aluminum (thickness = 1.6 mm), which results in a resonant frequency between 340 and
350 MHz. This is an important point because the higher operation frequency (relative to
that of the coil pairing used for WPT to the Myonode) allows the size of the receive coils
to be reduced while maintaining similar PTE performance. This is a wonderful piece of
enabling technology as it improves two conditions of the Myonode system: the
restrictive size of the animal monitoring environment and the coil size, which is
cumbersome at 1.2 cm.
The Bionode consists of a power module board and a core module, which has all
of the microelectronics needed for biopotential acquisition, neuromodulation
(stimulation), and bidirectional telemetry. Temperature sensing is also enabled through
the incorporation of a thermal sensor. The power module board and the core module
are separate PCBs which are assembled individually and then stacked to minimize the
footprint of the Bionode at the expense of increased thickness. The Bionode is designed
strategically so that it can take advantage of WPT using the novel cavity resonator
system. This includes the integration of a-biaxial receive coil system (two receive coils
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oriented in transverse planes) on the power module to minimize sensitivity to
misalignment between the receiving device and magnetic field direction. The profile of
the magnetic field ( ⃗ ) within the cavity is characterized by its TM110 resonant mode and
circulates about the feed point in its center [71]. The use of this cavity and its adaptation
for longitudinal collection of neuromuscular information in mice is detailed within the
experimental design and methods for chronic mouse work in Section 4.7.1.
Sections 4.6 and 4.7 detail the use of the Bionode within a series of acute and
chronic experiments in both rats and mice. These experiments serve importantly to
demonstrate device in vivo viability and data validity. More excitingly, though, they
include the application of the Bionode to the study of neuromuscular and motoneuron
disease mechanisms. The ability to use the Bionode to expose new information about
clinically relevant disease models is an exciting end result to this engineering design
challenge.

4.2

Power Module Development

The power module acts as a power supply by coupling RF energy sourced from a
large cavity resonator and rectifying the induced voltage to DC. Orientation mismatch of
the transmitter and receiver is a notorious problem for freely behaving animal
experiments. While the resonant cavity solution has improved performance compared
to conventional WPT systems, it is not immune. To lessen the effect of device
orientation as a result of animal movement on PTE, two perpendicular copper coils are
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connected to the power module: each with a separate optimally designed impedance
matching circuit. The methodology of the optimal impedance matching for the cavity is
described in [71].

4.2.1 Circuit Design for Power Management
Figure 4.1 shows a circuit diagram of the full power module board. The inputs to
this circuit are two AC voltages induced in the receive coils. These each pass through
their own J-inverter impedance matching network before both are rectified and
summed by a voltage doubler. This constitutes a biaxial RF-to-DC conversion circuit. This
rectified voltage is fed to a bank capacitor (68 μF capacitance) which stores excess
charge in a kind of reservoir. This storage capacitor serves to buffer the power supply
lines during periods of elevated current consumption such as ADC sampling or data
transmission.
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Figure 4.1 Circuit schematic of the Bionode’s power module board. AC voltages induced
in two receive coils by incident RF fields are passed through impedance matching
networks (J-inverters), rectified, then regulated to the four voltage supplies needed for
dual supply operation of the Bionode’s analog front-end (AFE) and stimulator.

The unregulated, rectified voltage is also surge protected by a 5.1 V Zener diode.
The rectified voltage is then applied to a network of voltage regulators and inverters
which output all the necessary power supplies for the main PCB. This network includes a
low-dropout (LDO) linear regulator to produce a 1.8 V supply (VDD) used by the AFE,
stimulator, and MCU. This supply is subsequently inverted by a switched capacitor
voltage inverter (MAX1720, ON Semiconductor) to create a -1.8 V supply (VSS) for the
AFE and stimulator. The rectified voltage is also doubled using another switched
capacitor voltage converter (TL7660, Texas Instruments) to generate a larger voltage
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headroom for the stimulator. The 5.1 V Zener diode on the rectified voltage limits the
output of the voltage doubler to 10.2 V in theory and 10.5 V in practice. A second
TL7660 is placed in series with the first and configured as a voltage inverter rather than
multiplier to generate the -10.5 V supply for the stimulator.
The power module has a footprint of 8mm x 13.5 mm and a thickness of 0.56
mm (unpopulated). The four-layer PCB is designed in Altium and fabricated by Advanced
Circuits using on FR-4 substrate. Once the microelectronics have been assembled on the
power module, it is stacked and electrically connected by wires to the core module
using five connection points (VDD, VSS, 10.5 V, -10.5 V, and ground). A picture of the
assembled power module is shown in Figure 4.2.

Figure 4.2 (a) Front view and (b) back view of assembled power module PCB board with
5 mm diameter biaxial receive coils. Footprint dimensions are 8 mm x 13.5 mm.

4.2.2 Flexible Substrates for Power Module Boards
An alternative to the rigid power module is designed using copper deposited on
a polyimide substrate with a polyimide coverlay in a manner similar to the flexible coil
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fabrication discussed in Section 3.3.3 and is shown in Figure 4.3. This has three key
advantages: 1) It reduces the power module board thickness by over 400%, which
decreases the total thickness of the device; 2) the flexible coil is able to conform to the
shape of the body once implanted, which makes it less of an obstruction than rigid coils;
and 3) the receive coil is continuous with the circuit board, reducing the chances of a
mechanical failure from a soldered joint at the coil terminals. The flexible power module
is used for one iteration of the Bionode as shown in Figure 4.4. It is not used in the final
Bionode design owing to changes in the power module circuit to accommodate a dual
supply mode as well as difficulties incorporating a second printed coil for the biaxial
receive coil system.

Figure 4.3 Flexible power module fabricated from a flexible polyimide substrate with a
thickness of 013 mm with an integrated. (a) Rendering of power module in Altium with a
round receive coil and (b) Photograph of fabricated power module with a 15 mm square
coil.
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Figure 4.4 Bionode core module stacked on top of a flexible power module board.

4.3

Bionode Core Module Development

The purpose of the Bionode’s core module is to integrate the microelectronics for
biopotenial acquisition, neuromodulation, thermal sensing, and telemetry. The power
supplies for all core module microelectronics are provided by the power module board
(see Section 4.2). The same Nordic Semiconductor SoC that is used in the Myonode is
used on the Bionode’s core module to run and coordinate its various tasks. The SoC has
256 kB of flash memory which, once again, allows for rapid changes to the device’s
protocol through reprogrammable firmware.
Wireless communication between the Bionode’s core module and a user interface
for saving data and changing the device’s functional parameters is facilitated by a base
station. The communication protocol, firmware development, and base station design
are the results of incredible work done by Dan Pederson and Zhi Wang: two members of
the Center for Implantable Devices at Purdue University. Briefly, the Bionode sends
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recorded data points, stimulation circuit status, and thermal measurements to the base
station. During the normal data collection phase, the Bionode digitizes data from each
recording channel using the SoC’s integrated ADC. The ADC can be set to collect data
using either 8- or 10-bit precision. Once 40 bytes of data have been acquired, the
Bionode sends a wireless data packet to the base station.
Multiple settings and instructions can be communicated in the opposite
direction—to the Bionode—through update packets sent by the base station to the
transceiver embedded in the SoC on the Bionode’s core module. Configurable settings
include recording parameters (sampling rate, ADC digital resolution, and selection of
ADC input channels) and stimulation parameters (amplitude, pulse width, frequency,
duration, and calibration settings). Instructions to begin or end a stimulation session as
well as update the temperature measurement are also permitted.

4.3.1 AFE for Biopotential Recording
Topologically the AFE on the Bionode is very similar to the AFE on the Myonode
(see Section 3.3.1) and consists of an instrumentation amplifier (first stage) followed by
a higher gain second stage and bandpass filter. Figure 4.5 displays the circuit diagram for
the Bionode’s AFE, which has undergone three changes since the Myonode: first, the
instrumentation amplifier is run in dual supply mode; second, the reference voltage is
generated by a resistor divider rather than a regulator; and third, an alternate second
stage op amp IC is used.
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The transition from single supply to dual supply eliminates the need for pull-up
resistors to maintain a common mode, mid-supply, DC bias on the inputs to the
instrumentation amplifier (first stage). This greatly increases the input impedance of the
recording channels, which equates to twice the pull-up resistance in the Myonode since
both input are tied to the same reference voltage for DC biasing. Alternatively, this
topology takes advantage of the high differential impedance (100 GΩ) of the INA333.
The input voltage range for the ADC on the Myonode is 0 to 1.8 V: a setup made
possible by prescaling the analog input to the MCU. Prescaling puts limitations on the
sampling rate and is not used in the Bionode where the ADC still operates in single
supply mode but uses the default input voltage range of 0 to 1.2 V. Therefore the AFE
output must still be offset to the middle of the ADC input voltage range. Here the AFE
takes advantage of a 1.2 V reference voltage readily available from the digital-to-analog
convert (DAC) that is introduced to the system as part of the stimulator circuit. This 1.2
V reference is voltage divided in half using equal valued resistors (R3 and R4 in Figure
4.5) and buffered to create a low impedance source.
The second stage op amp is the OPA313 (Texas Instruments), which has a higher
gain-bandwidth product (1 MHz) than its predecessor. This lessens the limitations on the
low-pass filter cutoff and allows it to be raised to 10k while maintaining that a majority
of signal gain occurs in the second stage (typically 40 dB). This makes the recording
channel more suitable for general neural recording since single unit potentials from
individual nerves, muscle fibers, and neurons have frequency content in the range of
several kHz [179].
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Figure 4.5 Bionode analog front-end (AFE) circuit diagram. Instrumentation amplifier
(first stage) is followed by a higher gain second stage with an integrated bandpass filter.
A reference of 0.6 V is needed to bias the AFE output to the middle of the ADC input
range. This reference comes from the digital-to-analog converter(DAC) following voltage
reduction through a resistor divider.

The Bionode contains two independent recording channels. The gain and
bandwidth of each channel’s AFE can be reconfigured through passive component
selection. The gain of the first stage is set by a single resistor, Rf, based on the
relationship given in [164] while the gain of the second stage may be approximated by
the known gain equation of an inverting operational amplifier (see equation 3.1).
Meanwhile, the bandwidth cutoffs may continue to be approximated by equations (3.2)
and (3.3) and verified using SPICE software for circuit simulation. The passive
component values selected in order to achieve the appropriate gain and bandwidth for
bioelectric activity of the peripheral nerves and muscles in mice are recorded in Table
4.1.
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Table 4.1 Passive component values used in Bionode analog front-end (AFE) for
neuromuscular target signals in mice.
Target Signal

Total AFE Gain

Rf

C1

R1

C2

R2

CMAP

60 dB

11 kΩ

1 μF

10kΩ

20 pF

1 MΩ

Spontaneous EMG and NAP

34 dB

25 kΩ

1 μF

10 kΩ

330 pF 100 kΩ

The frequency response for each of the two anticipated AFE configurations is
simulated in TINA-TI and shown in Figure 4.6. The gain of each channel must be selected
carefully since the Bionode does not have the ability to adjust gain after implantation.
Gain is selected for each channel based on results from in vivo experiments outlined in
Section 3.4 as well as within the literature [23]. Given the demonstrated capability of
maximum CMAP responses to exceed peak-to-peak amplitude of spontaneous EMG
activity by at least an order of magnitude, it is not judicious to use the same channel to
target both signals until adjustable gain is integrated. Rather, one channel should be
used specifically for CMAP responses and another for spontaneous EMG or NAP. The
Bionode’s AFE has a CMRR of at least 80 dB from DC to 60 Hz and an input referred
noise of 2.73 μVpp, which are measured using the same methodology outlined in Section
3.3.4.
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Figure 4.6 Simulated frequency response of the analog front-end (AFE) configured for
spontaneous EMG and NAP (solid line) and CMAP (dotted line).

4.3.2 Current-Controlled, Biphasic Stimulator
The first step to integrating a stimulator on the Bionode is selecting the
mechanism by which charge will be precisely injected into the excitable tissue. Voltagecontrolled (potentiostatic) stimulation is certainly easier to implement and, as
demonstrated by Simpson and Ghovanloo, more power efficient than current-controlled
(galvanostatic) or charge-controlled (switched-capacitor) stimulators [180]. However, a
voltage-controlled stimulator presents a critical limitation which is that it offers no
command over the level of current applied to the system. This is an issue because the
electrical model of the tissue-electrode interface includes a capacitive element on
account of the Helmholtz double layer which is forms between electrodes and
extracellular fluid. This means that each pulse will begin with a phase of rapidly decaying
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capacitive current and then approach a more stable Faradaic current. This means that
the current amplitude at any time during a stimulus pulse will be dependent on the
properties of the electrode and impedance between the working and counter electrode
(which is likely to change over time as scar tissue forms in and around a cuff electrode
placed on a nerve). Since the level of depolarization—and thus the electrophysiological
response—of an electrically excitable tissue membrane is directly related to the
amplitude of the current, an absence of this information makes it extremely difficult to
reproduce and compare results from different animals [181]. For this crucial reason, a
current-controlled rather than voltage-controlled stimulator is selected for the Bionode.
The recommended parameters for electrical stimulation are well characterized
and include biphasic pulse generation for charge balancing. This allows for the reversal
of electrochemical processes that occur during a stimulating pulse, which helps to
prevent electrode degradation and resulting deposition of chemical species into tissue
[181]. Other stimulation parameter such as frequency, pulse width, and pulse pattern
distribution are not as well studied and are of interest for biological efficacy and
decreased power consumption in the recently burgeoning field of electroceuticals [182,
183]. While outside the scope of this work, it is exciting to note that the Bionode and its
supporting hardware and software constitute a streamlined and comprehensive
platform for testing these additional parameters for functional electrical stimulation and
other therapeutic devices.
Figure 4.7 shows a circuit diagram of the biphasic, current-controlled stimulator
designed for the Bionode. Credit is due here to Muhammad Arafat, a student in the
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Center for Implantable Devices at Purdue University, who helped to develop the
stimulator topology in its current (dual supply) form. The output current to a stimulating
(working) electrode (designated STIM in Figure 4.7) is achieved using an op amp
constant current sink with parallel N-channel and P-channel MOSFETs for generating
either positive or negative current. The time-dependent features of the stimulus output
(pulse width and pulse period) are regulated by a single pole triple throw (SP3T) switch
that selects between an off-state (output connected to ground) and two possible onstates: one for a negative (cathodic) pulse and another for positive (anodic) pulse
relative to a counter electrode that is connected to circuit ground. All stimulation
parameters (rate, pulse width, and amplitude) are controlled by protocols in the MCU.
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Figure 4.7 Circuit schematic of the Bionode’s biphasic, current-controlled stimulator.
Both positive and negative stimulus pulses may be applied to the STIM node, which is
connected to a working electrode. Stimulus current is collected by a counter electrode
shorted to circuit ground.

The current amplitude during each stimulation phase is determined by a
programmable control voltage generated by a 12-bit DAC (MAX5535, Maxim Integrated)
either directly (for anodic pulses) or following a unity gain voltage inverter (for cathodic
pulses). The inverting op amp, which operates in dual supply mode, is needed since the
DAC (operated in single supply) cannot output negative voltages. The control voltage is
applied to the non-inverting terminal of an op amp during a stimulus pulse, which will
drive the inverting input to the same voltage. The voltage on the non-inverting input is
applied across a known resistor—R4 in Figure 4.7—to create a constant current sink
with a current amplitude easily derived from Ohm’s Law (equated to the control voltage
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divided by R4). The resistor R4 is set to 200 Ω by default and for all applications in this
work.
The current through R4 is replicated by current mirrors using matching P-channel
MOSFETs (UM6K34N, Rohm Semiconductor) or N-channel MOSFETs (NX3008PBKS, NXP
Semiconductors), depending on the direction of the current. This allows for isolation
between the portion of the circuit that sets the desired current and the portion of the
circuit that applies the desired current to the tissue. The matched current is directed to
the working electrode (STIM) and collected by a counter electrode referenced to circuit
ground. One disadvantage of this topology is that it requires a very close match in
MOSFET characteristics within each current mirror in order for the applied current to
match the set current through R4. Even though the MOSFETs selected for the current
mirrors are identical parts that even come in the same package, the relationship
between desired and applied current is non-linear and varies from build to build.
The same non-linearity is observed —to a lesser extent--in stimulus pulse width.
Lower stimulus currents necessitate a more dramatic positive calibration in the pulse
width. Figure 4.8 compiles stimulator calibration curves for four different stimulator
builds at a desired pulse width of 100 μs. Blue traces represent positive pulse calibration
and red traces represent negative pulse calibration. Pulse amplitude correction, which is
indicated by solid traces can range from -50 to +146 μA for positive pulses and from -80
to +6 μA for negative pulses. Pulse width correction for both negative and positive
pulses becomes less dramatic at higher current amplitudes; however, they are
significant in the lower range of requested current amplitude where correction may be
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as high as +50 μs (half the pulse width setting). The implication of Figure 4.8 is that the
stimulator topology implemented on the Bionode can supply predictable and reliable
stimulus waveforms provided that each stimulator build has been characterized and is
accompanied by its respective calibration data. This is an inconvenience but not an
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Figure 4.8 Stimulus pulse width (dotted lines) and amplitude (solid lines) calibration
curves for correcting nonlinearity between requested and actual parameters of positive
(blue) and negative (red) stimulus pulses. Requested pulse width is 100 μs.

The functional performance of the stimulator is evaluated on the bench top by
connecting its output to a known load impedance (10 kΩ), sweeping the stimulator’s
functional parameters (pulse width, current amplitude, and pulse repeat time/duty
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cycle), and calibrating the pulse width and current amplitude at each set of stimulation
parameters. Figure 4.9 illustrates a sampling of the biphasic stimulator outputs for a
range of stimulus current amplitude settings at a 50% duty cycle. When optimally
calibrated, the measured charge balance error is less than 1% at a pulse width of 100 μs.
This is calculated by integrating the current through a 10 kΩ resistor during 200
successive stimulus pulses (alternating between anodic and cathodic) Dividing this
integral by the number of pulses gives the average net charge imbalance per pulse pair.

Figure 4.9 Current-controlled, biphasic stimulator output measured on the bench top
using a 10 kΩ load between the working electrode and counter electrode (ground).
Pulse width, current amplitude, and duty cycle are all selectable in real-time telemetry
from the base station to the Bionode. A pulse width of 100 μs and a 50% duty cycle are
used here to illustrate the measured output current for a range of amplitude settings.

A significant challenge that appears repeatedly across iterations of the Bionode
is the propensity for erroneous stimuli during power up. These ultimately result from a
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delay between initial generation of the electromagnetic field and control of digital logic
lines to the switch that controls the phase (on or off) of the stimulator. This means that
the logic lines that designate switch position (see Figure 4.7 for an example) float to
unknown and likely high voltages on account of high line impedance before the MCU is
able to startup and carry out its programmed protocols, which include regulating the
voltages on these digital I/O lines. This issue is exacerbated by the relatively long
(compared to the other ICs on the core module) MCU startup time, which is over 100 ms
when powered from an ideal DC voltage supply. However, the delay between initial
voltage rise on the power supply line and MCU startup can increase dramatically as a
result of variable rise rates and possible fluctuations on the main voltage supply line;
both of which can occur unpredictably with WPT to a freely behaving animal.
Consider the following likely scenario: an electromagnetic field source is turned
on and couples energy to a receiving device within the cavity resonator. The induced AC
current is continuously rectified, which causes an increase in the rectified voltage as its
storage capacitor is charged. Once the rectified voltage reaches approximately 1.2 V, the
1.8 V LDO regulator will turn on and follow the input (rectified voltage) as it increases up
to 1.8 V. Once the LDO regulator turns on (at a rectified voltage as low as 1.2 V) current
will travel to and diffuse throughout the Bionode, partially turning on some ICs and
possibly inducing transient elevations in electrical potential in extremely close, short,
and high impedance traces. Simultaneously, as the DAC boots up (which will happen
faster than MCU boot up), its output will float until it receives directives from the MCU.
At the same time the digital logic pins for the switch on the output of the DAC are
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unregulated and may float to a logic high condition that connects the control voltage
from the DAC to the constant current sink. This results in erroneous and undesirable
stimuli within tissue and has been observed both on the bench top and in vivo.
Furthermore, this activity is erratic in nature, and so presents a challenge to the circuit
design, which is often done under the easier but limiting assumptions of constant DC
powering and steady state conditions.
This artifact is potentially catastrophic in situations where coupling between the
resonant cavity and receive coils on the power module may not offer a sufficient PTE to
run the device in all possible locations and positions of the animal. One can imagine a
scenario in which the animal moves into a position such that the device is beginning to
turn on when suddenly a large, unwanted stimulus is applied. This would likely cause
the animal to move abruptly, causing a quick shift in voltage supply amplitude. This
would, in the best case scenario, increase the supply voltage so the system continues to
turn on and, in the worst case scenario, decrease the supply voltage and return to
conditions in which the system is poised to deliver another unwanted stimulus. The
likelihood of frequent, unwanted stimulation to the peripheral nerve in this case would
likely lead to experimental confounds and unnecessary stress imparted on the animal.
Even more disastrous to study outcomes is the possible behavioral conditioning that
would result from a large and likely painful stimulus delivered every time the device
turns on. This might cause the animal to avoid areas of its environment where WPT is
adequate to power the device.
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One solution that is implemented in the course of iterating the Bionode’s core
module is the use of pull-down and pull-up resistors on the switch logic lines in order to
hold these to either high or low logic levels during startup at the expense of added
current consumption during normal operation. The stimulator topology shown in Figure
4.7 is no exception to this matter as the SP3T switch has two digital logic lines directing
the switch position. This switch is outfitted with a pull-up resistor to the positive voltage
supply (1.8 V) on one digital pin for a forced logic high and a pull-down resistor to
ground on the other digital pin for a forced logic low. This logic configuration ensures
that the output of the switch is toggled to ground by default even when the device is
starting up.
However, even when logic lines can be configured intelligently for startup as
they have been here, there is still the possibility that another critical node in the
stimulus circuit path will float to a non-zero voltage relative to circuit ground up until
the point when all active components in the system are turned on and operating in
steady state. This turns out to be the case for the assembled stimulator on the Bionode.
Despite control over the digital lines of the phase switch, high amplitude currents can be
measured on the stimulator output during startup. This reemerging problem is
addressed by observing that the only way for current to flow through the single Nchannel or P-channel MOSFETs on the output of the op amp is if the gate voltage is
biased. The likely explanation here is that the output of the op amp, which operates in
dual supply mode, runs positive for the short period of time between activation of the
positive rail and subsequent activation of the negative rail. To understand why this
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happens, recall that the-1.8 V supply voltage (VSS) is generated on the power module by
a voltage inverter preceded and supplied by the 1.8 V LDO regulator than generates
VDD. For this reason, the Bionode’s core module will always see changes in VDD before
changes in VSS during startup.
A pull-down resistor to ground on the gates of these MOSFETs is a simple and
elegant way to stifle this unwanted bias voltage as it cuts the problem off at its source.
The pull-down resistor (R3 in Figure 4.7) needs to be sufficiently small so that any
voltage applied to the gates will readily discharge to ground. The size of this resistor is
determined empirically by incrementally decreasing the resistance until the startup
artifact disappears. The value of R3 is 1 kΩ for the extent of this work. This solution
comes at very little expense since the op amp output is almost always 0 V under normal
operation (no stimulation) and only increases total device consumption during the brief
periods of stimulation. This does not noticeably affect the behavior of the stimulator
itself because once the op amp is fully turned on it can source enough current to
effectively bias the gate voltages as needed.

4.3.3 Thermal Sensing
The Bionode is equipped with a temperature sensor IC (TMP112, Texas
Instruments) on the core module in order to monitor thermal changes within the device.
Due to the position of the sensor on the surface of the core module PCB and the
packaging strategy, which placed a barrier between the internal microelectronics and
the external tissue environment, the sensor is not in direct contact with the device-
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tissue interface. Rather, it sits adjacent to the heat source. This makes it difficult to
compare temperature changes in the tissue to the appropriate safety thresholds and
recommendations outlined in Section 2.5. However the temperature change measured
by the sensor is more exacting than that experienced by the tissue because the
temperature at the source will always be greater than the temperature experienced by
the tissue. Resultantly, a limit may be imposed on the temperature rise at the source
which automatically shuts down the device once an established threshold has been
crossed. If this threshold is equated to maximum safe temperature changes in tissue,
this would prevent tissue damage from thermal toxicity.
The fidelity of the temperature monitoring protocol is demonstrated in a
controlled water bath. A packaged Bionode is submerged in the bath adjacent to a
commercial thermocouple (Fluke 80BK-A Type-K). The Bionode’s power supply terminals
are wired out of the device and connected to DC power supply. Wireless powering is not
desired in this experiment as it will likely cause local heating within the device as a result
of electromagnetic field induction and voltage rectification. This would unnecessarily
complicate the temperature gradient profile when the experimental objective is to
confirm that the thermal sensor—as it is implemented and packaged—will accurately
track known temperatures changes in its environment.
The temperature of the water bath is raised to 40 °C and then allowed to cool.
During cooling the temperatures measured by the thermocouple and IC thermal sensor
are recorded at a rate of one sample per minute. The results of this experiment are
plotted in Figure 4.10. The offset between the temperatures measured by the thermal
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sensor and the thermocouple over time is 0.525 ± 0.057 °C. These data suggest that
there is a consistent DC offset in the thermal sensor measurements across the range of
temperatures likely to occur near a subcutaneous implant in a rodent. This means that
accounting for this offset in each device can be done using a simple, single-point
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Figure 4.10 Comparison of temperature measurements from a thermal sensor IC
(TMP112 mounted on the Bionode’s core module PCB) and a commercial thermocouple
tracking change in water bath temperature over time.

4.3.4 Custom PCB Design for Integration of Core Microelectronics
The microelectronics for the Bionode’s core module are integrated on a six-layer
PCB made from FR-4 substrate with thickness of 1 mm. This PCB is fabricated by
Advanced Circuits and has a footprint of 8mm x 13.5 mm (the same as the power
module). Given the unavoidable close proximity of the mixed-signal electronics, care is
taken during layout tot physically isolate the analog, digital, and RF blocks of the
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Bionode. Figure 4.11 shows front and back views of a core module PCB designed and 3D
rendered in Altium as well as pictures of an assembled prototype.

Figure 4.11 Front and back view of the Bionode core module rendered in Altium and
fabricated on a custom PCB.

A monopole strip antenna for bidirectional telemetry at 2.4 GHz is printed on the
bottom layer of the PCB and replaces the chip antenna that is used for the same
purpose on the Myonode. Because of the RF communication frequency and the limited
real estate, this antenna is inevitably electrically small. Electrically small monopole
antennas exhibit better performance (measured in antenna gain) when the length of the
antenna increases to approach a quarter wavelength at the frequency of operation.
Consequently, the antenna is placed adjacent to the longer edge of the board to
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maximize its length, which is 11.5 mm. The input to the antenna is impedance matched
to maximize the power transferred to the antenna, which increases signal power and
fidelity.

4.4

Bionode Full System Bench Top Characterization

The power and core modules together constitute the implantable system, which
communicates wirelessly with an external base station. Figure 4.12 shows a block
diagram of the complete hardware system that highlights the key functional blocks. In
addition to two recording channels, one stimulating channel, and a thermal sensor, the
device also offers two optional input channels which connect directly to ADC input pins
on the SoC. These are included so that the Bionode device can be paired with other
types of sensors. The external base station serves to route incoming data from the
implant to a graphical user interface (GUI) for real-time viewing and data storage. The
GUI also enables communication of directives such as sampling rate, ADC resolution,
and stimulation parameters to the implant.
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Figure 4.12 Block diagram illustrating key sub-elements of the fully Bionode system. The
implantable Bionode device includes the power module board stacked on top of the
core module board. The power module board provides the supply voltages necessary to
run the microelectronics on the core module. The device is enabled with two-way
telemetry with an external base station, which relays data to a computer. The graphical
user interface (GUI) is written in Python3 and can be used to plot and save data. The GUI
is also able to control functional parameters of the remote device such as sampling rate,
ADC resolution, and stimulus waveform settings.

It is necessary to understand the cumulative power consumption profile of the
Bionode in order to make inferences about the PTE of the WPT link once the device is
operating in an animal. This information is also needed to select an appropriately sized
storage capacitor for the rectified voltage on the power module. This is because certain
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phases of the device’s functional protocol (like sampling and transmitting) draw
additional current for short periods of time. It is important that during these phases of
elevated current consumption the supply voltages do not droop and initiate shutdown
of any onboard ICs. The power consumption profile over time is compiled using a smallvalue (5 Ω) resistor in series with the each of device’s voltage supplies and measuring
the differential voltage across the series resistor over time. The current drawn from
each supply is calculated using Ohm’s Law and then all the individual currents are
summed. Figure 4.13 illustrates the cumulative, temporal power consumption of the
device when it is sampling at a total rate of 5 kHz. The average power consumption
under these conditions is 5.03 mW. Figure 4.14 illustrates the total temporal power
consumption of the device when it is sampling at a total rate of 25 kHz. The average
power consumption under this condition is 6.72 mW.
The smaller spikes observed in Figures 4.13 and 4.14 are associated with ADC
operation during data sampling. Also clear in these figures are much larger, sustained
spikes that occur less frequently and are attributed to transmitter use. In both scenarios
the ADC resolution is maintained at 8-bit, which means that after every 40 samples
(small spikes) a larger spike should occur as the transmitter is turned on to send a
packet of data as established by the telemetry protocol. This is confirmed by the
matching count of small spikes between large spikes during both 5 kHz and 25 kHz
sampling.
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Figure 4.13 Power consumption profile of the Bionode over time when sampling rate is
set to 5kHz and stimulator is off.
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Figure 4.14 Power consumption profile of the Bionode over time when sampling rate is
set to 25 kHz and stimulator is off.

The average power consumption is a useful metric for comparing this system to
other bioelectric sensors (see Table 2.1), but doesn’t by itself reveal the dynamic loading
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conditions that must be considered when designing an effective power management
strategy. It is established in Section 4.2.1 that the rectified voltage is limited to
approximately 5.25 V in practice as a result of a 5.1 V Zener diode and that this rectified
voltage is applied across a large storage capacitor that serves as a charge bank. Since the
amount of charge stored in a capacitor is directly proportional its capacitance, it is
desirable to make this capacitor as large as possible so that it can buffer periods of large
current draw. This is especially important when the system has recently turned on and
the rectified voltage may be just barely above the 1.8 V needed for stable operation of
the most ICs—including the MCU. In this vulnerable state, rapid fluctuations on the
power supply might cause the device to turn off and on repeatedly: prohibiting the
collection of continuous data. A worst case scenario approximation for the amount of
charge that may need to be available at any time is calculated by integrating the large
power spike corresponding to data transmission at 25 kHz. This results in a total charge
budget of 6.44 μC. A 47 μF capacitor is able to source this quantity of charge while
experiencing a voltage drop of only 0.14 V. This means that a rectified voltage as low as
1.94 V is all that needs to be reached between the time when the MCU turns on and the
first transmission occurs in order to prevent untimely shutdown in the middle of startup.
In practice, this makes it much easier for the system to start up and immediately reduce
power supply ripple.
Each device undergoes the same series of engineering confidence tests prior to
implantation as outlined in Section 3.3.4. Figure 4.15 shows an example of an
affirmative data fidelity check for the two channel configurations given in Table 4.1.
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During this test a known input waveform (sine wave) is applied to both input channels,
and the telemetered signals are reconfigured and plotted. The amplitude of the test
signal is set to 2mVpp—the lowest amplitude sine wave that can be generated cleanly
by available equipment. A frequency outside of the AFE bandwidth (10 Hz in this case) is
used to prevent the signal from railing in the high gain (60dB) channel.

Figure 4.15 Full system response to a known input sine wave with an amplitude of 2
mVpp and a frequency of 10 Hz. Channel 1 is the output from the high gain (60 dB in
bandpass) analog front-end (AFE) intended for spontaneous muscle and nerve activity
while channel 2 is the output from the low gain (34 dB) in bandpass) AFE intended for
larger CMAP responses.

The peak-to-peak amplitude of the signal into the ADC (after the effects of AFE
gain and filtration) is predicted in circuit simulation to be 1.07 V for the high gain
channel and measured to be 0.92 V. The predicted peak-to-peak amplitude of the signal
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outputted from the second, low gain (34 dB) channel is 52.7 mV and measured to be
42.7 mV. The slight discrepancies between simulated and measured results at this outof-band frequency are likely due to the tolerances (1-5%) of the passive components
used to set the bandwidth. However, deviations in the AFE frequency response on this
minor scale will not perceivably alter the quality of measured bioelectric signals.
The performance characteristics of the full system Bionode as well as those
specific to the AFE and stimulator are summarized in Table 4.2. Typical values represent
either measured system parameters or default parameters, although some of these may
be altered during assembly or within the firmware. When given, minimum and/or
maximum values designate the permitted ranges of parameters that can be adjusted at
any time using the GUI and wireless communication to the device. The Bionode’s high
level of functionality and flexibility is reflected in Table 4.2, which specs out the most
advanced implantable system available for mouse electrophysiology.
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Table 4.2 Bionode performance characteristics. Typical values represent measured
characteristics for the default configuration. Minimum and maximum values represent
ranges for adjustable parameters.
Conditions

Other

Stimulator

Recording Channels

1

Gain
High-pass cutoff 1
Low-pass cutoff 1
CMRR
Input Impedance 2
Input-referred noise
Ch.1  Ch.2 crosstalk
Ch. 2  Ch.1 crosstalk
ADC resolution
ADC input voltage range
Total sampling rate (SR)
Voltage headroom 3
Current amplitude
Current amplitude resolution
Pulse width (PW)
Pulse width resolution
Pulse rate
Charge Balance Error
Mass 4
Average power consumption
Peak power consumption
Temperature resolution

DC to 60 Hz
f =0.01-3 kHz
f =100Hz

Load = 10 kΩ

PW = 100 μs
SR = 5 kHz
SR = 25 kHz
Transmitter on
0-65 °C

Min.

Typ.

Max.

Units

---80
----8
-1
±4
50
-50
-----

60
0.01
1
-100
50
-99
-98
-1.2
-±10.5
-1.5
-1
-<1
2.2
5.0
6.7
20.5
0.07

--------10
-25
±10.5
1,050
---20
---

dB
kHz
kHz
dB
GΩ
nV/√Hz
dB
dB
bits
V
kHz
V
µA
µA
µs
µs
kHz
%
g

--

mW

---

mW
°C

----

1

These parameters may be modified during the build phase based on signal of interest.
Input impedance reported by INA333 datasheet released by Texas Instruments [25]
3
Voltage headroom depends on power transfer efficiency (PTE) and is limited to 10.5V to
prevent damage to the voltage regulator IC.
4
Mass measured after medical epoxy encapsulation.
2

4.5

Implant Assembly for Mice

The Bionode’s power and core modules are placed inside a cylindrical capsule
when implanted in rats. This packaging strategy allows the contents of the capsule to be
removed and adapted at the expense of greatly increasing the total volume of the
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implant. At over 3 cm long and 1 cm wide this implant is unsuitable for a mouse of any
size. An alternative packaging strategy is needed that maximally reduces the dimensions
of the device. The strategy must also support a modular electrode interface whereby
different types of electrodes may be easily connected for different experimental goals
and disconnected for reuse.
This second objective does not necessarily preclude the use of parylene-C
deposition, which is used to seal the Myonode (see Section 3.3.3). Sealing the device
with a 15 to 20 μm-thick layer of parylene-C layer is certainly the least bulky packaging
strategy and would lead to the smallest total volume and mass. However, such a thin
barrier between the biaxial receive coils and the tissue means that the coil properties
are likely to be affected and thereby detuned by the tissue. This would make it difficult
to achieve optimal impedance matching conditions as the tuning process would have to
somehow anticipate the variable conditions of the device’s environment once implanted.
More importantly, though, the conformal dielectric does not offer structural support to
mechanically stabilize the now complex assembly of modules and coils. These present
multiple points of weakness for the flexural and torsional loading likely to occur once
implanted. For this reason an alternative coating process is used, which results in a
more rigid and permanent fixture of the device modules.
The process of packaging the Bionode for implantation in mice is described in
Section 4.5.1. This process simultaneously addresses the requirements for
miniaturization, reusability, robustness, and post-packaging coil tuning. The ability to
replace or add capacitive elements to alter the coils’ impedance matching networks
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after the device has been sealed is a crucial capability since the process of sealing the
coils has been shown to detrimentally alter their tuning. A method of protecting and
isolating this circuitry so that it is always accessible is integrated into the build process
that produces a packaged, readily implantable device. Sections 4.5.2 and 4.5.3 describe
the build and electrical performance of the two types of electrodes used in this work:
cuff electrodes and anchored intramuscular electrodes.

4.5.1 Packaging of Bionode Modules
Figure 4.16 illustrates the step-by-step packaging process for a Bionode intended
for implantation in mice. It begins with a fully assembled core module, which includes a
temporary 10-pin header for ease of programming and debugging. The first step is to
remove this header and solder 0.51 mm-diameter male pins (Mill-Max, 3320-0-00-15-0000-03-0) to the now exposed pads of the recording and stimulating channels’ inputs and

outputs. These pins will be used to modularly connect to different types of electrodes
and are manufactured at a length of 6.35 mm. However, they are trimmed to two thirds
this length prior to mounting to avoid lengthening the device more than is necessary
why still ensuring electrical continuity to the companion female header (Mill-Max, 30610-19-15-21-27-10-0). At this stage a small piece of clear tape is placed above the
microelectronics on the core module to isolate them electrically from components and
traces on the bottom side of the power module, which is stacked on top of the core
module to reduce the total footprint of the device. The two modules are mechanically
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and electrically affixed to one another through five parallel wires. Each wire connects a
supply voltage or, in one case, ground between the two modules.

Figure 4.16 Bionode packaging process for implantation in mice.

Next, a two-part mold putty is mixed and press-fit into the space around the coils’
impedance matching circuitry to protect it from direct contact with the epoxy which will
permanently secure the modules and electrode pins in place. The putty is again used to
create a cylindrical mold for the device that will allow it to be inserted lengthwise while
protruding the electrode pins. The mold is filled halfway with a medical epoxy (Loctite,
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M-31CL) and the device is slowly inserted into the mold. Additional epoxy is added from
the top to fill open space around the device. Care is taken to make sure the level of the
epoxy does not surpass the top edge of the board where it can begin to detrimentally
coat the electrode pins, which should be left exposed.
Once the epoxy has set, the device is removed from the mold and excess epoxy
is removed using a rotary contour sander (Dremel, 100-N/6). During the sanding process
the epoxy above the putty insert protecting the impedance matching circuitry is etched
away and the insert is removed. At this point the coils undergo their final tuning to
account for any changes in performance on account of the epoxy shell. After tuning a
second putty insert is placed above the impedance matching network to prevent
detuning from epoxy adjacent to the capacitors and to allow for future access to the
matching network as needed.
A second, shorter, cylindrical mold is made in order to seal the open part of the
device around the putty insert. Half of the device is placed inside the mold and a second
round of medical epoxy is injected and allowed to set. The device is then removed from
the mold and excess epoxy is once again removed by the rotary contour sander to
minimize the volume of the finished device. The average mass of the Bionode in this
form (without electrodes) is 2.24 g (n = 4). The maximum dimensions are 8 mm x 8 mm x
15 mm, resulting in an estimated volume of 0.96 cm3. A comparison to other fully
implantable devices that have been used in mice (see Table 1.1) demonstrates that the
Bionode is suitably small for mice that are 16 g or larger.
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The pin terminals between the Bionode and the selectable electrodes present a
challenge in that they, too, must be isolated from the tissue environment. However,
since it is desirable that the devices be reusable, these interfaces must be sealed with
something that is less permanent than medical epoxy but still biologically inert. After
the desired electrodes have been attached to the electrode pins, a two-part silicone
adhesive (Nusil, MED2-4213) is mixed and applied between and around the pin
terminals and heat set at 100 °C. This adhesive serves to isolate the input and output
channels from the surrounding tissue while also easing flexural stresses on the leads
wires where they are crimped into the female headers. The transition from flexible wire
to rigid header is the most likely point of mechanical failure due to repeated or
excessive bending, so extra silicone is built up around this junction to add springiness
to—and prevent very small radii of curvature from occurring at—the joint.

4.5.2 Recording Electrodes for Chronic imEMG
The epimysial recording electrodes that are used for EMG collection with the
Myonode are phased out in the Bionode on account of the lack of success with
anchoring them to the muscle while simultaneously avoiding catastrophic failure of the
joint between the lead and electrode surface. They are replaced by anchored imEMG
electrodes, the build process of which is described in [184]. Briefly, two 7-stranded
stainless steel (type 316) wires coated in perfluoroalkoxy alkane (PFA) (A-M Systems,
793200) are placed in parallel and crimped together inside the barrel of a 27 gauge
needle on one end. A knot is tied with both wires approximately 4 cm from the needle
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and a 1 mm-long exposures is cut with a scalpel on each wire between the knot and the
needle. On one wire this exposure begins 2 mm from the knot and on the other wires
this exposure begins 4 mm from the knot, resulting in an inter-electrode spacing of 2
mm. The free ends of the wires that are not crimped together into the needle are
crimped individually to female header pins that connect to the male electrode pins on
the Bionode. Figure 4.17 illustrates two sets of these imEMG electrodes (as well as a
stimulating cuff electrode, which is the subject of Section 4.5.3) affixed to the Bionode.

Figure 4.17 Bionode implant equipped with two pairs of intramuscular EMG (imEMG)
recording electrodes and a stimulating cuff electrode.

The implantation procedure is fairly simple and involves threading the needle
and its wires through the target muscle until the knot stops further advancement of the
wire. When this is done care must be taken to ensure that the distance from the
insertion point (where the knot is now flush with the muscle) to the exit point is at least
5mm so that both electrode exposures are embedded within the muscle. A second knot

153
is tied with both wires at the exit point such that the tightened knot sits flush with the
surface of the muscle. Finally, the needle and excess wire are removed by making a cut
close to the second knot.

4.5.3 Cuff Electrodes for Peripheral Nerves
A cuff electrode is designed specifically for either recording or stimulating of
peripheral nerves in mice. This cuff electrode is an adaptation of the build process
described in [23]. The base of each cuff electrode is a 3 mm length of silicone tubing (AM Systems, 806700), which has an inner diameter of 0.635 mm and an outer diameter
of 1.2 mm. A 30 gauge needle is inserted into the tube interior and then out of the tube
approximately 1 mm circumferentially from the insertion point. A 6 cm length of 7stranded stainless steel wire—the same wire used for the imEMG electrodes (see
Section 4.5.2)—is cut and a 5 mm length of the wire is bared at one end by stripping off
the PFA coating with a scalpel. The stripped end of the wire is threaded through the
needle and then the needle is extracted, leaving behind the wire interwoven in the tube
wall. The portion of the bare wire inside the tube is then shaped to the interior wall of
the tube, forming a semicircular electrode contact that occupies at least 75% of the
tube’s interior circumference. This process is repeated 1 mm down the length of the
tube to create a second electrode contact and an inter-electrode spacing of 1 mm.
The bare ends of both wires protruding from the tubing are trimmed to
approximately 1 mm from the surface of the tube and then fixed in place with the same
silicone adhesive used to seal the electrode interface (see Section 4.5.1). This prevents
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the bare wire ends from slipping back through the tubing wall. The other end of the
wires which are still coated with PFA and form the electrode leads are also fixed to the
tubing with silicone adhesive. Finally, a lengthwise cut is made in the wall of the tubing
between where the lead wires enter and the extra wire exits so that the cuff can be
slipped around the nerve. Each lead wire is then crimped into a female header pin
compatible with the male electrode pins on the Bionode. Figure 4.17 illustrates one of
these cuff electrode as well as two recording imEMG electrodes connected to the
Bionode.
The electrical performance of these cuff electrodes needs to be characterized
since it can affect the performance of the stimulator circuit. For simplicity the stimulator
is evaluated on the bench top using a 10 kΩ resistor to represent the electrode and
tissue impedance load at the stimulator output. In reality, this is not a good model for
an electrode surrounded by an electrolyte. As pointed out in Section 4.3.2, the
electrode-tissue interface can be modeled by a resistor in parallel with a capacitor, so
the electrode impedance will have some dependence on the frequency content of an
applied voltage. It is possible that by a combination of electrode material and small
surface area the impedance of the electrode might be high enough that the voltage
headroom (±10.5 V) might be reached before the desired current amplitude is reached.
For this reason the frequency-dependent impedance profile of each cuff electrode is
measured using a Gamry Reference 600+ potentiostat. During the electrochemical
impedance spectroscopy (EIS) test the cuff electrode is submerged in a phosphate
buffer solution (PBS) bath with a measured pH of 7.4. Figure 4.18 plots the impedance
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of a series of fabricated cuff electrodes. As a point of comparison to other cuff
electrodes, the average total impedance of these cuff electrodes is reported at 1 kHz
and is 13.8 ± 6.8 kΩ (n = 16). The high standard deviation of the measured impedance is
likely due to the fact that the cuff electrodes are made by hand and the surface area of
the wire exposed inside the silicone tube can change on account of process variation.
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Figure 4.18 Impedance profiles of 16 mouse nerve cuff electrodes. Average impedance
at 1 kHz is 13.8 kΩ.
The rectangular waveform of the current pulse applied during stimulation (see
Figure 4.9) will result in a complex frequency composition of the corresponding voltage
waveform. What’s more, the voltage needed to source the desired current will depend
on the amplitude and pulse width of the stimulus. This makes it difficult to predict
whether or not the stimulator will reach its voltage headroom and undesirably cap the
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output current based on the data of Figure 4.18 alone. Instead, the current through the
cuff electrode is measured directly to confirm that currents up to 1 mA may be applied
through the cuff electrode without reaching the voltage headroom. During this test the
cuff electrode is submerged in 0.9% PBS and the voltage across a low-value (5 Ω)
resistor in series with the cuff electrode is measured over time. Figure 4.19 compiles the
measured current through the cuff electrode for the same series of stimulus waveforms

Stimulus Amplitude (μA)

given in Figure 4.9 (where a 10 kΩ load is used in place of the cuff electrode in PBS).
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Figure 4.19 Stimulus current measured in series with a nerve cuff electrode submerged
in 0.9% phosphate buffer solution (PBS) for five different current amplitude settings.
Pulse width is set to 100 μs.

The added noise observed in Figure 4.19 compared to Figure 4.9 is due to the
fact that very small voltages are being measured across a 5 Ω series resistor instead of
much larger voltages measured across a 10 kΩ load resistor. However, the rectangular
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current pulse is still seen clearly and closely matches the current amplitude setting. This
affirms that the current amplitude is not being clipped as a result of high electrode
impedance. A moment is taken here to point out a slight discrepancy in the measured
current amplitudes of Figures 4.19 and 4.9. Particularly at higher pulse amplitudes there
is an overshoot of achieved current as compared to desired current. This can be
attributed to the fact that the stimulus amplitude calibration (see Section 4.3.2) is
performed when the stimulator’s load is a 10 kΩ resistor. This issue might be addressed
to some extent by performing the stimulator calibration using a cuff electrode in PBS as
the stimulator’s output load. However, this still does not guarantee a perfect replication
of in vivo load conditions, and there will always be some mismatch between optimal
calibrations on the bench top and in vivo.
The sensitivity of the stimulator’s amplitude calibration to changes in the load
impedance, part-to-part variation in current mirror MOSFETs, desired pulse width, and
supply voltages is a weakness of this stimulator topology. However, these shortcomings
can be handled by anticipating the stimulus pulse configurations that will be used in a
chronic animal study and determining the optimal calibration for each of these potential
configurations on the bench top under stimulator load conditions proximate to those
that will exist in vivo. This strategy is employed for each Bionode used in this work.
The data of Figure 4.19 confirms that these cuff electrodes are suitable for the
environment and stimulus pulse parameters anticipated for this work. However, it
would also be useful to know how close the stimulator is to reaching its voltage
headroom in case a change in electrode-tissue impedance should occur and necessitate
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a higher voltage to achieve the same current. For this reason the voltage at the output
of the stimulator connected to a cuff electrode in 0.9% PBS is measured during a 100 μs,
maximal (1 mA) stimulus pulse, which can be seen in Figure 4.20. Figure 4.20 shows that
the voltage under these stimulus conditions will not exceed 3.25 V, which means that
the cuff electrode impedance would have to more than triple before the voltage
headroom (10.5 V) is reached. This is unlikely to occur given that the current necessary
to generate a maximum CMAP from a peripheral nerve cuff in a mouse remained
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unchanged over the course of 60 days in a previous study [23].
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Figure 4.20 Stimulator output voltage corresponding to a 100 μs rectangular current
pulse of 1 mA. Dotted red lines delineate stimulus pulse duration.

4.6

Acute In Vivo Performance in Rodents

The Bionode is intended for use in both rats and mice. The first in vivo evaluation
of full system functionality involves concurrent use of the stimulator and recording
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channels to measure stimulus evoked potentials in an anesthetized rat. The procedures
and outcomes of this experiment are covered in this section. This experiment is
followed by a similar procedure in a mouse in order to verify the efficacy of the
recording and stimulating electrode strategies designed specifically for mouse work as
described in Sections 4.5.2 and 4.5.3. This second experiment also serves to illustrate
the expected amplitude of evoked CMAP signals, which will validate the gain selected
for the recording channel. For the sake of CMAP amplitude resolution the maximum
CMAP should occupy most of the ADC input voltage range, but it is important that the
gain not be so high that the signal rails before the maximum CMAP is achieved. This
experiment allows the gain on the channel intended for CMAP collection to be chosen
intelligently.

4.6.1 Experimental Design and Methods
Simultaneous nerve stimulation using the Bionode’s biphasic, current-controlled
stimulator and measurement of CMAP response with the Bionode’s AFE is performed
first in a female Long Evans rat weighing 330 grams obtained from Envigo (Indianapolis,
IN). This is done by first connecting a two-contact cuff electrode between the stimulator
output and circuit ground then placing the cuff around the sciatic nerve of the rat.
Stimulus pulses are then applied to the nerve and the CMAP response those stimuli are
recorded from the biceps femoris muscle using the imEMG electrode described in
Section 4.5.2. The current amplitude is gradually increased until the peak-to-peak
amplitude of the CMAP response plateaus. The stimulus pulse width is fixed at 100 μs
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during this experiment and a stimulation frequency of 2 Hz is used to avoid timedependent changes in the measured response. Since CMAP responses in rats can be ten
of mV in magnitude, the Bionode’s AFE is configured for a gain of 25 (28 dB) to prevent
saturation. The Bionode is powered from a DC supply during these experiments and the
AFE output recorded on an oscilloscope for ease of data collection. These procedures
are subsequently repeated in an anesthetized mouse.

4.6.2 Graded CMAP Response to Applied Stimuli
Figure 4.21 illustrates the peak-to peak amplitude of the CMAP measured in the
biceps femoris muscle resulting from increasing stimulus current amplitude applied to
the sciatic nerve of a rat. The threshold current needed to elicit a measurable CMAP
response is 300 μA and the maximum CMAP amplitude is 30 mVpp. Figure 4.22 shows a
series of CMAPs recorded for stimulus current amplitudes ranging from 300 μA to 400
μA. During this experiment the stimulus artifact precedes the CMAP response by
approximately 2 ms and is not shown.
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Figure 4.21 Peak-to-peak compound motor action potential (CMAP) response measured
in the biceps femoris muscle by the Bionode’s analog front-end (AFE) in response to
increasing stimulus current amplitude from Bionode’s stimulator applied to the sciatic
nerve. Pulse width and stimulus frequency are fixed at 100 μs and 2 Hz, respectively.

Figure 4.22 Samples of measured compound motor action potentials (CMAP) responses
to stimulus amplitudes ranging from 300 μA to 400 μA applied to sciatic nerve of a rat.
CMAP responses are measured using an intramuscular EMG (imEMG) electrode in the
biceps femoris. Pulse width and stimulus frequency are fixed at 100 μs and 2 Hz,
respectively.
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This series of measurements is repeated in a wild-type (Black 6) mouse with the
recording channel gain adjusted to 50 (34 dB) in anticipation that the maximum CMAP
response will be smaller in the mouse than in the rat. Figure 4.23 shows the stimulus
evoked muscle response to stimulus pulses ranging from 50 μA to 1 mA (the full range
of the stimulator). Each waveform represents the average of three consecutive CMAP
responses. The CMAP responses are recorded at a higher resolution in the range where
it is expected that most axons will be recruited and rapid changes in CMAP amplitude
will occur (200 μA to 400 μA). The waveforms compiled in Figure 4.23 are synchronized
by the stimulus artifact, which precedes the CMAP response by approximately 1 ms and
is not shown. It makes sense that the delay between stimulus artifact and evocation of
the muscle response would be shorter in the mouse than in the rat owing to the shorter
distance along the nerve from the cuff electrode to the innervated muscle.
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Figure 4.23 Measured compound motor action potential (CMAP) response to increasing
stimulus amplitude applied to the sciatic nerve in a mouse. Each waveform represents
the average of three consecutive responses measured from the biceps femoris muscle.
Pulse width and stimulus frequency are fixed at 100 μs and 2 Hz, respectively.

The data shown in Figure 4.23 suggest that a maximum CMAP amplitude of
approximately 20 mVpp can be expected from this electrode configuration. The
conclusion being that the low gain channel (34 dB) would be appropriate to measure
this signal in a chronic experiment without exceeding the input voltage limitations of the
ADC. One exciting thing to note about Figure 4.23 is a second, delayed waveform that
can be observed starting around 2.5 ms at current amplitudes as low as 360 μA. Based
on the characteristic delay and size, it is possible that this is an F-wave resulting from
antidromic current reaching the motoneuron cell bodies in the spinal cord and causing a
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small percentage of them to fire. This leads to a second, smaller CMAP, the delay of
which can be used to measure NCV [185]. Since NCV is a common metric used for
tracking neuromuscular and motoneuron diseases, the measured F-wave could be
valuable in quantifying pathological changes in the nerve in future animal disease model
studies [186, 187].

4.7

Chronic Recording and Stimulating of Bioelectric Activity in Rodents

The broad motivation for this project is to enable untethered collection of
bioelectric activity in rodents. The more specific goal is to utilize this novel
instrumentation in the study of neuromuscular and motoneuron disease mechanisms in
mice. The acute, in vivo experiments of Section 4.6 indicate that the Bionode meets the
desired performance criteria for study of normal and pathological activity of the
neuromuscular system. The first chronic implantation of the Bionode is described in
Section 4.7.2 and entails long-term EKG monitoring in a rat. Being both periodic and
easily recognized, the EKG waveform is a good target for a first attempt at chronic data
collection. This experiment serves three purposes: first, to evaluate the powering
fidelity that might be expected from a freely behaving animal within the cavity
resonator; second, to quantify the loss of data (BER) from the wireless data link
operating within the cavity; and third, to demonstrate long-term, in vivo viability of the
fully wireless and implantable system.
The chronic performance of the Bionode in mice is demonstrated here in three
experiments. The first is a validation trial that tests the full functionality of the device in
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a single implant. The second is an experiment comparing NAP activity in a CMT type 2D
disease model to a wild-type control. The third is an experiment comparing CMAP
responses to pulse trains in an ALS disease model compared to a wild-type control. The
procedures for each of these experiments are covered in Section 4.7.1. Results of the
validation experiment are discussed in Sections 4.7.3 and 4.7.4 while preliminary data
from the disease models and their controls are presented in Section 4.7.5. These
experiments represent only a small subset of possible chronic applications for the
Bionode in mice, but serve to highlight a couple of experimental paradigms which are
either enabled or improved by an untethered, batteryless implant.

4.7.1 Experimental Design and Methods
The first longitudinal experiment—a Bionode configured to measure two
channels of EKG (Leads I and II configurations [188])—is performed in a female Long
Evans rat obtained from Harlan Laboratories (Indianapolis, IN). The Bionode used in this
experiment is not the final design iteration described in this chapter (see Section 4.1 for
a description of the three Bionode iterations). The only important different to note for
this experiment, though, is that the AFE operates in single supply mode and is identical
to the AFE used in the Myonode (see Figure 3.5). This AFE is configured for a bandwidth
of 1 Hz to 1 kHz and a gain of 60 dB.
The surgical procedures begin with the rat in the prone position. A 3 cm rostralcaudal incision is made on the side of the rat 0.5 cm left of midline. A subcutaneous
pocket is created ventral to the initial incision that is large enough to accommodate the

166
implant, which is packaged in a 3D-printed capsule and coated with medical epoxy as
shown in Figure 4.24. The implant is inserted into the pocket and oriented lengthwise
such that the front coil lies fully in the transverse plane and the top coil lies fully in the
sagittal plane, which are optimal for PTE in the magnetic field while the animal is
walking normally on all fours and while rearing up on its hind limbs. Suture points on the
implant are using to connect the device to the muscle surface and keep it oriented
properly.

Figure 4.24 Bionode packaging for chronic implantation in rats. (a) Stacked power and
core modules prior to encapsulation. (b) Closed capsule coated in medical epoxy and
ready for implantation. Two pairs of electrodes are connected for lead I and lead II
measurement of EKG.

The EKG is recorded by differential electrode pairs, which are routed to their
target locations through subcutaneous tunneling to a second, lateral 0.5 cm incision
close to the desired recording site. Once each lead reaches its target location it is
sutured into place on the surface of proximate muscle. After each electrode has been
anchored in place, both incision sites (the one over the device and the one over the
electrode targets) are sutured shut. The efforts of Dr. John Jefferys, who performed the
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surgery, should be acknowledged as well as those of Dan Pederson and Henry Mei, who
periodically collected EKG data from the animal.
The Bionode is used in three different chronic mouse experiments. In all cases
the configuration of the AFE channels is the same: one low gain (34 dB) channel for
larger signals such as stimulus evoked CMAP and one high gain (60 dB) channel for
smaller signals such as spontaneous imEMG or NAP. The goal of the first experiment is
to stimulate and measure CMAP as well as record voluntary evoked EMG from the same
mouse. This comprehensive test is performed in a 25 g, wild-type (Black 6) mouse and is
intended to confirm that all of the device’s functional blocks work correctly and
concurrently once implanted. The surgical procedure for this and all subsequent chronic
mouse experiments begins the same way: the animal is placed in the prone position and
a 10 to 15 mm rostral-caudal incision is made beginning near the division of the vastus
lateralis and the biceps femoris muscles and approximately 5 mm to the right of midline.
Each implantation requires subcutaneous blunt dissection in the rostral direction until a
pocket large enough to house the device is made. The device is inserted under the skin
and anchored in place by a suture stitches through connective tissue on either side of
the silicone adhesive-coated electrode pins. This stitch prevents the device from slipping
backward towards the hind limb, which it is has a tendency to do without any anchoring.
At this point the surgical technique will diverge depending on the number of electrodes
and their respective targets.
For the purposes of the comprehensive validation test, the device is equipped
with a peripheral nerve cuff electrode on the stimulating channel and an imEMG
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electrode pair on each recording channel. This configuration is shown in Figure 4.17. The
cuff electrode is slipped around the sciatic nerve and closed with a loose suture loop
around the cuff circumference. Both imEMG electrodes are threaded through the biceps
femoris muscle parallel to the muscle fibers. A second anchoring knot is made and the
needle along with the excess wire is cleft from the electrode as described in Section
4.5.2. The incision is then sutured closed and the animal is placed in the cavity for initial
data collection. The mouse is returned periodically to the cavity following implantation
for data collection. Recording sessions in the cavity need not be very long in this study
as the objective is successful collection of spontaneous EMG, which will occur any time
the animal moves. The other objective of this study—successful provocation of CMAP
responses from a fully implanted system—is done under anesthesia to reduce stress on
the animal and improve data quality. A small coil (diameter = 7 mm) that is tuned to
resonate at the same frequency as the cavity is used to wirelessly power the device at
close proximities, which is possible when the animal is under anesthesia. This small coil
is also used mid-surgery to confirm that the device is working properly prior to suturing
the animal closed.
The second mouse experiment—and the first to integrate disease models—seeks
to illustrate motor evoked potentials in the sciatic nerve of a healthy mouse as well as
those present in a mouse carrying a genetic mutation of the GARS gene, which encodes
for glycyl-tRNA synthetase. Mutations of the GARS gene are associated with phenotypes
of CMT type 2D and are known to affect the properties of the peripheral nerves [189,
190], but questions still remain regarding the electrophysiological signature of this
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disease. The target signals in this study are voluntary peripheral NAPs and possible
aberrant nerve activity associated with visible tremors in the disease model. The
Bionode’s electrode configuration for this study is comprised of a single recording cuff
electrode connected to the high gain channel. The surgical procedures are identical to
the wild-type validation experiment except that no electrodes are inserted into the
muscle and the high gain recording channel terminates in a cuff electrode that is
attached to the sciatic nerve.
The purpose of the third experiment is to record stimulus evoked CMAP in the
Tg.SODG93A, which is a disease model for ALS. These CMAP responses will be evoked in
two ways: first, with low frequency (1-2 Hz) supramaximal stimuli to observe changes in
maximum CMAP, which should decrease over time based on prior evidence [23]. Second,
with sequences of faster (3-50 Hz) repetitive nerve stimulation (RNS) to observe the
percentage difference in peak-to-peak CMAP response from the first to the last pulse in
a stimulus train (typically ten pulses) [18]. This change should be more significant in the
disease model than a healthy control, especially as both get older. Both of these
changes in stimulus evoked CMAP behavior have been previously observed in the
Tg.SODG93A model, so this experiment will serve to corroborate these findings while
leveraging significant gains in efficiency and data resolution on account of the Bionode
substituting for instrumentation of established protocols. For example, the procedure
used to collect CMAP responses to RNS involves anesthetizing the animal, inserting
transcutaneous needle electrodes for nerve stimulation, and affixing an EMG cuff to the
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surface of the hind limb. This setup is complex and repetitively invasive, which means
that the measurements are typically taken only once every few weeks in a single animal.
This experiment is intended to show how the Bionode can patently simplify the
procedure for measuring stimulus evoked CMAP responses over time, which would have
at least the immediate benefit of allowing changes in CMAP behavior to be observed at
much higher temporal resolution. The surgical procedure for this experiment is nearly
identical to that of the first validation experiment except that the high gain channel
which is used previously for collection of spontaneous EMG is not used. A peripheral
nerve cuff connected to the Bionode’s stimulator is fastened to the sciatic nerve and an
imEMG electrode from the low gain AFE is anchored inside the biceps femoris muscle as
described in Section 4.5.2. For simplicity CMAP responses will be measured while the
animal is awake and freely behaving within the resonant cavity. If for any reason this
presents a significant issue, the mouse can, alternatively, be anesthetized briefly while
the stimulus protocol and CMAP collection are carried out. Under these circumstances
the device can be powered wireless using the same small, precisely tuned coil used for
CMAP collection in the first chronic mouse experiment.
Data collection for each chronic mouse experiment is performed inside the
resonant cavity. This testing environment is adapted for mouse work by introducing a
motorized wheel, which is built with the assistance of Curtis Slaughbaugh, a student in
the Center for Implantable Devices at Purdue University. In this way data can be
collected either from the animal freely behaving in the open space within the cavity or
during forced exercise inside the wheel. The wheel itself is placed strategically within

171
the cavity such that it resides within the strongest part of the magnetic field [71]. This
considerably de-risks the WPT link by ensuring that the animal can always be placed and
made to behave in an optimal position for power transfer. The wheel itself should incite
cyclic behavior in the peripheral nerves and muscles of the hind limb, which can be
useful in verifying and comparing measured data. The cavity’s resonant mode and
performance are highly sensitive to electrically conductive materials, so care is taken to
ensure that all parts of the motorized wheel that reside within the cavity are made from
plastic. Figure 4.25 shows the motorized wheel within the cavity; its drive shaft passes
into the WPT environment through a 9.5 mm hole. The shaft is driven by a DC motor
(McMaster-Carr, 6409K17) that allows up to 25 rpm and 20 in·lbs of torque at 12 V. The
supply voltage is regulated by a DC power supply on the bench top.

Figure 4.25 Resonant cavity WPT environment equipped with mouse wheel for
controlled, cyclic behavior located where peak power transfer efficiency (PTE) is
expected within the cavity.
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During each recording session the animal is placed in the desired space—either
the wheel or the open field—and then a lid is secured to the top of the cavity. In
addition to routing data packets and instructions, the base station provides up to 4 W of
power at the appropriate frequency (340 to 350 MHz) to the resonant cavity. The base
station is placed outside of the cavity and communicates via Wi-Fi with a nearby
computer running the GUI. Figure 4.26 captures the full testing setup and demarcates
each of these system elements.

Figure 4.26 Comprehensive testing environment for fully wireless data collection from
freely behaving animals including the resonant cavity (red), base station (yellow), power
supply for mouse wheel operation (green), and a computer running the software user
interface (blue).
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4.7.2 Longitudinal EKG Measurement
Data collection from the Bionode implanted in the rat and configured for EKG
measurement is performed in the resonant cavity as described in [71]. Following
implantation and animal recovery, the rat is placed in the cavity for initial (day 0) data
collection. Data is collected periodically over the course of 79 days in order to confirm
continued device operation and to tack the quality of the EKG over time. Figure 4.27
shows a sampling of EKG measured over time from post-surgical days 0, 7, 43, and 79. In
each instance the data is sampled at 2.5 kHz. The signal strength is quantified by the
peak-to-peak amplitude of the EKG signal average over 30 heartbeats during each
recording session. On day 0 the measured signal strength is 0.95 ± 0.045 mV. A decrease
in the signal strength is observed on day 7 from a measured peak-to-peak EKG
amplitude of 0.72 ± 0.041 mV. However, signal strength remains steady through day 43
(0.69 ± 0.069 mV) and day 79 (0.73 ± 0.089 mV). This signal degradation is likely due to
formation of scar tissue around the electrodes contacts in combination with the
relatively small (10 MΩ) input impedance of the now obsolete AFE used in this
experiment. The unwanted voltage division of the recorded signal will likely improve
greatly in subsequent chronic implantations where the final AFE (see Figure 4.5), which
has an input impedance of 100 GΩ, is used.
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Figure 4.27 EKG collected longitudinally by a Bionode implanted in a rat.

The data collected in this experiment allows for an applied quantification of BER
which offers a more realistic estimation of the Bionode’s wireless performance as
compared to bench top measurements where the transmitting and receiving antennas
may be stationary and very close to one another. The BER is calculated by the
percentage of data packets lost out of total data packets sent within a recording session.
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A recording session is defined here as any period of data collection from a freely
behaving animal within the resonant cavity lasting longer than 30 minutes. This
measurement is performed over the course of nine recording sessions ranging from day
– to day 64 post-implantation. The minimum and maximum BERs observed across the
nine recording sessions were, respectively, 0.07% (measured on day 5) and 1.07%
(measured on day 23). The combined recording time of these nine sessions is 39 hours,
over which the total BER is 0.38%.
This experiment also allows powering fidelity to be quantified from a freely
behaving animal within the WPT environment. If the monitoring period is long enough
(a few hours), the ratio between the total time the device is on and total monitoring
session time will represent the applied powering fidelity, which accounts for normal
animal behaviors such as walking, resting, eating, drinking, and grooming. This offers a
more practical and objective metric than peak PTE, which is how the quality of WPT links
are often reported. The applied powering fidelity measured from the rat in the cavity
over eight recording sessions—each last at least half an hour—for a total monitoring
time of 35.5 hours is over 93% [71].
The outcomes of the chronic rat experiment are useful for understanding and
setting expectations for the long-term performance of the full system. In this way they
help to guide the experimental setup for the chronic mouse studies. For example, the
calculated powering fidelity of 93% is likely sufficient for metrics like RMS or peak-topeak amplitude of voluntary evoked EMG from normal ambulation. However, more
sensitive measurements such as CMAP responses to stimulus pulse trains might require
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a more consistent WPT link if only because this will greatly simplify data parsing. This
observation led to the development of the mouse wheel (see Figure 4.25). This structure
keeps the animal in a portion of the cavity where the magnetic field strength is
strongest and the implanted device has the best chance for continuous, uninterrupted
data acquisition.

4.7.3 Stimulus Evoked CMAP
The ability to generate chronic, stimulus evoked CMAP is demonstrated in a wildtype mouse during the first chronic mouse experiment with the Bionode. All stimulus
pulse widths are 100 μs in duration and are evoked at a rate of 1 Hz. By convention,
data from the cathodic stimulating phases are used when reporting CMAP responses
[181]. To minimize the amount of time the animal is anesthetized, the stimulus
amplitude is increased until an incipient CMAP response is observed. In this experiment
to first observable CMAP occurs at 300 μA. The presumed maximum CMAP is then
evoked immediately thereafter by setting the current amplitude to the upper limit of 1
mA. Figures 4.28(a) and 4.28(b) show superimposed threshold CMAPs and maximum
CMAPs, respectively, measured in a wild-type mouse seven days post-surgery. Each
CMAP is detected and synchronized by the stimulus artifact, which can be observed
preceding the beginning of the CMAP by approximately 1 ms. The data shown in Figure
4.28 represent the first reported CMAPs evoked and measured in mice by a fully
implantable recording device
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Figure 4.28 Series of (a) incipient and (b) maximum CMAP measured from Bionode
implanted in wild-type mouse on Day 7 post-surgery.

4.7.4 Voluntary Evoked EMG
In the course of the validation experiment, voluntary evoked EMG is measured
periodically from the wild-type mouse while it is freely behaving in the open field of the
resonant cavity (see Figure 4.25). Figure 4.29 plots representative data from days 0, 2,
and 5 post-surgery. This is already a marked improvement over the longevity of the
electrode interface used on the Myonode, which failed within 48 hours of implantation.
While the timespan is relatively short, this series of data is a promising indication for the
long-term viability of the packaging and electrode schemes.
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Figure 4.29 Samples of voluntary evoked EMG collected from a freely behaving wildtype mouse using the fully wireless Bionode system.

The intended course of the validation study is to collect voluntary evoked EMG
as well as threshold and maximum CMAPs (like those shown in Figure 4.28) for as long
as possible. However, beginning on day 9 the device becomes ostensibly detuned and
ceases to operate in the cavity. Performance while powered with the small coil for
stationary experiments is also considerably degraded to the point that only faint
contractions are observed in response to purportedly large stimuli. This seems to
suggest that the microelectronics are intact but some change has occurred in either the
coils or the matching network to significantly drop the PTE to the point that the
stimulator’s voltage headroom is far below where it should be. Nevertheless the device
is left implanted for a total of two weeks so that behavioral monitoring could continue
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and complete healing of the incision wound can occur. This allows for some inferences
to be made about how well the animal fares with the device as it is positioned and
whether or not chronic implantation of the Bionode in such a small specimen is realistic.
It seems that the device is generally tolerated; the mouse is observed eating and
grooming shortly after surgery and its gait is only marginally affected by the cuff around
the sciatic nerve: an effect which becomes less noticeable over time. Figure 4.30(a)
depicts the Bionode next to the animal subject prior to implantation. Figures 4.30(b) and
4.29(c) depict the animal subject from the top and the side after the device has been
implanted for two weeks. Full wound closure and healing is achieved and the device is
still positioned above the hip. These are both promising results since two potentially
catastrophic events that can occur are that the mouse chews its stitches and they fall
out prior to wound closure and that the device slips backwards until it rests on top of
the hind limb flexor muscles. The latter scenario causes impairment of hind limb motion
and puts hazardous stresses on the electrode leads as they undergo sharp bending
between the electrode interface on the Bionode and their target nerve or muscle. One
caveat should be noted here and that is that this implantation is performed in a fairly
large (25 g) mouse. It remains to be seen how well smaller mice tolerate the implant.
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Figure 4.30 (a) Bionode device next to mouse immediately prior to implantation (day 0).
(b) Top view of mouse 2 weeks after device implantation (day 14). (c) Side view of
mouse two weeks after implantation.

The device is explanted after two weeks so that the point of failure can be
determined. Careful dissection results in confirmed integrity and continuity of the
electrode leads. The crimped terminals of the recording and stimulating electrodes as
well as the entire electrode interface on the Bionode are inspected for displacement,
breaches, or breakage. The electrode interface is still fully intact following explantation,
which is yet another promising outcome of the experiment. The source of the failure is
discovered to be the epoxy around the putty insert which encases the impedance
matching circuit. This particular segment of epoxy is applied during the second
deposition phase as described in Section 4.5.1, and is spongy to the touch following
removal from the animal. When set properly the epoxy should be firm, so the likely
explanation is that it did not set properly and allowed fluid to leak into the cleft that
houses the impedance matching circuitry. This conclusion is reinforced by the detection
of liquid and unset epoxy beneath the putty insert. For this reason care is taken on all
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future assemblies to be sure that the second epoxy deposition phase which forms the
barrier around the putty insert is properly set.

4.7.5 Ongoing Study in CMT and ALS Disease Models
The experiments for evaluating voluntary evoked nerve activity in the CMT type
2D disease model and stimulus evoked CMAP from the hereditary ALS disease model are
ongoing. However, some preliminary findings and data are discussed here. Figure 4.31
illustrates recurrent bursts of sciatic nerve activity resulting from forced walking inside
the wheel shown in Figure 4.25. These data are collected from a GARSC201R mouse: a
model for CMT Type 2D. There is no clear precedent within the literature for collecting
and quantifying voluntary peripheral nerve activity in awake and behaving mice. These
data comprise the first reported voluntary NAP to be collected by a fully implantable
measurement system.

Figure 4.31 Voluntary nerve action potentials (NAPs) collected from an awake and
behaving mouse while performing forced walking within a wheel.

This new instrumentation and methodology may be used to track changes in
amplitude and frequency composition of the data shown in Figure 4.31 over time.
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Additionally, they can be used to test the effects of pharmacological agents on nerve
activity. For example, sodium channel blockers introduced into the extracellular
environment around the nerve might disparately impact nerve behavior in the CMT
Type 2D disease model compared to its control, which might implicate sodium channel
deficiencies as playing a role in the disease mechanism. This is just one of many
potential experimental protocols which would be easy to carry out once the Bionode is
implanted and stabilized in its environment.
Another early result of the GARSC201R mouse study is the observation of
intermittent, low-amplitude potentials which occur while the animal is at rest. Three
examples of such activity as well as the baseline signal measured while the animal is
under anesthesia are compiled in Figure 4.32. The sampling rate and ADC resolution
used while collecting these data are 2.5 kHz and 8-bit, respectively. It may be that this
activity is the result of nerve injury or irritation by the cuff electrode. However, one of
the established phenotypes of this model is a visible tremor in the hind limb and tail.
Another explanation for the observed spontaneous nerve activity might be that it
correlates with this tremor. If this is the case, then these data are the first of their kind
measured from this model. However, more instances of this activity will need to be
recorded in the disease model and an absence of comparable activity in the wild-type
control will need to be proven before other possible explanations can be ruled out.
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Figure 4.32 Sciatic nerve activity recorded from a disease model for CMT type 2D during
stationary periods within the open field of the resonant cavity. Baseline data represents
nerve activity while the animal is anesthetized. Examples 1, 2, and 3 represent
intermittent, low-level potentials measured while the animal is at rest.

The ability to both elicit stimuli and record the response allows the Bionode to
collected stimulus evoked CMAP from awake and freely behaving animals. The change
in amplitude of the CMAP response to a fixed stimuli over time can indicate changes in
muscle mass (resulting from growth or atrophy) or impairments of somatic signal
transduction. Figure 4.33(a) illustrates a series of CMAPs recorded from an awake and
freely behaving Tg.SODG93A mouse the day after implantation of the Bionode using a
stimulus pulse width of 100 μs. The threshold current needed to elicit a CMAP is 450 μA
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and the CMAP amplitude plateaus near 700 μA. This gives the minimum and
supramaximal conditions for this pulse width, which can be tracked over time.
In order to confirm that the observed response is a CMAP and not an artifact, the
pulse width is doubled to 200 μs and the current amplitude is gradually increased once
again. Figure 4.33(b) plots the result of this second sweep. In this instance the threshold
current needed to elicit a CMAP is 400 μA and the CMAP amplitude plateaus near 650
μA. The consistent and appropriate duration of the muscle response in both cases
(approximately 2 ms) as well as the observation that the stimulus intensity needed to
trigger a measurable response is smaller when the stimulus duration is longer (which is
consistent with the known behavior of strength-duration curves for excitable tissues)
suggest that the implanted instrumentation is effectively collecting the signal of interest.

Figure 4.33 Evoked compound muscle action potential (CMAP) measured from the
biceps femoris of a Tg.SODG93A mouse in response to a stimulus pulse with a duration of
(a) 100 μs and (b) 200 μs. All waveforms shown are averages of ten successive CMAPs
recorded at each level of stimulus intensity.
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Another measurement of interest in the Tg.SODG93A mouse is the trend in
stimulus evoked CMAP amplitude in response to higher frequency (3 to 50 Hz) stimulus
pulse trains. Figure 4.34 plots the average amplitude of successive CMAPs resulting from
RNS at 20 Hz. These data are collected the day after surgery using a pulse width of 100
μs and a resting period of at least 10 seconds between subsequent pulse trains. This
creates an RNS response signature which can be used to detect deficits of the
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neuromuscular junction or the muscles themselves over time [18, 191].
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Figure 4.34 Peak-to-peak compound muscle action potential (CMAP) response to
repetitive nerve stimulation (RNS) measured as a percentage of the amplitude of the
first pulse in a 20 Hz pulse train. The stimulus pulse train uses supramaximal conditions
Error bars at each pulse number reflect standard deviation (n = 7).

4.8

Conclusion

The Bionode represents the state-of-the-art in fully wireless and implantable
biosensors for mice. Its capabilities far exceed those of any battery operated system and,
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furthermore, allow anesthesia and tethering to be removed entirely from experimental
protocols for long-term bioelectric data collection. This offers significant gains in
efficiency as well as data resolution and consistency compared to many established,
long-term electrophysiology protocols for mice. The fully implantable recording device
developed in this work is able to collect two crucial target signals useful in studying
neuromuscular disease progression–CMAP and voluntary nerve activity—that have
never before been measured in a mouse by a fully wireless system.
The Bionode follows the same design principle as the Myonode—that is, all the
microelectronic elements integrated on the Bionode’s power and core modules are
commercially available. This offers flexibility and consistency in the finished product (not
to mention faster turnaround on design iterations) which would have been
impracticable had the systems been designed all or partially in CMOS technology.
Despite the added volume and power consumption that come with compiling
individually packaged and standalone ICs, the Bionode maintains a form factor that is
tolerable for subcutaneous implantation in mice and effectively powered by the
resonant cavity WPT environment.
The demonstrated performance of each of the Bionode’s functionalities while
implanted in freely behaving mice supports its capacity to serve as an implement for
finding new electrophysiological information about neuromuscular disease mechanisms.
Two possible applications for this novel instrumentation are presently underway, which
examine bioelectric markers of CMT and ALS. However, this system can be feasibly
adapted for dozens of interesting electrophysiological studies. This work has resulted in
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the collection of CMAP waveforms as well as voluntary muscle and nerve activity from
devices implanted chronically in mice, but other useful metrics such as NCV, single fiber
EMG, and CNAPs could certainly be targeted as well through appropriate AFE
configuration paired with clever electrode design and placement.
An added benefit of having two recording channels is the capability to measure
both the input to and output from muscles, which can degenerate for a variety of
reasons in different neuromuscular disease models. This pairing of measurements might
paint a more complete picture of disease progression by, as an example, allowing the
user to identify which part of the neuromuscular system is affected first (nerve,
neuromuscular junction, or muscle) and then monitor the temporal changes in each
location relative to one another. This is yet another nod to the appreciable adaptability
of the device, which implies that this work only scratches the surface of possible
utilizations for longitudinal electrophysiology or behavioral monitoring in rodents.
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CHAPTER 5.

CONCLUSION

This work describes the development of a fully wireless and implantable device
capable of recording both spontaneous and stimulus evoked bioelectric activity in mice.
These efforts are driven by a need for improved instrumentation to study the
electrophysiological mechanism by which neuromuscular and motoneuron diseases
manifest and progress in mouse models. The finished device, which is termed the
Bionode, improves on current technologies outlined in Table 1.1 by offering more
capabilities and better performance in a comparably small volume (less than 1 cm3).
Moreover, the Bionode is designed for compatibility with a resonant cavity, which is the
largest (by volume) reported WPT environment for rodents.
One of the early efforts of this work explores the feasibility of far field RF power
transfer to bioelectric sensors embedded in tissue. The theoretical and numerical
analyses of the power link budget between an electromagnetic field source and a
receiving antenna inside mammalian tissue show conclusively that this WPT strategy is
unsuitable for continuous operation of bioelectric sensors. This type of WPT link is more
suitable for passive systems or those with much lower average power consumption that
can leverage trickle charging and power cycling.
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The Myonode—the precursor to the Bionode—serves to establish and debug build
procedures, optimize the implant’s functional protocol, and fine-tune the AFE topology
and configuration. The Myonode is limited by only a single channel of recording, but is
able to collect voluntary evoked EMG from mice, including some interesting diseaserelated aberrant muscle activity. The Myonode is also replicated and powered in an
array for the purpose of relaying EMG for myoelectric-controlled prostheses. This offers
some improvements to the versatility of wireless neural interfaces for upper-limb
amputees.
The design procedures for both the Myonode and Bionode are predicated on the
assumption that CMOS design and fabrication are not suitable for the development
phase of new instrumentation. This is especially true considering the evolution of the
WPT strategy in parallel with the evolution of the implantable device, which brings with
it a handful of unanticipated issues. The dozen PCB design iterations used in this work is
the best evidence in support of the decision to avoid an ASIC implementation until the
system’s topology is solidified. The use of only commercially available ICs and passives
to build the Bionode did greatly improve yield and reliability compared to the CMOS
tape-out described in Chapter 3. The end result is a batteryless implant which is capable
of one channel of stimulating, two channels of recording, thermal sensing, and
bidirectional telemetry. It is possible at this point to consider the benefits of condensing
large blocks of this system on CMOS in order to further miniaturize and improve the
efficiency of the end product.
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A few limitations of the Bionode should be noted. First, owing to its volume and
mass, there is a limitation on the size of the mouse in which the device can be implanted.
An estimate of this limitation can be inferred from the reported device volume to
minimum mouse size reported in Table 1.1.Being approximately 1 cm3, the Bionode may
be theoretically placed in animals as small as about 16 g. This does preclude the study of
some neuromuscular diseases with prominent musclular atrophy or reduced body mass,
but it should be suitable for most adult mice without such severe degenerative
phenotypes. Second, the rate of data lost from fully wireless powering and
communication will never be better than what one can expected from a tethered setup.
The combination of powering and data fidelity—both of which are less than 100%—
means that some data will invariably be lost when using the Bionode in an animal within
the WPT environment. This should not pose a serious problem unless extremely rare,
transient behaviors are the target. This particular scenario has been anticipated and
partially addressed by the construction of a smaller testing environment (mouse wheel)
placed in the optimal position within the cavity and close to the base station antenna.
One of the things that makes this device such a powerful tool is the fact that it
addresses with very little compromise the limitations of tethered headstages, wireless
headstages, and battery powered implants all at the same time. The Bionode has been
used to collect both voluntary and stimulus evoked bioelectric signals in freely behaving
animals. It is the first fully implantable system to collect voluntary nerve activity and
CMAP in mice and the first one capable of recording its own evoked potentials. Also, on
account of it dual, high-bandwidth recording channels, it is the only implantable system
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that can record both the input and the output of muscles, which might allow it to
pinpoint important pathological information like disease origin and clocked, directional
progression.
This project’s criteria for success should be revisited at this point. Recall that the
main objective is to create novel instrumentation for chronic electrophysiology that is 1)
small enough to be fully implanted in a mouse, 2) given sufficient functionality to be
used in a variety of electrophysiological experiments, 3) able to function in the living
environment once implanted, and 4) compatible with a WPT environment that enables
the continuous collection of bioelectric activity from freely behaving mice. The chronic
animal experiments described in Chapter 4 serve as the final indication that each of
these criteria has been fulfilled. Furthermore, the applications of this novel
instrumentation to the study of neuromuscular and motoneuron diseases underscores
its immediate utility within the scientific community and newly supported capabilities
for future experiments.
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